



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07H 21/02, 21/04, C12P 19/34, C12Q 1/68	A1	(11) International Publication Number: WO 96/40717 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/09537 (22) International Filing Date: 4 June 1996 (04.06.96) (30) Priority Data: 08/477,527 7 June 1995 (07.06.95) US 08/481,710 7 June 1995 (07.06.95) US (71) Applicant: NEXSTAR PHARMACEUTICALS, INC. [US/US]; Suite 200, 2860 Wilderness Place, Boulder, CO 80301 (US). (72) Inventors: TASSET, Diane; 2954 Kalmia Avenue #36, Boulder, CO 80301 (US). PAGRATIS, Nikos; 5813 North Orchard Creek Circle, Boulder, CO 80301 (US). JAYASENA, Sumedha; 5875 North Orchard Creek, Boulder, CO 80301 (US). GOLD, Larry; 1033 5th Street, Boulder, CO 80301 (US). (74) Agents: SWANSON, Barry, J. et al.; Swanson & Bratschun, L.L.C., Suite 200, 8400 East Prentice Avenue, Englewood, CO 80111 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: HIGH-AFFINITY NUCLEIC ACID LIGANDS OF CYTOKINES (57) Abstract Methods for identifying and preparing high-affinity nucleic acid ligands to cytokines and the ligands obtained thereby are disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

HIGH AFFINITY NUCLEIC ACID LIGANDS OF CYTOKINES

FIELD OF THE INVENTION

Described herein are methods for identifying and preparing high-affinity nucleic acid ligands to cytokines. The method utilized herein for identifying such nucleic acid ligands is called SELEX, an acronym for Systematic Evolution of Ligands by Exponential enrichment. This invention specifically includes methods for the identification of high affinity nucleic acid ligands of the following cytokines: IFN-gamma, IL-4, IL-10, TNF α , and RANTES.

Further disclosed are RNA ligands to IFN-gamma, IL-4, IL-10, and TNF α . Also disclosed are DNA ligands to RANTES. Specific examples are provided of oligonucleotides containing nucleotide derivatives chemically modified at the 2'-positions of pyrimidines. The oligonucleotides of the present invention are useful as pharmaceuticals or diagnostic agents.

BACKGROUND OF THE INVENTION

Cytokines are a diverse group of small proteins that mediate cell signaling/communication. They exert their biological functions through specific receptors expressed on the surface of target cells.

Cytokines can be subdivided into several groups, including the immune/hematopoietins, interferons, tumor necrosis factor (TNF)-related molecules, and the chemokines. Representative immune/hematopoietins include erythropoietin (EPO), granulocyte/macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), leukemia inhibition factor (LIF), oncostatin-M (OSM), ciliary neurotrophic factor (CNTF), growth hormone (GH), prolactin (PRL), interleukin (IL)-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, and IL-12. Representative interferons (IFN) include IFN α , IFN β , and IFN-gamma. Representative TNF family members include TNF α , interferon (IFN) β , gp³⁹ (CD40-L), CD27-L, CD30-L, and nerve growth factor (NGF). Representative chemokines include platelet factor (PF)₄, platelet basic protein (PBP), gro α , MIG, ENA-78, macrophage inflammatory protein (MIP)_{1 α} , MIP_{1 β} , monocyte chemoattractant protein (MCP)-1, I-309, HC14, C10, Regulated on Activation, Normal T-cell Expressed, and Secreted (RANTES), and IL-8.

IFN-gamma

IFN-gamma was first described 30 years ago as an antiviral agent (Wheelock, 1965). Since that time the protein has been shown to be a remarkably pleiotropic cytokine which plays important roles in modulating virtually all phases of immune and inflammatory responses. The cDNAs for murine IFN-gamma (Gray and Goeddel, 1983) and human IFN-gamma (Gray and Goeddel, 1982) have been cloned, sequenced, and characterized.

IFN-gamma is a member of a family of proteins related by their ability to protect cells from viral infection. This family has been divided into three distinct classes based on a variety of criteria, IFN-alpha (originally known as Type I IFN or Leukocyte IFN), IFN-beta (also originally known as Type I IFN or Fibroblast IFN) and IFN-gamma (originally known as Type II IFN or Immune IFN). IFN-gamma is unrelated to the Type I interferons at both the genetic and protein levels (Gray *et al.*, 1982). The human and murine IFN-gamma proteins display a strict species specificity in their ability to bind to and activate human and murine cells. This is due at least in part to their modest homologies at both the cDNA and amino acid levels (60% and 40% respectively).

IFN-gamma is produced by a unique set of stimuli and only by T lymphocytes and natural killer (NK) cells. The human and murine genes for IFN-gamma are 6 kb in size, and each contain four exons and three introns. These genes have been localized to human chromosome 12 (12q24.1) and murine chromosome 10. Activation of the human gene leads to the transcription of a 1.2 kb mRNA that encodes a 166 amino acid polypeptide (Derynck *et al.*, 1982). The human protein contains a 23 residue amino terminal hydrophobic signal sequence which gets proteolytically removed, giving rise to a mature 143 residue positively charged polypeptide with a predicted molecular mass of 17 kDa. Variable post-translational enzymatic degradation of the positively charged carboxy terminus (Rinderknecht *et al.*, 1984) is responsible for the charge heterogeneity of the fully mature molecule. Proteins with six different carboxy termini have been detected for both natural and recombinant forms of IFN-gamma. Two polypeptides self-associate to form a homodimer with an apparent molecular mass of 34 kDa (Scahill *et al.*, 1983). The homodimer is the biologically active form of the protein. Mature human IFN-gamma contains no cysteine residues, thus the homodimer is held together entirely by noncovalent

forces. This quaternary structure of the native protein explains its characteristic sensitivity to extremes of heat (protein denatured at temperatures above 56°), and pH (activity rapidly lost at pH values less than 4.0 and greater than 9.0) (Mulkerrin and Wetzel, 1989).

The remarkable pleiotropic effects of IFN-gamma are mediated through binding to a single
5 type of IFN-gamma receptor. The structure and function of murine and human IFN-gamma receptors have been described (Schreiber *et al.*, 1992). These receptor proteins are expressed on nearly all cells (except erythrocytes), and platelets (Anderson *et al.*, 1982). The receptor binds ligand with high affinity ($K_d = 10^{-9} - 10^{-10}M$) and is expressed on most cells at modest levels (200 - 25,000 sites/cell). Upon IFN-gamma
10 binding to the receptor at the cell surface, the intracellular domain of the receptor is phosphorylated at serine and threonine residues (Hershey *et al.*, 1990).

One of the major physiologic roles of IFN-gamma is as a regulator of immune response induction, specifically its ability to regulate expression of class I and II major histocompatibility (MHC) antigens on a variety of immunologically important cell types
15 (Trinchieri and Perussia, 1985). Functionally, IFN-gamma dependent upregulation of MHC gene expression is an important step in promoting antigen presentation during the inductive phase of immune responses and may play a role in antitumor activity of IFN-gamma (Buchmeier and Schreiber, 1985).

Another major physiologic role for IFN-gamma is its ability to activate human
20 macrophage cytotoxicity (Schreiber and Celada, 1985). Therefore, IFN-gamma is the primary cytokine responsible for inducing nonspecific cell-mediated mechanisms of host defense toward a variety of intracellular and extracellular parasites and neoplastic cells (Bancroft *et al.*, 1987). This activation is a result of several distinct functions of IFN-gamma. IFN-gamma has been shown to effect the differentiation of immature
25 myeloid precursors into mature monocytes (Adams and Hamilton, 1984). IFN-gamma promotes antigen presentation in macrophages, through the induction of MHC class II expression as described above, but also by increasing levels of several intracellular enzymes important for antigen processing (Allen and Unanue, 1987). Macrophage cell surface proteins such as ICAM-1 are upregulated by IFN-gamma, thus enhancing the
30 functional results of the macrophage-T cell interaction during antigen presentation

(Mantovani and Dejana, 1989). IFN-gamma activates the production of macrophage derived cytotoxic compounds such as reactive oxygen- and reactive nitrogen-intermediates and tumor necrosis factor- α (TNF- α) (Ding *et al.*, 1988). IFN-gamma also reduces the susceptibility of macrophage populations to microbial infections (Bancroft *et al.*, 1989).

5 Animal models have been used to study the role of IFN-gamma in the clearance of microbial pathogens. Neutralizing monoclonal antibodies to IFN-gamma were injected into mice before infecting them with sublethal doses of various microbial pathogens. These mice lost their ability to resolve the infection initiated with *Listeria monocytogenes* (Buchmeier and Schreiber, 1985), *Toxoplasma gondii* (Suzuki *et al.*, 1988), or *Leishmania*

10 *major* (Green *et al.*, 1990).

Besides these nonspecific cell mediated cytotoxic activities, IFN-gamma also enhances other macrophage immune response effector functions. IFN-gamma up-regulates expression of Fc receptors on monocytes/macrophages (Fc γ RI), thus enhancing the capacity of the macrophage for antibody dependent cell killing (Erbe *et al.*,

15 1990). IFN-gamma also promotes humoral immunity through enhancement of complement activity. It does this in two ways, i) by promoting the synthesis of a variety of complement proteins (ie., C2, C4, and Factor B) by macrophages and fibroblasts, and ii) by regulating the expression of complement receptors on the mononuclear phagocyte plasma membrane (Strunk *et al.*, 1985).

20 IFN-gamma also exerts its effects on other cells of the immune system. It regulates immunoglobulin isotype switching on B cells (Snapper and Paul, 1987). IFN-gamma plays a positive role in the generation of CD8⁺ cytolytic T cells (CTLs) (Landolfo *et al.*, 1985) and enhances NK cell activity. Recently, it has been unequivocally established that CD4⁺ T cells do not constitute a homogeneous class of cells. Indeed, a

25 paradigm of lymphokine biology and of the function of CD4⁺ T cells has arisen, the so-called Th1/Th2 paradigm (for a review see Paul and Seder, 1994). The T_{H1} clones, through their production of IFN-gamma, are well suited to induce enhanced microbicidal and antitumor activity in macrophages as detailed above (enhanced cellular immunity), while the Th2 clones make products (IL-4, IL-5, IL-6, IL-10, IL-13) that are well adapted

30 to act in helping B cells develop into antibody-producing cells (enhanced humoral immunity). The role played by IFN-gamma at this crucial nexus of T cell effector function

is fundamental to the success or failure of the immune response.

IFN-gamma plays a major role in promoting inflammatory responses both directly, and indirectly through its ability to enhance TNF- α production. During an inflammatory response, cells leave the circulation and migrate to the point of infection. During this process they must first bind to and then extravasate through vascular endothelium. Both IFN-gamma and TNF- α can promote the expression of overlapping sets of cell adhesion molecules (ICAM-1, E-selectin, and others) that play an important role in this process (Pober *et al.*, 1986; Thornhill *et al.*, 1991). In fact, experiments have shown that these two cytokines exhibit synergistic effects in up-regulating cell adhesion molecules *in vivo* (Munro *et al.*, 1989). One can envision microbial infections in which the microorganism is already widespread at the time the immune response develops or in which the response does not quickly rid the host of the infectious agent. This results in continued T cell activation inducing both local inflammation and tissue damage with ensuing loss of normal function. Indeed, when the infectious agent is of little intrinsic pathogenicity, the disease induced by the infection may largely reflect the consequences of such a response.

Excessive production of IFN-gamma may play a role in autoimmune disorders (for review see Paul and Seder, 1994 and Steinman, 1993). The mechanism for this may involve excessive tissue damage due to aberrant or enhanced expression of class I and class II MHC molecules or the role of an excessive T_{H1} cellular response. A role for IFN-gamma and the tissue-damaging effects of immune responses mediated by T_{H1}-like cells has been suggested in autoimmune disorders such as rheumatoid arthritis (Feldmann, 1989), juvenile diabetes (Rapoport *et al.*, 1993), myasthenia gravis (Gu *et al.*, 1995), severe inflammatory bowel disease (Kuhn *et al.*, 1993), and multiple sclerosis (Traugott, 1988).

IL-4

Interleukin-4 (IL-4) is a remarkably pleiotropic cytokine first identified in 1982 as a B cell growth factor (BCGF) (Howard *et al.*, 1982). In that same year, IL-4 was identified as an IgG1 enhancing factor (Isakson *et al.*, 1982). Because of the effect IL-4 has on B cells, it was first called BCGF-1, later termed BSF-1 (B-cell stimulatory factor-1), and in 1986 it was given the name IL-4. The cDNAs for murine IL-4 (Noma *et*

al., 1986; Lee *et al.*, 1986) and human IL-4 (Yokota *et al.*, 1986) have been cloned, sequenced, and characterized.

IL-4 can be regarded as the prototypic member of a family of immune recognition-induced lymphokines designated the "IL-4 family" (for a review see Paul,
5 1991). This family consists of IL-4, IL-5, IL-3, and granulocyte-macrophage colony-stimulating factor (GM-CSF). The properties shared by these proteins leads to this grouping and include, i) the linkage of the genes for the members of the family (van Leeuwen *et al.*, 1989), ii) the action of each member of the family as a hematopoietic growth factor in addition to any effects it may exert on lymphoid cells, iii) the receptors
10 for these proteins are all members of the hematopoietin family of receptors (Bazan, 1990a), and iv) coexpression of these factors by a subpopulation of cloned CD4⁺ T cells (the so-called T_{H2} cells) (Mosmann *et al.*, 1989) and by mast cells (Plaut *et al.*, 1989).

The remarkable pleiotropic effects of IL-4 are mediated through binding to cell surface receptors (IL-4R). The murine IL-4R (Mosely *et al.*, 1989; Harada *et al.*, 1990),
15 and the human IL-4R (Idzerda *et al.*, 1990; Galizzi *et al.*, 1990) have been cloned, sequenced, and characterized. IL-4R are present on a variety of hematopoietic (Park *et al.*, 1987) and nonhematopoietic cells (Lowenthal *et al.*, 1988). On both human and murine resting T and B cells, IL-4R are present in low numbers (<400) and are regulated by cytokines and other factors. The receptor binds IL-4 with high affinity ($K_d = 10^{-10}$ M).
20 Now that most of the receptors for immunoregulatory and hematopoietic cytokines have been cloned, it is apparent that the majority of these receptors fall into a large family. This hematopoietic cytokine receptor superfamily includes receptors for IL-4, IL-2 (b and g chains), IL-7, IL-9, and IL-13 which modulate the lymphoid system; and receptors for erythropoietin, granulocyte-colony stimulating factor (G-CSF), GM-CSF, IL-3, and IL-5
25 which modulate the hemopoietic system. The superfamily also includes receptors for factors believed to normally function outside the immune and hematopoietic systems, including receptors for growth hormone (GH), prolactin, leukemia inhibitory factor (LIF), IL-6, IL-11, and ciliary neurotrophic factor (CNF) (for a review see Kishimoto *et al.*, 1994).

30 A general first step in the signaling processes of immune and hematopoietic cytokines may be ligand-induced dimerization of receptor components whose cytoplasmic

regions interact to initiate a downstream signaling cascade. The IL-4 receptor has a long putative intracellular domain (553 amino acids in mouse, 569 in human) with no known consensus sequences for kinase activity or for nucleotide-binding regions. The biochemical nature of signals induced by the binding of IL-4 to its receptor have not been elucidated. It does appear that the cytosolic domain of the receptor is essential for its signaling function (Mosely *et al.*, 1989). Ligand induced dimerization of the IL-4 receptor appears to be a critical first step in IL-4 mediated signal transduction.

One of the major physiologic roles of IL-4 is as a B lymphocyte activation and differentiation factor (Rabin *et al.*, 1985; Oliver *et al.*, 1985). The protein was first isolated based on this activity. In this regard, IL-4 activates production of IgG1 (Vitetta *et al.*, 1985), but is also responsible for isotype switching in B cells from production of IgG to IgE immunoglobulins (Coffman *et al.*, 1986; Lebman and Coffman, 1988, Del Prete *et al.*, 1988). The effect of IL-4 on the *in vivo* regulation of IgE has been clearly demonstrated. Neutralization of IL-4 by treatment with a monoclonal anti-IL-4 antibody (Finkelman *et al.*, 1986) or a monoclonal antibody to the IL-4 receptor (Finkelman *et al.*, 1990) will block the IgE response. A recombinant soluble IL-4 receptor has been shown to inhibit IgE production by up to 85% *in vivo* (Sato *et al.*, 1993). IL-4 deficient mice produced by gene-targeting in murine embryonic stem cells have normal B and T cell development, but serum levels of IgG1 and IgE are strongly reduced (Kuhn *et al.*, 1991). IL-4 augmented IgE production leads to an atopic state (allergy/asthma) (Finkelman *et al.*, 1989; Katona *et al.*, 1991).

The IL-4 mediated up-regulation of IgG1 may play a role in the inflammation cascade. IgG1 has recently been shown to form immune complexes which bind to the cellular receptors for the Fc domain of immunoglobulins (FcRs) leading to an inflammatory response (Sylvestre and Ravetch, 1994; Ravetch, 1994). IL-4 transgenic mice have been produced that hyperexpress IL-4 (Tepper *et al.*, 1990). These mice have elevated levels of serum IgG1 and IgE and they develop allergic inflammatory disease. These findings demonstrate the critical role IL-4 plays in the humoral immune response.

Another major physiologic role for IL-4 is as a T lymphocyte growth factor (Hu-Li *et al.*, 1987; Spits *et al.*, 1987). IL-4 enhances the proliferation of precursors of cytotoxic T cells (CTLs) and their differentiation into active CD8⁺ CTLs (Widmer and Grabstein,

1987; Trenn, 1988). IL-4 appears to augment the IL-2 driven induction of lymphokine-activated killer (LAK) cells (Higuchi *et al.*, 1989), which have been shown to lyse a variety of tumor cell targets without major histocompatibility complex (MHC) restriction. The role played by IL-4 at this crucial nexus of T cell effector function is
5 fundamental to the success or failure of the immune response.

IL-4 has been shown to affect nonlymphoid hematopoietic cells in a variety of ways. IL-4 has been shown to modulate monocyte/macrophage growth (McInnes and Rennick, 1988; Jansen *et al.*, 1989) while enhancing their differentiation and cytotoxic activity for certain tumor cells (Crawford, *et al.*, 1987; Te Velde *et al.*, 1988). IL-4 also
10 has activity as a stimulant of mast cell growth (Mosmann *et al.*, 1986; Brown *et al.*, 1987), and increases production and recruitment of eosinophils (Tepper *et al.*, 1989).

IL-4 alone or in conjunction with other cytokines can promote the expression of a variety of cell-surface molecules on various cell types with diverse implications for disease. Specifically, IL-4 can interact with tumor necrosis factor (TNF) to selectively
15 enhance vascular cell adhesion molecule-1 (VCAM-1) expression contributing to T cell extravasation at sites of inflammation (Briscoe *et al.*, 1992). IL-4 alone or in combination with TNF or IFN-gamma has been shown to increase both MHC antigen and tumor-associated antigen expression on a variety of neoplastic cells (Hoon *et al.*, 1991).

As detailed above, IgG1 immune complexes bind to the cellular receptors for the
20 Fc domain of immunoglobulins (FcRs) leading to an inflammatory response. Inhibition of IL-4 and the subsequent reduction in IL-4 mediated IgG1 expression may prove efficacious against immune complex inflammatory disease states. Indeed, inhibitory ligands to IL-4 might also prevent the IL-4 mediated overexpression of VCAM-1, thus attenuating the ability of T cells to extravasate at sites of inflammation.

25 Inhibition of IL-4 activity with a monoclonal antibody, a recombinant soluble IL-4 receptor, or gene knock-out, results in a reduction of serum IgE levels. An inhibitory oligonucleotide ligand to IL-4 could be clinically effective against allergy and allergic asthma.

A recent report has described a disorder in bone homeostasis in transgenic mice
30 that inappropriately express IL-4 under the direction of the lymphocyte-specific proximal promoter for the *lck* gene (Lewis *et al.*, 1993). Bone disease in these mice resulted from

markedly decreased bone formation by osteoblasts, features identical to those found in human osteoporosis. Inhibiting this IL-4 mediated reduction in osteoblast activity may prove beneficial against osteoporosis.

Graft-versus-host disease (GVHD) is a major complication of human tissue transplantation. GVHD does not exist as a single clinical manifestation but can involve immunologic abnormalities ranging from immunodeficiency to systemic autoimmunities (Ferrara *et al.*, 1991). These systemic autoimmunities include clinical and serological manifestations of human systemic lupus erythematosus (SLE). Several murine models of SLE have been developed (Gleichmann *et al.*, 1982; van Rappard-van Der Veen *et al.*, 1982), and the induction of systemic GVHD in mice has been described (Via *et al.*, 1988). Two recent studies have shown *in vivo* efficacy of a mouse monoclonal antibody to IL-4 in preventing GVHD and SLE in these murine model systems (Umland *et al.*, 1992; Ushiyama *et al.*, 1995). These observations suggest that an inhibitor of human IL-4 may be effective in treatment of chronic systemic autoimmunities such as SLE and GVHD.

A variety of microbicidal infections are characterized by depressed cellular but enhanced humoral immune responses, which suggests a T_{H2} type of response to infection. This T_{H2} phenotype is characterized by T cell secretion of IL-4, as detailed earlier. IL-4 blocks the microbicidal activity of IFN-gamma activated macrophages in fighting *Leishmania major* infection (Liew *et al.*, 1989; Leal *et al.*, 1993). Inhibition of IL-4 would enhance the T_{H1} effector arm of the immune response enhancing cellular immunity and leading to the resolution of infection. Neutralization of IL-4 *in vivo* allows mice otherwise susceptible to *Leishmania major* infection to fight off the parasite and clear the infection (Heinzel *et al.*, 1989). Several informative studies have looked at the T_{H1}/T_{H2} phenotypic distinction in infected mice, and suggest a T_{H1} dominated response being most effective in fighting microbial infection (for a review, see Sher and Coffman, 1992).

IL-10

IL-10 is a cytokine produced by the Th2 cells, but not Th1 cells, and inhibits synthesis of most of all cytokines produced by Th1 cells but not Th2 cells (Mosmann *et al.*, 1991). In addition to the effect on CD4⁺ cells with Th1 phenotype, IL-10 also inhibits CD8⁺ T cells with "Th1-like" phenotype. IL-10 is a potent suppressor of macrophage activation. It can suppress the production of proinflammatory cytokines, including TNF α , IL-1, IL-6, IL-8 and IFN-gamma. Overall, these results suggest that IL-10 is a potent macrophage deactivator and an effective anti-inflammatory reagent. In addition, IL-10 prevents the IFN- γ -induced synthesis of nitric oxide, resulting in decreased resistance to intracellular parasites (Gazzinelli *et al.*, 1992).

Both human and mouse (hIL-10 and mIL-10, respectively) have been cloned and expressed (Moore *et al.*, 1990; Vieira *et al.*, 1991). The two cDNAs exhibit high degree of nucleotide sequence homology (>80%) throughout and encode very similar open reading frames (73% amino acid homology). Both proteins are expressed as noncovalent homodimers that are acid labile (Moore *et al.*, 1993). Whether monomers are equally bioactive is not clear yet. Based on the primary structure IL-10 has been categorized into the four α -helix bundle family of cytokines (Shanafelt *et al.*, 1991). Possibly due to high degree of sequence homology and similar structure hIL-10 has been shown to be active on mouse cells (Moore *et al.*, 1993) but not vice versa. hIL-10 is an 18 kDa polypeptide with no detectable carbohydrate; however, in mIL-10 there is one N-linked glycosylation. The recombinant hIL-10 has been expressed in CHO cells, COS7 cells, mouse myeloma cells, the baculovirus expression system and *E. coli*. The rIL-10 expressed in these systems have indistinguishable biological behavior (Moore *et al.*, 1993).

Parasitic infection often leads to polarized immune response of either Th1 or Th2 type which can mediate protection or susceptibility. The outcome of a parasitic infection depends on the nature of the parasite and the host. The best understood example is *Leishmania major* infection in mice. *L. major* is a protozoan parasite that establishes an intracellular infection in macrophages, where it is mainly localized in phagolysosomes. Activated macrophages can efficiently destroy the intracellular parasite and thus parasitic protection is achieved by macrophage activation. Nonactivated macrophages do not kill these organisms. As expected, activation of macrophages upon IFN-gamma treatment

enhanced the protection, whereas IL-4 and IL-10 blocked the increased microbicidal activity induced by IFN-gamma (Liew *et al.*, 1989). In most inbred strains (example, C57/BL6) cutaneous infection of *L. major* often leads to localized infection with spontaneous healing and confers resistance to reinfection. However, in BALB/c mice, *L. major* infection induces nonprotective immune response by producing IL-4. The antibody response mediated by IL-4 is ineffective and leads to death (Howard *et al.*, 1980). In healing strains a strong Th1 response has been noticed with high level of IFN- γ , whereas in susceptible BALB/c mice a nonproductive Th2 response with significant levels of IL-4 was found (Heinzel *et al.*, 1991). Further it was shown that a single injection of monoclonal anti-IFN-gamma antibody can convert a resistance into a susceptible mouse (Belosevic *et al.*, 1989). As expected, the treatment of BALB/c mice with anti-IL-4 antibody led to the development of Th1 response and healing (Sher & Coffman, 1992). Thus, depending on the nature of the pathogen, changing the immune response to a T cell subset with a protective phenotype can lead to therapeutic intervention of the disease state. Understanding the regulation between the Th1 and Th2 phenotype mediated by cytokines will help in designing cytokine-antagonist in therapeutics. The production of IL-10 is strongly increased in mice infected with various pathogens such as *Leishmania major*, *Schistosoma mansoni*, *Trypanosoma cruzi* and *Mycobacterium Leprae* (Sher *et al.*, 1992; Salgame *et al.*, 1991, Heinzel *et al.*, 1991).

When designing immune therapy to facilitate mounting the right arm of defense mechanism toward pathogens, it is important to maintain a balance between the two arms also. Th2-type responses may be important in controlling the tissue damage mediated by Th1 cells during the response to an intracellular infectious agent. Keeping some Th1 cells functioning in a predominantly Th2 environment can help abrogate damaging effects of Th1 by secreting IL-10 and IL-4. One extreme of the spectrum of Th1/Th2 is reflected in transgenic mice lacking the IL-10 gene (Kuhn *et al.*, 1993). The IL-10 deficient mouse is normal with respect to its development of T and B cell subsets. However these mice develop chronic enterocolitis (or inflammatory bowel disease) due to chronic inflammation via continuous overproduction of cytokines such as TNF α and IFN-gamma(Th1 response).

IL-12 can also induce the development of the Th1 subset. By using *Lysteria monocytogen*, an intracellular gram-positive bacterium, infection in antibody T cell receptor transgenic mice as a model it has been shown that IL-10 can block the production of IL-12 from macrophages (Hsieh *et al.*, 1993). Thus an IL-10-antagonist will tip the

5 Th1/Th2 population predominantly to Th2 type environment by 1, preventing the inhibition of the production of Th1 cytokines 2 by allowing the production of a cytokine that induces the development of Th1 subset.

With experimental evidence in hand it has been proposed that the resistance and/or progression to AIDS is dependent on a Th1/Th2 stage of an individual (Clerici & Shearer,

10 1993). This hypothesis is based on the findings that progression to AIDS is characterized by loss of IL-2 and IFN-gamma production (loss of Th1 response) with increase in IL-4 and IL-10 (acquired Th2 response). Many seronegatives (HIV-exposed individuals) generate a strong Th1-type response. It is important to note that after seroconversion both IL-4 and IL-10 levels go up at the expense of IL-4 and IFN-gamma. However, in

15 full-blown AIDS patients, Th2 response seems to be mediated by high levels of IL-10 but not with IL-4, the level of which goes down to normal in these individuals. An anti-IL-10 reagent may serve as a potential therapeutic in shifting the Th2 response to Th1 in AIDS patients to offer protection.

20 $\text{TNF}\alpha$

$\text{TNF}\alpha$ is an extracellular cytokine and a central mediator of the immune and inflammatory response (Beutler *et al.*, 1989; Vassalli, 1992). It is a homo-trimer (Smith *et al.*, 1987, Eck *et al.*, 1988), and has a subunit size of 17 kD. It circulates at concentrations of less than 5 pg/ml in healthy individuals (Dinarello *et al.*, 1993) and it can go as high as

25 1000 pg/ml in patients with sepsis syndrome (Casey *et al.*, 1993). The human $\text{TNF}\alpha$ is nonglycosylated, whereas in some other species (notably the mouse) glycosylation occurs on a single N-linked site in the mature protein, but the sugar moiety is not essential for biological activity (Beutler *et al.*, 1989). The human $\text{TNF}\alpha$ is acidic with a pH of 5.3 (Aggarwal *et al.*, 1985). Each $\text{TNF}\alpha$ subunit consists of an anti parallel β -sandwich and it

30 participates in a trimer formation by an edge-to-face packing of β -sheets. The structure of the $\text{TNF}\alpha$ trimer resembles the "jelly-roll" structural motif characteristic of viral coat

proteins (Jones *et al.*, 1989). $\text{TNF}\alpha$ is a relatively stable molecule and may be exposed to chaotropic agents such as urea, SDS, or guanidinium hydrochloride, and renatured with recovery of as much as 50% of the initial biological activity. The $\text{TNF}\alpha$ renaturability may reflect the limited number of internal disulfide bonds (one per monomer) required for
5 maintenance of structure (Beutler *et al.*, 1989).

Another related molecule, $\text{TNF}\beta$, has the same bioactivity as $\text{TNF}\alpha$. The interspecies sequence identity within the $\text{TNF}\alpha$ and $\text{TNF}\beta$ families is 71% and 61%, respectively (Beutler *et al.*, 1989). The sequence identity between h $\text{TNF}\alpha$ and h $\text{TNF}\beta$ is only 29% (Beutler *et al.*, 1989). Despite their low similarity, both h $\text{TNF}\alpha$ and h $\text{TNF}\beta$
10 bind to the same receptors with comparable affinities.

$\text{TNF}\alpha$ mediates its bioactivity through binding to cell surface receptors. The $\text{TNF}\alpha$ receptors are found on the surface of virtually all somatic cells tested (Vassalli, 1992). Two distinct $\text{TNF}\alpha$ receptors have been characterized of apparent molecular weights 55kD (p55 $\text{TNF}\alpha$ -R1) and 75kD (p75 $\text{TNF}\alpha$ -R2) (Hohmann *et al.*, 1989;
15 Brockhaus *et al.*, 1990; Loetscher *et al.*, 1991). Both receptors bind $\text{TNF}\alpha$ and $\text{TNF}\beta$ with high affinities ($K_d=0.3-0.6$ nM) (Loetscher *et al.*, 1990; Schall *et al.*, 1990; Pennica *et al.*, 1992).

$\text{TNF}\alpha$ has diverse activities, and thus is implicated in several diseases as follows:

Septic shock. Sepsis incidents have been increasing for the last 60 years and is the
20 most common cause of death in intensive care units in the United States (Parrillo, 1991). The mortality of septic shock remains at approximately 50% despite the standard use of aggressive antibiotics and cardiovascular support for the past 10 years (Parrillo, 1991). The evidence implicating $\text{TNF}\alpha$ in sepsis is as follows. Pretreatment of mice or baboons with monoclonal antibodies to $\text{TNF}\alpha$ protects them from lethal doses of *E. coli* LPS
25 (Beutler *et al.*, 1985). Anti- $\text{TNF}\alpha$ antibodies protect primates against lethal endotoxin sepsis and against lethal *S. aureus*-induced shock (Fiedler *et al.*, 1992; Hinshaw *et al.*, 1992). Soluble- $\text{TNF}\alpha$ -receptor (p55)-IgG-Fc fusions ($\text{TNF}\alpha$ receptor immunoadhesin) were found to protect mice from endotoxic shock, even when administered 1hr after endotoxin infusion. The same immunoadhesin was also effective against listeriosis in
30 mice (Haak-Frendscho *et al.*, 1994). Another immunoadhesin based on the p75 receptor

was also shown to be effective in lethal endotoxemia and it was functioning simultaneously as both TNF α carrier and TNF α antagonist (Mohler *et al.*, 1993).

Cachexia. *In vivo* administration of TNF α causes cachexia in mice (Oliff *et al.*, 1987). Therefore, TNF α antagonists may protect cancer or AIDS infected patients from
5 cachexia.

Cerebral malaria. High levels of TNF α are associated with poor prognosis in children with cerebral malaria, and antibodies to TNF α protect mice from cerebral complications of *Plasmodium berghei* infection (Grau *et al.*, 1987).

Arthritis. Antibodies to TNF α reduce the production of the inflammatory
10 cytokine, IL-1 in synovial cells (Brennan *et al.*, 1989). TNF α is an inducer of collagenase, the major destructive protease in rheumatoid arthritis (Brennan *et al.*, 1989). Anti-TNF α antibodies were found to ameliorate joint disease in murine collagen-induced arthritis (Williams *et al.*, 1992). Transgenic mice carrying the hTNF α gene develop arthritis which can be prevented by *in vivo* administration of a monoclonal antibody
15 against hTNF α (Keffer *et al.*, 1991).

Graft Rejection and Graft versus Host Reaction (GVHR). TNF α has been implicated in the acute phase of graft-versus-host disease and in renal allograft rejection. Antagonists of TNF α may then be able to prevent these life-threatening conditions. Anti-TNF α antibodies have been found to delay graft rejection in experimental animals
20 (Piguet, 1992). Also, injection of anti-TNF α antibodies during the acute phase of GVHR reduces mortality, and the severity of intestinal, epidermal, and alveolar lesions (Piguet, 1992). Clinical trials of the efficacy of anti-TNF α antibody in human bone marrow transplantation are underway.

AIDS. Studies of intracellular signal transduction pathways revealed that TNF α
25 induces proteins that bind to kB-like enhancer elements and thus takes part in the control of NF-kB-inducible genes (Lenardo *et al.*, 1989; Lowenthal *et al.*, 1989; Osborn *et al.*, 1989). The antiviral activity of TNF α at least in part is mediated by the interaction of NF-kB with a virus-inducible element in the β -interferon gene (Goldfeld *et al.*, 1989; Visvanathan *et al.*, 1989). By an analogous mechanism, TNF α appears to activate human
30 immunodeficiency virus type I (Duh *et al.*, 1989; Folks *et al.*, 1989). Therefore, TNF α

antagonists may prove useful in delaying the activation of the AIDS virus and may work in conjunction with other treatments in the cure of AIDS.

Parkinson's disease. Recently, elevated $\text{TNF}\alpha$ levels have been found in the brain and the cerebrospinal fluid of Parkinsonian patients (Mogi *et al.*, 1994). This report
5 speculates that elevated $\text{TNF}\alpha$ levels may be related to neuronal degeneration associated with the disease.

RANTES

RANTES is a small (MW 8-kD) highly basic (pI~9.5) chemokine that belongs to
10 the CC group (Schall, 1991; Baggiolini *et al.*, 1994). It does not appear to be glycosylated (Schall, 1991) and is a chemoattractant for monocytes (Schall *et al.*, 1990; Wang *et al.*, 1993; Wiedermann *et al.*, 1993), basophils (Bischoff *et al.*, 1993; Kuna *et al.*, 1993), eosinophils (Rot *et al.*, 1992), and $\text{CD4}^+/\text{UCHL1}^+$ T lymphocytes which are thought to be
15 prestimulated or primed helper T cells involved in memory T cell function (Schall *et al.*, 1990). RANTES is not only a chemoattractant but it also stimulates cells to release their effectors leading to tissue damage. For example, RANTES causes histamine release from basophils (Kuna *et al.*, 1992; Kuna *et al.*, 1993; Alam *et al.*, 1993). It also causes the secretion of eosinophil basic peptide (Alam *et al.*, 1993) and the production of oxygen free radicals (Rot *et al.*, 1992) by eosinophils.

20 Initially, it was thought that RANTES was synthesized by activated T cells but recently other cells were found to synthesize it very fast upon stimulation. RANTES mRNA is expressed late (3 to 5 days) after activation of resting T cells, whereas in fibroblasts, renal epithelial and mesangial cells, RANTES mRNA is quickly up-regulated by $\text{TNF}\alpha$ stimulation (Nelson *et al.*, 1993).

25 Receptors for RANTES have been identified. There is a promiscuous receptor on the surface of erythrocytes that binds all chemokines with a $K_d=5\text{nM}$ (Horuk *et al.*, 1993; Neote *et al.*, 1993). This receptor is thought to be a sink for chemokines to help in the establishment of chemotactic gradients. Signal transducing receptors have also been identified and cloned (Gao *et al.*, 1993; Neote *et al.*, 1993; Van-Riper *et al.*, 1993; Wang
30 *et al.*, 1993). Monocytes carry a G-protein coupled receptor that binds RANTES with estimated K_d of 400 pM, but also MCAF and MIP-1a with lower affinities (estimated K_d

of 6 and 1.6 nM respectively) (Wang *et al.*, 1993). A receptor molecule has been cloned from neutrophils that can bind RANTES with a lower affinity of about 50 nM (Gao *et al.*, 1993).

Disease State. RANTES antagonists may have therapeutic application in
5 inflammation. Blockage of the chemoattractant and effector cell activation properties of RANTES would block local inflammation and tissue damage. The mechanism of action of the RANTES antagonist will be the inhibition of RANTES binding to cell surface receptors.

RANTES is chemoattractant for monocytes, basophils, eosinophils and memory
10 lymphocytes. Basophils are the major source of mediators such as histamine and peptido-leukotrienes, and are an essential element of the late-phase responses to allergens in hypersensitivity diseases. These cells are also involved in other inflammatory pathologies, including certain autoimmune reactions, parasitic infections and inflammatory bowel diseases. In these conditions, basophil recruitment and activation is independent
15 of IgE. Numerous reports have accumulated over the years that describe the effects of a group of elusive stimuli operationally called "histamine-releasing factors." A large number of these elusive stimuli may well be contributed by RANTES.

Eosinophiles also are important in allergic inflammation, and together with lymphocytes, form prominent infiltrates in the bronchial mucosa of patients with asthma.
20 They are believed to be the cause of epithelial damage and the characteristic airway hyper-reactivity. The recruitment of lymphocytes of the Th2 type, which comigrate with eosinophiles into sites of late-phase reactions, is an important source of other chemoattractant cytokines and growth factors that prime eosinophils.

RANTES, with its effects on monocytes, basophils, eosinophils and lymphocytes
25 appears to be a potent stimulator of effector-cell accumulation and activation in chronic inflammatory diseases and in particular, allergic inflammation.

The recruitment system of inflammatory cells has some redundancy built into it. However, RANTES has some unique properties. It is a more potent chemoattractant than MCP-1 and MIP-1 α , while MCP-1 is more potent stimulator of histamine release from
30 basophils (Baggiolini *et al.*, 1994). RANTES causes the production of oxygen radicals by eosinophiles while MIP-1 α cannot (Rot *et al.*, 1992). RANTES is as potent as C5a in the

recruitment of eosinophiles, but not as potent a trigger of the eosinophil oxydation burst (Rot *et al.*, 1992). C5a is a very potent chemoattractant: however, it lacks the specificity of RANTES. It attracts not only basophils and eosinophils but also neutrophils. Since the eosinophils, but not the neutrophils, are important in the pathophysiology of some inflammatory conditions, such as the allergen-induced late-phase reaction and asthma, specific chemoattractants such as RANTES are expected to be involved.

Using *in situ* hybridization, RANTES expression has been found in interstitial mononuclear cells and proximal tubular epithelial cells in human kidney transplants undergoing rejection. Antibody staining revealed the presence of RANTES not only within the interstitial infiltrate and renal tubular epithelial cells but also in high abundance in inflamed endothelium (Wiedermann *et al.*, 1993). Based on these results a haptotactic mechanism was postulated. Haptotaxis is defined as cell migration induced by surface-bound gradients. The haptotactic mechanism was supported by *in vitro* experiments and anti-RANTES antibodies have been found to prevent that *in vitro* haptotaxis.

Human rheumatoid synovial fibroblasts express mRNA for RANTES and IL-8 after stimulation with TNF α and IL-1 β (Rathanaswami *et al.*, 1993). There is a differential regulation of expression of IL-8 and RANTES mRNA. Cycloheximide enhanced the mRNA levels for IL-8 and RANTES after stimulation with IL-1 β but reduced the levels of RANTES mRNA after stimulation with TNF α . Also, IL-4 down-regulates and IFN-gamma enhances the TNF α and IL-1 β induced increase in RANTES mRNA, whereas the induction of IL-8 mRNA by TNF α or IL-1 β was inhibited by IFN-gamma and augmented by IL-4. Moreover, the combination of TNF α and IL-1 β synergistically increased the level of IL-8 mRNA, whereas under the same conditions, the levels of RANTES mRNA were less than those induced with TNF α alone. These studies suggest that the synovial fibroblasts may participate in the ongoing inflammatory process in rheumatoid arthritis, and RANTES might be one of the participating effectors. The observed differential regulation of IL-8 and RANTES indicates that the type of cellular infiltrate and the progress of the inflammatory disease is likely to depend on the relative levels of stimulatory and inhibitory cytokines.

RANTES has also been implicated in atherosclerosis and possibly in postangioplasty restenosis (Schall, 1991). The participation of MCP-1 in atherosclerosis has been studied to a greater extent. Recently mRNAs for RANTES, MIP-1 α and MIP-1 β have been detected in *in situ* in normal carotid plaque and heart transplant atherosclerosis. RANTES mRNA is not detected in the same cells expressing MIP-1 α and MIP-1 β , but it is expressed in lymphocytes and macrophages typically more proximal to the lumen. The data argue for positive feed-back mechanisms for the CC chemokines and possible differential expression of these chemokines at various stages in the progression of arterial disease.

Finally, elevated RANTES levels have been correlated with endometriosis (Khorram *et al.*, 1993). RANTES levels were elevated in pelvic fluids from women with endometriosis, and these levels correlate with the severity of the disease.

Protein Homology between Human and Animal. The murine RANTES has been cloned (Schall *et al.*, 1992). Sequence analysis revealed 85% amino acid identity between the human and mouse proteins. The human and murine RANTES exhibit immune crossreactivity. Boyden chamber chemotaxis experiments reveal some lack of species specificity in monocyte chemoattractant potential, as recombinant muRANTES attracts human monocytes in a dose-dependent fashion *in vitro*. Also, hRANTES transfection into mouse tumor cell lines produce tumors in which the secretion of hRANTES by those tumors correlates with increased murine monocyte infiltration *in vivo* (Schall *et al.*, 1992).

SELEX

A method for the *in vitro* evolution of nucleic acid molecules with highly specific binding to target molecules has been developed. This method, Systematic Evolution of Ligands by EXponential enrichment, termed SELEX, is described in United States Patent Application Serial No. 07/536,428, entitled "Systematic Evolution of Ligands by Exponential Enrichment," now abandoned, United States Patent Application Serial No. 07/714,131, filed June 10, 1991, entitled "Nucleic Acid Ligands," United States Patent Application Serial No. 07/931,473, filed August 17, 1992, entitled "Nucleic Acid Ligands," now United States Patent No. 5,270,163 (see also PCT/US91/04078), each of which is herein specifically incorporated by reference. Each of these applications,

collectively referred to herein as the SELEX Patent Applications, describes a fundamentally novel method for making a nucleic acid ligand to any desired target molecule.

The SELEX method involves selection from a mixture of candidate
5 oligonucleotides and step-wise iterations of binding, partitioning and amplification, using the same general selection scheme, to achieve virtually any desired criterion of binding affinity and selectivity. Starting from a mixture of nucleic acids, preferably comprising a segment of randomized sequence, the SELEX method includes steps of contacting the
10 mixture with the target under conditions favorable for binding, partitioning unbound nucleic acids from those nucleic acids which have bound specifically to target molecules, dissociating the nucleic acid-target complexes, amplifying the nucleic acids dissociated from the nucleic acid-target complexes to yield a ligand-enriched mixture of nucleic acids, then reiterating the steps of binding, partitioning, dissociating and amplifying through as many cycles as desired to yield highly specific, high affinity nucleic acid ligands to the
15 target molecule.

The basic SELEX method has been modified to achieve a number of specific objectives. For example, United States Patent Application Serial No. 07/960,093, filed October 14, 1992, entitled "Method for Selecting Nucleic Acids on the Basis of Structure," describes the use of SELEX in conjunction with gel electrophoresis to select nucleic acid
20 molecules with specific structural characteristics, such as bent DNA. United States Patent Application Serial No. 08/123,935, filed September 17, 1993, entitled "Photoselection of Nucleic Acid Ligands" describes a SELEX based method for selecting nucleic acid ligands containing photoreactive groups capable of binding and/or photocrosslinking to and/or photoinactivating a target molecule. United States Patent Application Serial No.
25 08/134,028, filed October 7, 1993, entitled "High-Affinity Nucleic Acid Ligands That Discriminate Between Theophylline and Caffeine," describes a method for identifying highly specific nucleic acid ligands able to discriminate between closely related molecules, termed Counter-SELEX. United States Patent Application Serial No. 08/143,564, filed October 25, 1993, entitled "Systematic Evolution of Ligands by EXponential Enrichment:
30 Solution SELEX," describes a SELEX-based method which achieves highly efficient partitioning between oligonucleotides having high and low affinity for a target molecule.

United States Patent Application Serial No. 07/964,624, filed October 21, 1992, entitled "Methods of Producing Nucleic Acid Ligands" describes methods for obtaining improved nucleic acid ligands after SELEX has been performed. United States Patent Application Serial No. 08/400,440, filed March 8, 1995, entitled "Systematic Evolution of Ligands by
5 EXponential Enrichment: Chemi-SELEX," describes methods for covalently linking a ligand to its target.

The SELEX method encompasses the identification of high-affinity nucleic acid ligands containing modified nucleotides conferring improved characteristics on the ligand, such as improved *in vivo* stability or improved delivery characteristics. Examples of such
10 modifications include chemical substitutions at the ribose and/or phosphate and/or base positions. SELEX-identified nucleic acid ligands containing modified nucleotides are described in United States Patent Application Serial No. 08/117,991, filed September 8, 1993, entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides," that describes oligonucleotides containing nucleotide derivatives chemically modified at
15 the 5- and 2'-positions of pyrimidines. United States Patent Application Serial No. 08/134,028, *supra*, describes highly specific nucleic acid ligands containing one or more nucleotides modified with 2'-amino (2'-NH₂), 2'-fluoro (2'-F), and/or 2'-O-methyl (2'-OMe). United States Patent Application Serial No. 08/264,029, filed June 22, 1994, entitled "Novel Method of Preparation of 2' Modified Pyrimidine Intramolecular
20 Nucleophilic Displacement," describes oligonucleotides containing various 2'-modified pyrimidines.

The SELEX method encompasses combining selected oligonucleotides with other selected oligonucleotides and non-oligonucleotide functional units as described in United States Patent Application Serial No. 08/284,063, filed August 2, 1994, entitled
25 "Systematic Evolution of Ligands by Exponential Enrichment: Chimeric SELEX" and United States Patent Application Serial No. 08/234,997, filed April 28, 1994, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Blended SELEX," respectively. These applications allow the combination of the broad array of shapes and other properties, and the efficient amplification and replication properties, of
30 oligonucleotides with the desirable properties of other molecules. Each of the above

described patent applications which describe modifications of the basic SELEX procedure are specifically incorporated by reference herein in their entirety.

BRIEF SUMMARY OF THE INVENTION

5 The present invention includes methods of identifying and producing nucleic acid ligands to cytokines and the nucleic acid ligands so identified and produced. In particular, RNA sequences are provided that are capable of binding specifically to IFN-gamma, IL-4, IL-10, and TNF α . In addition, DNA sequences are provided that are capable of binding specifically to RANTES. Specifically included in the invention are the RNA ligand
10 sequences shown in Tables 3, 4, 7, 8, 10, and 12 (SEQ ID NOS:7-73; 79-185; 189-205; 209-255).

 Further included in this invention is a method of identifying nucleic acid ligands and nucleic acid ligand sequences to a cytokine comprising the steps of (a) preparing a candidate mixture of nucleic acids, (b) contacting the candidate mixture of nucleic acids
15 with a cytokine, (c) partitioning between members of said candidate mixture on the basis of affinity to the cytokine, and (d) amplifying the selected molecules to yield a mixture of nucleic acids enriched for nucleic acid sequences with a relatively higher affinity for binding to the cytokine.

 Further included in this invention is a method of identifying nucleic acid ligands and nucleic acid ligand sequences to a cytokine selected from the group consisting of
20 IFN-gamma, IL-4, IL-10, TNF α , and RANTES comprising the steps of (a) preparing a candidate mixture of nucleic acids, (b) contacting the candidate mixture of nucleic acids with said cytokine, (c) partitioning between members of said candidate mixture on the basis of affinity to said cytokine, and (d) amplifying the selected molecules to yield a
25 mixture of nucleic acids enriched for nucleic acid sequences with a relatively higher affinity for binding to said cytokine.

 More specifically, the present invention includes the RNA ligands to IFN-gamma, IL-4, IL-10, and TNF α identified according to the above-described method, including those ligands shown in Tables 3, 4, 7, 8, 10, and 12 (SEQ ID NOS:7-73; 79-185; 189-205;
30 209-255). Also included are RNA ligands to IFN-gamma, IL-4, IL-10, and TNF α that are substantially homologous to any of the given ligands and that have substantially the same

ability to bind IFN-gamma, IL-4, IL-10, and TNF α and inhibit the function of IFN-gamma, IL-4, IL-10, and TNF α . Further included in this invention are nucleic acid ligands to IFN-gamma, IL-4, IL-10, and TNF α that have substantially the same structural form as the ligands presented herein and that have substantially the same ability to bind
5 IFN-gamma, IL-4, IL-10, and TNF α and inhibit the function of IFN-gamma, IL-4, IL-10, and TNF α .

The present invention also includes modified nucleotide sequences based on the nucleic acid ligands identified herein and mixtures of the same.

10 DETAILED DESCRIPTION OF THE INVENTION

This application describes high-affinity nucleic acid ligands to cytokines identified through the method known as SELEX. SELEX is described in U.S. Patent Application Serial No. 07/536,428, entitled Systematic Evolution of Ligands by EXponential Enrichment, now abandoned, U.S. Patent Application Serial No. 07/714,131, filed June
15 10, 1991, entitled Nucleic Acid Ligands, United States Patent Application Serial No. 07/931,473, filed August 17, 1992, entitled Nucleic Acid Ligands, now United States Patent No. 5,270,163, (see also PCT/US91/04078). These applications, each specifically incorporated herein by reference, are collectively called the SELEX Patent Applications.

In its most basic form, the SELEX process may be defined by the following series
20 of steps:

- 1) A candidate mixture of nucleic acids of differing sequence is prepared. The candidate mixture generally includes regions of fixed sequences (i.e., each of the members of the candidate mixture contains the same sequences in the same location) and regions of randomized sequences. The fixed sequence regions are selected either: (a) to assist in the
25 amplification steps described below, (b) to mimic a sequence known to bind to the target, or (c) to enhance the concentration of a given structural arrangement of the nucleic acids in the candidate mixture. The randomized sequences can be totally randomized (i.e., the probability of finding a base at any position being one in four) or only partially randomized (e.g., the probability of finding a base at any location can be selected at any
30 level between 0 and 100 percent).

2) The candidate mixture is contacted with the selected target under conditions favorable for binding between the target and members of the candidate mixture. Under these circumstances, the interaction between the target and the nucleic acids of the candidate mixture can be considered as forming nucleic acid-target pairs between the target and those nucleic acids having the strongest affinity for the target.

3) The nucleic acids with the highest affinity for the target are partitioned from those nucleic acids with lesser affinity to the target. Because only an extremely small number of sequences (and possibly only one molecule of nucleic acid) corresponding to the highest affinity nucleic acids exist in the candidate mixture, it is generally desirable to set the partitioning criteria so that a significant amount of the nucleic acids in the candidate mixture (approximately 5-50%) are retained during partitioning.

4) Those nucleic acids selected during partitioning as having the relatively higher affinity to the target are then amplified to create a new candidate mixture that is enriched in nucleic acids having a relatively higher affinity for the target.

5) By repeating the partitioning and amplifying steps above, the newly formed candidate mixture contains fewer and fewer weakly binding sequences, and the average degree of affinity of the nucleic acids to the target will generally increase. Taken to its extreme, the SELEX process will yield a candidate mixture containing one or a small number of unique nucleic acids representing those nucleic acids from the original candidate mixture having the highest affinity to the target molecule.

The SELEX Patent Applications describe and elaborate on this process in great detail. Included are targets that can be used in the process; methods for partitioning nucleic acids within a candidate mixture; and methods for amplifying partitioned nucleic acids to generate enriched candidate mixture. The SELEX Patent Applications also describe ligands obtained to a number of target species, including both protein targets where the protein is and is not a nucleic acid binding protein.

The nucleic acid ligands described herein can be complexed with a lipophilic compound (e.g., cholesterol) or attached to or encapsulated in a complex comprised of lipophilic components (e.g., a liposome). The complexed nucleic acid ligands can enhance the cellular uptake of the nucleic acid ligands by a cell for delivery of the nucleic acid ligands to an intracellular target. U.S. Patent Application No. 08/434,465, filed May 4,

1995, entitled "Nucleic Acid Ligand Complexes," which is incorporated in its entirety herein, describes a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or a non-immunogenic, high molecular weight compound.

5 The methods described herein and the nucleic acid ligands identified by such methods are useful for both therapeutic and diagnostic purposes. Therapeutic uses include the treatment or prevention of diseases or medical conditions in human patients. Diagnostic utilization may include both *in vivo* or *in vitro* diagnostic applications. The SELEX method generally, and the specific adaptations of the SELEX method taught and
10 claimed herein specifically, are particularly suited for diagnostic applications. SELEX identifies nucleic acid ligands that are able to bind targets with high affinity and with surprising specificity. These characteristics are, of course, the desired properties one skilled in the art would seek in a diagnostic ligand.

 The nucleic acid ligands of the present invention may be routinely adapted for
15 diagnostic purposes according to any number of techniques employed by those skilled in the art. Diagnostic agents need only be able to allow the user to identify the presence of a given target at a particular locale or concentration. Simply the ability to form binding pairs with the target may be sufficient to trigger a positive signal for diagnostic purposes. Those skilled in the art would also be able to adapt any nucleic acid ligand by procedures
20 known in the art to incorporate a labeling tag in order to track the presence of such ligand. Such a tag could be used in a number of diagnostic procedures. The nucleic acid ligands to cytokines described herein may specifically be used for identification of the cytokine proteins.

 SELEX provides high affinity ligands of a target molecule. This represents a
25 singular achievement that is unprecedented in the field of nucleic acids research. The present invention applies the SELEX procedure to the specific target. In the Example section below, the experimental parameters used to isolate and identify the nucleic acid ligands to cytokines are described.

 In order to produce nucleic acids desirable for use as a pharmaceutical, it is
30 preferred that the nucleic acid ligand (1) binds to the target in a manner capable of achieving the desired effect on the target; (2) be as small as possible to obtain the desired

effect; (3) be as stable as possible; and (4) be a specific ligand to the chosen target. In most situations, it is preferred that the nucleic acid ligand have the highest possible affinity to the target.

In co-pending and commonly assigned U.S. Patent Application Serial No. 07/964,624, filed October 21, 1992 ('624), methods are described for obtaining improved nucleic acid ligands after SELEX has been performed. The '624 application, entitled Methods of Producing Nucleic Acid Ligands, is specifically incorporated herein by reference.

This invention includes the SELEX process for identification of nucleic acid ligands of cytokines. Cytokines are a diverse group of small proteins that mediate cell signaling/communication. Cytokines include immune/ hematopoietins (e.g., EPO, GM-CSF, G-CSF, LIF, OSM, CNTF, GH, PRL, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12), interferons (e.g., IFN α , IFN β , IFN-gamma), TNF-related molecules (e.g., TNF α , IFN β , gp³⁹ (CD40-L), CD27-L, CD30-L, NGF), and chemokines (e.g., PF4, PBP, gro α , MIG, ENA-78, MIP1 α , MIP1 β , MCP-1, I-309, HC14, C10, RANTES, IL-8, MIP-1). In one embodiment, cytokines are derived from T-lymphocytes.

In the present invention, SELEX experiments were performed in order to identify RNA with specific high affinity for the cytokines IFN-gamma, IL-4, IL-10, hTNF α , and RANTES from degenerate libraries containing 30 or 40 random positions (40N for IFN-gamma, IL-4, IL-10 and RANTES; 30N for hTNF α) (Tables 1, 5, 9, 11, and 16). This invention includes the specific RNA ligands to IFN-gamma, IL-4, IL-10, and TNF α shown in Tables 3, 4, 7, 8, 10, and 12 (SEQ ID NOS:7-73; 79-185; 189-205; 209-255), identified by the methods described in Examples 1, 3, 5, 7, and 12. This invention further includes RNA ligands to IFN-gamma, IL-4, IL-10, and TNF α which inhibit the function of IFN-gamma, IL-4, IL-10, and TNF α . This invention further includes DNA ligands to RANTES which inhibit the function of RANTES. The scope of the ligands covered by this invention extends to all nucleic acid ligands of IFN-gamma, IL-4, IL-10, TNF α , and RANTES modified and unmodified, identified according to the SELEX procedure. More specifically, this invention includes nucleic acid sequences that are substantially homologous to the ligands shown in Tables 3, 4, 7, 8, 10, and 12 (SEQ ID NOS:7-73; 79-185; 189-205; 209-255). By substantially homologous it is meant a degree of primary

sequence homology in excess of 70%, most preferably in excess of 80%. A review of the sequence homologies of the ligands of IFN-gamma, IL-4, IL-10, and TNF α shown in Tables 3, 4, 7, 8, 10, and 12 (SEQ ID NOS:7-73; 79-185; 189-205; 209-255) shows that sequences with little or no primary homology may have substantially the same ability to bind IFN-gamma, IL-4, IL-10, and TNF α . For these reasons, this invention also includes nucleic acid ligands that have substantially the same structure and ability to bind IFN-gamma, IL-4, IL-10, and TNF α as the nucleic acid ligands shown in Tables 3, 4, 7, 8, 10, and 12 (SEQ ID NOS:7-73; 79-185; 189-205; 209-255). Substantially the same ability to bind IFN-gamma, IL-4, IL-10, and TNF α means that the affinity is within one or two orders of magnitude of the affinity of the ligands described herein. It is well within the skill of those of ordinary skill in the art to determine whether a given sequence -- substantially homologous to those specifically described herein -- has substantially the same ability to bind IFN-gamma, IL-4, IL-10, and TNF α .

This invention also includes the ligands as described above, wherein certain chemical modifications are made in order to increase the *in vivo* stability of the ligand or to enhance or mediate the delivery of the ligand. Examples of such modifications include chemical substitutions at the sugar and/or phosphate and/or base positions of a given nucleic acid sequence. See, e.g., U.S. Patent Application Serial No. 08/117,991, filed September 9, 1993, entitled High Affinity Nucleic Acid Ligands Containing Modified Nucleotides which is specifically incorporated herein by reference. Other modifications are known to one of ordinary skill in the art. Such modifications may be made post-SELEX (modification of previously identified unmodified ligands) or by incorporation into the SELEX process.

As described above, because of their ability to selectively bind IFN-gamma, IL-4, IL-10, hTNF α , and RANTES, the nucleic acid ligands to IFN-gamma, IL-4, IL-10, TNF α , and RANTES described herein are useful as pharmaceuticals. This invention, therefore, also includes a method of inhibiting cytokine function by administration of a nucleic acid ligand capable of binding to a cytokine.

Therapeutic compositions of the nucleic acid ligands may be administered parenterally by injection, although other effective administration forms, such as intraarticular injection, inhalant mists, orally active formulations, transdermal

iontophoresis or suppositories, are also envisioned. One preferred carrier is physiological saline solution, but it is contemplated that other pharmaceutically acceptable carriers may also be used. In one preferred embodiment, it is envisioned that the carrier and the ligand constitute a physiologically-compatible, slow release formulation. The primary solvent in
5 such a carrier may be either aqueous or non-aqueous in nature. In addition, the carrier may contain other pharmacologically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the carrier may contain still other pharmacologically-acceptable excipients for modifying or maintaining the stability, rate of
10 dissolution, release, or absorption of the ligand. Such excipients are those substances usually and customarily employed to formulate dosages for parental administration in either unit dose or multi-dose form.

Once the therapeutic composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder.
15 Such formulations may be stored either in a ready to use form or requiring reconstitution immediately prior to administration. The manner of administering formulations containing nucleic acid ligands for systemic delivery may be via subcutaneous, intramuscular, intravenous, intranasal or vaginal or rectal suppository.

The following Examples are provided to explain and illustrate the present
20 invention and are not intended to be limiting of the invention.

EXAMPLE 1. EXPERIMENTAL PROCEDURES FOR 2'-NH₂ AND 2'-F-MODIFIED LIGANDS TO IFN-GAMMA

This example provides general procedures followed and incorporated in Example 2
25 for the evolution of nucleic acid ligands to IFN-gamma.

A. Oligonucleotides

2'F modified CTP and UTP were prepared according to the method of Pieken *et al.*, 1991. 2'NH₂ modified CTP and UTP were prepared according to the method of McGee *et al.*, U.S. Patent Application No. 08/264,029, filed June 22, 1994, which is incorporated
30 herein by reference (see also McGee *et al.* 1995). DNA oligonucleotides were synthesized by Operon Technologies (Alameda CA).

B. SELEX

The SELEX procedure has been described in detail in U.S. Patent No. 5,270,163 (see also Tuerk and Gold, 1990; Gold *et al.*, 1993). Three SELEX procedures were performed to evolve high affinity ligands to IFN-gamma. Each SELEX procedure utilized
5 RNA pools containing pyrimidines modified at the 2' position as follows, 1) 2'F-CTP and 2'F-UTP referred to as 2'F, 2) 2'F-CTP and 2'NH₂-UTP referred to as 2'F/NH₂, and 3) 2'NH₂-CTP and 2'NH₂-UTP referred to as 2'NH₂. For each SELEX, the DNA template 40N7 was designed to contain 40 random nucleotides, flanked by 5' and 3' regions of fixed sequence (Table 1; SEQ ID NO:1). The fixed regions include DNA primer annealing sites
10 for PCR and cDNA synthesis as well as the consensus T7 promoter region to allow *in vitro* transcription.

Single-stranded DNA primers and templates were synthesized and amplified into double-stranded transcribable templates by PCR. Preparation of the initial pool of RNA molecules involved PCR amplification of 1000 pmoles of single-stranded template (Table
15 1; SEQ ID NO:1) and 2500 pmoles of both the 5'- (5P7; SEQ ID NO:2) and 3'- (3P7; SEQ ID NO:3) primers. These were incubated in a reaction mixture containing 50 mM KCl, 10 mM Tris-Cl (pH 8.3), 3 mM MgCl₂, 0.5 mM of each dATP, dCTP, dGTP, and dTTP. *Taq* DNA Polymerase (Perkin-Elmer, Foster City CA) at 0.1 U/ μ l was added and the reaction incubated at 97°C for 3 min to denature the template and primers. Following the initial
20 denaturing step, the reaction was cycled 10 times at 93°C for 30 sec, 53°C for 30 sec, and 72°C for 1 min to denature, anneal, and extend, respectively, the primers and template. To get an accurate concentration of double-stranded PCR product for the initial round of SELEX, the PCR product was purified using QIAquick-spin PCR purification columns (QIAGEN Inc., Chatsworth CA) as specified by the manufacturer.

25 For *in vitro* transcription using modified nucleotides 200 pmoles (final concentration of 1 μ M) of double-stranded DNA template was incubated in a reaction mixture containing 40 mM Tris-Cl (pH 8.0), 12 mM MgCl₂, 5 mM DTT, 1 mM spermidine, 0.002% Triton X-100, 4% PEG 8000, 0.5 μ M α -³²P-ATP, 5 U/ μ l T7 RNA Polymerase (Davanloo *et al.*, 1984), and concentrations of other nucleotides as follows, 1)
30 for the 2'F SELEX: 1 mM ATP and GTP, 3 mM 2'F-CTP and 2'F-UTP, 2) for the 2'F/NH₂ SELEX: 1 mM ATP, GTP, and 2'NH₂-UTP and 3 mM 2'F-CTP, and 3) for the

2'NH₂ SELEX: 1 mM ATP, GTP, 2'NH₂-CTP, and 2'NH₂-UTP. These incubations were performed in a 37°C incubator for between 6 hrs and overnight. Typically the RNA was purified by gel purification and elution. To expedite the process, for rounds 11, 12, and 14-17 the RNA was purified using Bio-Spin 6 chromatography columns (Bio-Rad Laboratories, Hercules CA) according to manufacturer's specifications. To reduce background, the RNA was pre-filtered prior to all rounds of SELEX except rounds 1, 2, 4, 6, 14, and 16. The pre-filtration step involved bringing the RNA up to 200 µl in phosphate buffered saline (PBS), modified to contain 1mM Mg²⁺ ions, (138 mM NaCl, 2.7 mM KCl, 8.1 mM Na₂HPO₄, 1.1 mM KH₂PO₄, 1mM MgCl₂, pH 7.4), (mPBS), and passing this RNA solution through three filter discs (0.45 µm, nitrocellulose/ cellulose acetate, Millipore Corporation, Bedford MA) pre-wetted with mPBS.

For initial binding, 1000 pmoles of RNA were incubated with human IFN-gamma protein in binding buffer, (mPBS plus 0.01% human serum albumin (HSA)), for 5-10 min at 37°C to allow binding to occur. Human recombinant IFN-gamma used in this SELEX procedure was purchased from two different sources. The first three rounds of both the 2'F and 2'F/NH₂ SELEX were performed with protein obtained from Upstate Biotechnology, Lake Placid NY. The subsequent rounds of these two SELEX procedures as well as the entire 2'NH₂ SELEX were performed with protein obtained from Genzyme Inc., Cambridge MA. For each round of SELEX the concentration of RNA and protein was carefully chosen to provide optimum stringency. Increased stringency was obtained during rounds 8-13 of SELEX by adding NaCl to the binding buffer to bring the final chloride ion concentration up to 250 mM. Preliminary experiments had shown that IFN-gamma had a tendency to aggregate at high protein concentrations. To prevent the evolution of RNA species having an affinity for this aggregated IFN-gamma, beginning with round 4 of SELEX and for all subsequent rounds of the SELEX procedure, the binding mix was centrifuged at 16,000 x g for 3 min in an eppendorf centrifuge before nitrocellulose filter partitioning. IFN-gamma/RNA complexes were separated from unbound RNA by nitrocellulose filter partitioning described below.

For nitrocellulose partitioning, the 2'F and 2'F/NH₂ SELEX procedures used 0.2 µm pore size pure nitrocellulose filters (Schleicher & Schuell, Keene NH) for the first two rounds of SELEX. All subsequent rounds of these two SELEX procedures and the entire

2'NH₂ SELEX were performed with 0.45 μ m pore size nitrocellulose/cellulose acetate mixed matrix filters (Millipore Corporation, Bedford MA). Filter discs were placed into a vacuum manifold and wetted with 5 ml of mPBS buffer. The IFN-gamma/RNA binding mix was aspirated through the filter discs which were immediately washed with 5 ml of mPBS buffer. To further increase stringency and reduce background for rounds 8-13, and 15, this washing step was modified to include washing of the filter discs with 15 ml 0.5 M urea followed by 20 ml mPBS buffer. Bound RNA was isolated from filters by extraction in a solution of 400 ml phenol (equilibrated in Tris-Cl, pH 8.0)/300 ml 7 M urea (freshly prepared). The filters were bathed in the phenol/urea solution at room temperature for 30 min and at 95°C for 2 min. The RNA was phenol/chloroform extracted and ethanol precipitated with 20 mg tRNA.

The RNA was reverse transcribed into cDNA by addition of 50 pmoles DNA primer, 0.4 mM each of dNTPs, and 1 U/ μ l AMV reverse transcriptase (AMV RT) (Life Sciences, Inc., St. Petersburg FL) in buffer containing 50 mM Tris-Cl (pH 8.3), 60 mM NaCl, 6 mM Mg(OAc)₂, 10 mM DTT. The reaction was incubated at 37°C for 30 min then 48°C for 30 min then 70°C for 10 min, to ensure the melting of secondary structure present in the isolated RNA.

To begin a new round of SELEX, the cDNA was PCR amplified by addition of 250 pmoles of both the 5' (5P7; SEQ ID NO:2) and 3' (3P7; SEQ ID NO:3) primer in reaction conditions identical to those detailed above. The number of cycles of PCR required to amplify the cDNA was carefully calculated for each round of SELEX so that 250 pmoles double-stranded DNA template would be used to initiate the next round of SELEX.

C. Equilibrium Dissociation Constants (Kds)

The determination of equilibrium dissociation constants (Kds) for RNA pools was made subsequent to rounds 5, 8, 12, and 17 to monitor the progress of each SELEX. The Kds of RNA pools for mouse IFN-gamma (Genzyme Inc., Cambridge MA) were also determined after rounds 8 and 17. Kds were determined for individual ligands after cloning and sequencing of RNA pools and truncations (described below). Nitrocellulose filter binding was used to determine Kds as follows: filter discs were placed into a vacuum manifold and wetted with 5 ml of mPBS buffer. ³²P-labeled-RNA was incubated

with serial dilutions of IFN-gamma in binding buffer for 5-10 min at 37°C to allow binding to occur. Binding mixes were centrifuged as described above to remove aggregates, aspirated through the filter discs, and then immediately washed with 5 ml mPBS buffer. The filter discs were dried and counted in a liquid scintillation counter
5 (Beckmann Instruments, Palo Alto CA). Equilibrium dissociation constants were determined by least square fitting of the data points using the Kaleidagraph™ graphics program (Synergy Software, Reading PA). Many ligands and evolved RNA pools yield biphasic binding curves. Biphasic binding can be described as the binding of two affinity species that are not in equilibrium. Biphasic binding constants were calculated according
10 to standard procedures. Kds were determined by least square fitting of the data points using the Kaleidagraph™ graphics program.

D. Cloning and Sequencing

After the 17th round of SELEX, RNA molecules were reverse transcribed to cDNA
15 and made double-stranded by PCR amplification with primers containing recognition sites for the restriction endonucleases *Hind* III (Table 1; 5' primer 5P7H; SEQ ID NO:4) and *Bam* HI (Table 1; 3' primer 3P7B; SEQ ID NO:5). Using these restriction sites the DNA sequences were inserted directionally into the pUC19 vector. These recombinant plasmids were transformed into Epicurian coli JM109 competent cells (Stratagene, La Jolla CA).
20 Plasmid DNA was prepared with the PERFECTprep™ plasmid DNA kit (5 prime--->3 prime, Boulder CO). Plasmid clones were sequenced using a PCR sequencing protocol (Adams *et al.*, 1991) using PCR sequencing primer pUC19F30 (SEQ ID NO:6).

E. Ligand Truncation

25 Boundary experiments were carried out to determine the minimal sequence necessary for high affinity binding of the RNA ligands to IFN-gamma using end-labeled RNA. Prior to end-labeling, RNA transcribed with T7 RNA polymerase was gel purified by UV shadowing. The 5'-end of 20 pmoles of each RNA was dephosphorylated in a reaction mixture containing 20 mM Tris-Cl (pH 8.0), 10 mM MgCl₂ and 0.1 U/μl shrimp
30 alkaline phosphatase (SAP), (United States Biochemical, Cleveland OH) by incubating for 30 min at 37°C. Alkaline phosphatase activity was destroyed by incubating for 30 min at

70°C. RNA was subsequently 5'-end labeled in a reaction mixture containing 50 mM Tris-Cl (pH 7.5), 10 mM MgCl₂, 5 mM DTT, 0.1 mM EDTA, 0.1 mM spermidine, 0.75 mM γ-³²P-ATP and 1 U/μl T4 polynucleotide kinase (New England Biolabs, Beverly MA) by incubating for 30 min at 37°C.

- 5 3'-end-labeling of 20 pmoles of each RNA was performed in a reaction mixture containing 50 mM Tris-Cl (pH 7.8), 10 mM MgCl₂, 10 mM β-mercaptoethanol, 1 mM ATP, 0.9 mM (5'-³²P)pCp and 1 U/μl T4 RNA ligase (New England Biolabs, Beverly MA) by incubating for 18 hrs at 4°C. 5'- and 3'- end-labeled RNAs were gel band purified on a 12%, 8M urea, polyacrylamide gel. After partial alkaline hydrolysis of the
- 10 end-labeled RNA by addition of Na₂CO₃ to a final concentration of 50 mM and incubation in a boiling water bath for 3 min, radiolabeled RNA ligands were incubated with IFN-gamma at three different protein concentrations, 1) 5-fold below the approximate K_d, 2) at the approximate K_d, and 3) 5-fold above the approximate K_d. Protein-bound RNA was separated by nitrocellulose partitioning. RNA truncates were analyzed on a
- 15 high-resolution denaturing 12% polyacrylamide gel. To orient the sequences, a ladder of radioactively labeled ligands terminating with G-residues was generated by RNase T1 digestion of end-labeled RNA. The T1 digest was carried out in a reaction mixture containing 7 M urea, 20 mM sodium citrate (pH 5.0), 1 mM EDTA and 5 units RNase T1 (Boehringer Mannheim, Indianapolis IN) by incubating for 5 min at 50°C.
- 20 Complementary single-stranded DNA oligonucleotides containing the sequence of the T7 promoter (5'-TAATACGACTCACTATAG-3'; fragment of SEQ ID NO:2) and the sequence of the truncated ligand were annealed to form a double-stranded template for transcription of each truncated ligand.

25 **F. Receptor Binding Competitions**

- Human lung carcinoma cells (A549; ATCC) were plated in 24-well plates at a density of 5 X 10⁵ cells/well in RPMI 1640 plus 10% fetal bovine serum (FBS) and incubated overnight or until confluent. The cells were washed 3 times with PBS. Growth media was replaced with 200 μl RPMI 1640 plus 0.2% human serum albumin/0.02%
- 30 sodium azide/20 mM Hepes, pH 7.4 together with increasing amounts (20 pg/ml-100 ng/ml) of ¹²⁵I-IFN-gamma (New England Nuclear) with or without an excess (200 fold) of

unlabeled IFN-gamma. Incubations were carried out at 4°C with shaking for 2 hrs. The cells were washed 2 times with cold PBS to remove free IFN and detached with 0.5% SDS. Cell-associated ^{125}I -IFN-gamma was determined by measuring the radioactivity of the detached cells in a gamma counter. The data was corrected for nonspecific binding and the affinity of ^{125}I -IFN-gamma was determined by Scatchard analysis of the binding data. Scatchard analysis suggests that there are high-affinity binding sites ($K_d = 20\text{pM}$) and low-affinity binding sites ($K_d = 0.5\text{nM}$). For competition with oligonucleotide, the cells were incubated for 2 hr at 4°C as above with 30 pM ^{125}I -IFN-gamma and increasing concentrations (1.01-500 nM) of competitor oligonucleotide. Cell-associated ^{125}I -IFN-gamma was determined as above.

EXAMPLE 2. 2'-NH₂ AND 2'-F-MODIFIED RNA LIGANDS TO IFN-GAMMA

A. SELEX

Three libraries of RNAs modified at the 2' position of pyrimidines, 1) 2'F incorporating 2'F-CTP and 2'F-UTP, 2) 2'F/NH₂ incorporating 2'F-CTP and 2'NH₂-UTP and 3) 2'NH₂ incorporating 2'NH₂-CTP and 2'NH₂-UTP were used in simultaneous SELEX protocols to generate a diverse set of high-affinity modified RNA ligands to human IFN-gamma. Each of these libraries contained between 10^{13} - 10^{14} molecules with a variable region of 40 nucleotides. The template and primers used for the SELEX and the conditions of the SELEX, as described in Example 1, are summarized in Tables 1 and 2, respectively.

B. RNA Sequences and Dissociation Constants

The random modified RNA pools bound human IFN-gamma with approximate Kds of greater than 0.7 μM . After 17 rounds of SELEX, the approximate Kds of the evolving pools had improved to, 1) 70 nM for the 2'F SELEX, 2) 115 nM for the 2'F/NH₂ SELEX, and 3) 20 nM for the 2'NH₂ SELEX. For mouse IFN-gamma, the approximate Kds of the RNA pools after 17 rounds of SELEX were 1) 410 nM for the 2'F SELEX, 2) 175 nM for the 2'F/NH₂ SELEX, and 3) 85 nM for the 2'NH₂ SELEX. These Kds did not shift further in subsequent rounds.

In order to determine to what extent the evolving pool was still random, PCR product from the final round of SELEX was sequenced as detailed above and found to be non-random. RNA from the 17th round was reverse transcribed, amplified and cloned. The sequences of 32 of the 2'F, 40 of the 2'NH₂, and 11 of the 2'F/NH₂ individual clones
5 were determined (Table 3; SEQ ID NOS:7-65). The sequences were analyzed for conserved sequences and aligned by this criterion (Table 3). The 2'F sequences fell in to 2 groups with 9 orphan sequences. Group 1 2'F RNAs were the most abundant, representing 18 of 32 sequences, while group 2 2'F RNAs represented 5 of 32 sequences. The 2'NH₂ sequences fell into 2 groups with 25 of 40 2'NH₂ RNAs in group 1 and 15 of 40 2'NH₂
10 RNAs in group 2. The 2'F/NH₂ sequences were of a single group.

The Kds of individual RNAs within each group were determined by nitrocellulose filter binding as described above. The Kds were determined using either a monophasic or biphasic least squares fit of the data.

Minimal sequence requirements for high-affinity binding of the best clones were
15 determined by 5' and 3' boundary experiments as described. The truncated RNAs were transcribed from double-stranded templates containing the T7 promoter and the truncated sequence. For those successful transcriptions, the Kd of the truncated ligand was determined. The sequence of the truncated ligands and their Kds, both for full-length and for the truncate (if determined) are shown in Table 4 (SEQ ID NOS:66-73).

20

C. Receptor Competition

Both full-length 2'NH₂ (2'NH₂_{random}, 2'NH₂₋₁₇, 2'NH₂₋₃₀) and 2'F (2'F random, 2'F-1, and 2'F-28) oligonucleotides were tested for their ability to inhibit receptor binding. This competition was targeted primarily to the high-affinity binding component using a
25 concentration of ¹²⁵I-IFN-gamma of 30pM. At this concentration, neither the 2'NH₂ nor the 2'F random oligos showed inhibition, while varying degrees of inhibition were seen with the 4 clones tested. The 2'NH₂ ligand #30 (SEQ ID NO:72) was the best inhibitor and showed 50% inhibition at 10 nM.

EXAMPLE 3. EXPERIMENTAL PROCEDURES FOR 2'-NH₂ AND 2'-F-MODIFIED LIGANDS TO IL-4

This Example provides general procedures followed and incorporated in Example 4 for the evolution of nucleic acid ligands to IL-4.

5

A. Oligonucleotides

2'F modified CTP and UTP were prepared according to the method of Pieken *et al.*, 1991. 2'NH₂ modified CTP and UTP were prepared according to the method of McGee *et al.*, U.S. Patent Application No. 08/264,029, filed June 22, 1994, which is incorporated
10 herein by reference (see also McGee *et al.* 1995). DNA oligonucleotides were synthesized by Operon Technologies (Alameda CA).

B. SELEX

The SELEX procedure has been described in detail in U.S. Patent No. 5,270,163
15 (see also Tuerk and Gold, 1990; Gold *et al.*, 1993). Three SELEX procedures were performed to evolve high affinity ligands to IL-4. Each SELEX procedure utilized RNA pools containing pyrimidines modified at the 2' position as follows, 1) 2'F-CTP and 2'F-UTP referred to as 2'F, 2) 2'F-CTP and 2'NH₂-UTP referred to as 2'F/NH₂, and 3) 2'NH₂-CTP and 2'NH₂-UTP referred to as 2'NH₂. For each SELEX, the DNA template
20 40N8 was designed to contain 40 random nucleotides, flanked by 5' and 3' regions of fixed sequence (Table 5; SEQ ID NO:74). The fixed regions include DNA primer annealing sites for PCR and cDNA synthesis as well as the consensus T7 promoter region to allow *in vitro* transcription.

Single-stranded DNA primers and templates were synthesized and amplified into
25 double-stranded transcribable templates by PCR. Preparation of the initial pool of RNA molecules involved PCR amplification of 1000 pmoles of single-stranded template (Table 5; SEQ ID NO:74) and 2500 pmoles of both the 5' (5P8; SEQ ID NO:75) and 3' (3P8; SEQ ID NO:76) primers. These were incubated in a reaction mixture containing 50 mM KCl, 10 mM Tris-Cl (pH 8.3), 3 mM MgCl₂, 0.5 mM of each dATP, dCTP, dGTP, and
30 dTTP. *Taq* DNA Polymerase (Perkin-Elmer, Foster City CA) at 0.1 U/ μ l was added and the reaction incubated at 97°C for 3 min to denature the template and primers. Following

the initial denaturing step, the reaction was cycled 7 times at 93°C for 30 sec, 53°C for 30 sec, and 72°C for 1 min to denature, anneal, and extend, respectively, the primers and template. To get an accurate concentration of double-stranded PCR product for the initial round of SELEX, the PCR product was purified using QIAquick-spin PCR purification
5 columns (QIAGEN Inc., Chatsworth CA) as specified by the manufacturer.

For *in vitro* transcription using modified nucleotides 200 pmoles (final concentration of 1 μ M) of double-stranded DNA template was incubated in a reaction mixture containing 40 mM Tris-Cl (pH 8.0), 12 mM MgCl₂, 5 mM DTT, 1 mM spermidine, 0.002% Triton X-100, 4% PEG 8000, 0.5 μ M α -³²P 2'OH ATP, 5 U/ μ l T7
10 RNA Polymerase (Davanloo *et al.*, 1984), and concentrations of other nucleotides as follows, 1) for the 2'F SELEX: 1 mM ATP and GTP, 3 mM 2'F-CTP and 2'F-UTP, 2) for the 2'F/NH₂ SELEX: 1 mM ATP, GTP, and 2'NH₂-UTP and 3 mM 2'F-CTP, and 3) for the 2'NH₂ SELEX: 1 mM ATP, GTP, 2'NH₂-CTP, and 2'NH₂-UTP. These incubations were performed in a 37°C incubator for between 6 hrs and overnight. Typically the RNA
15 was purified by gel purification and elution. To expedite the process for rounds 11, 12, and 14-17 the RNA was purified using Bio-Spin 6 chromatography columns (Bio-Rad Laboratories, Hercules CA) according to manufacturer's specifications. To reduce background, the RNA was pre-filtered prior to all rounds of SELEX except rounds 1, 2, 4, 6, 14, and 16. The pre-filtration step involved bringing the RNA up to 200 μ l in phosphate
20 buffered saline (PBS), modified to contain 1 mM Mg²⁺ ions, (138 mM NaCl, 2.7 mM KCl, 8.1 mM Na₂HPO₄, 1.1 mM KH₂PO₄, 1mM MgCl₂, pH 7.4), (mPBS), and passing this RNA solution through three filter discs (0.45 μ m, nitrocellulose/ cellulose acetate, Millipore Corporation, Bedford MA) pre-wetted with mPBS.

For initial binding, 1000 pmoles of RNA were incubated with human IL-4 protein
25 in binding buffer, (mPBS plus 0.01% human serum albumin (HSA)), for 5-10 min at 37 °C to allow binding to occur. Human recombinant IL-4 used in this SELEX procedure was purchased from R & D Systems, Minneapolis MN. For each round of SELEX the concentration of RNA and protein was carefully chosen to provide optimum stringency. Preliminary experiments had shown that IL-4 had a tendency to aggregate at high protein
30 concentrations. To prevent the evolution of RNA species having an affinity for this aggregated IL-4, beginning with round 4 of SELEX and for all subsequent rounds of the

SELEX procedure, the binding mix was centrifuged at 16,000 X g for 3 min in an eppendorf centrifuge before nitrocellulose filter partitioning. IL-4/ RNA complexes were separated from unbound RNA by nitrocellulose filter partitioning described below.

For nitrocellulose partitioning, the 2'F and 2'F/NH₂ SELEX procedures used 0.2 μ m pore size pure nitrocellulose filters (Schleicher & Schuell, Keene NH) for the first two rounds of SELEX. All subsequent rounds of these two SELEX procedures and the entire 2'NH₂ SELEX were performed with 0.45 μ m pore size nitrocellulose/cellulose acetate mixed matrix filters (Millipore Corporation, Bedford MA). Filter discs were placed into a vacuum manifold and wetted with 5 ml of mPBS buffer. The IL-4/RNA binding mix was aspirated through the filter discs which were immediately washed with 5 ml of mPBS buffer. To further increase stringency and reduce background for rounds 8-13, and 15, this washing step was modified to include washing of the filter discs with 15 ml 0.5 M urea followed by 20 ml mPBS buffer. Bound RNA was isolated from filters by extraction in a solution of 400 μ l phenol (equilibrated in Tris-Cl, pH 8.0)/ 300 μ l 7 M urea (freshly prepared). The filters were bathed in the phenol/urea solution at room temperature for 30 min and at 95°C for 2 min. The RNA was phenol/chloroform extracted and ethanol precipitated with 20 μ g tRNA.

The RNA was reverse transcribed into cDNA by addition of 50 pmoles DNA primer, 0.4 mM each of dNTPs, and 1 U/ μ l AMV reverse transcriptase (AMV RT) (Life Sciences, Inc., St. Petersburg FL) in buffer containing 50 mM Tris-Cl (pH 8.3), 60 mM NaCl, 6 mM Mg(OAc)₂, 10 mM DTT. The reaction was incubated at 37°C for 30 min then 48°C for 30 min then 70°C for 10 min, to ensure the melting of secondary structure present in the isolated RNA.

To begin a new round of SELEX, the cDNA was PCR amplified by addition of 250 pmoles of both the 5' (5P8; SEQ ID NO:75) and 3' (3P8; SEQ ID NO:76) primer in reaction conditions identical to those detailed above. The number of cycles of PCR required to amplify the cDNA was carefully calculated for each round of SELEX so that 250 pmoles double-stranded DNA template would be used to initiate the next round of SELEX.

C. Equilibrium Dissociation Constants (Kds)

The determination of equilibrium dissociation constants (Kds) for RNA pools was made subsequent to rounds 5, 8, 12, and 17 to monitor the progress of each SELEX. The Kds of RNA pools for mouse IL-4 (R & D Systems, Minneapolis MN) were also
5 determined after round 8. Kds were determined for individual ligands after cloning and sequencing of RNA pools and truncations (described below). Nitrocellulose filter binding was used to determine Kds as follows: filter discs were placed into a vacuum manifold and wetted with 5 ml of mPBS buffer. ³²P-labeled-RNA was incubated with serial dilutions of IL-4 in binding buffer for 5-10 min at 37°C to allow binding to occur.
10 Binding mixes were centrifuged as described above to remove aggregates, aspirated through the filter discs, and then immediately washed with 5 ml mPBS buffer. The filter discs were dried and counted in a liquid scintillation counter (Beckmann Instruments, Palo Alto CA). Equilibrium dissociation constants were determined by least square fitting of the data points using the Kaleidagraph™ graphics program (Synergy Software, Reading
15 PA). Many ligands and evolved RNA pools yield biphasic binding curves. Biphasic binding can be described as the binding of two affinity species that are not in equilibrium. Biphasic binding constants were calculated according to standard procedures. Kds were determined by least square fitting of the data points using the Kaleidagraph™ graphics program.

20

D. Cloning and Sequencing

After the 17th round of SELEX, RNA molecules were reverse transcribed to cDNA and made double-stranded by PCR amplification with primers containing recognition sites for the restriction endonucleases *Hind* III (Table 5; 5' primer 5P8H; SEQ ID NO:77) and
25 *Bam* HI (Table 5; 3' primer 3P8B; SEQ ID NO:78). Using these restriction sites the DNA sequences were inserted directionally into the pUC19 vector. These recombinant plasmids were transformed into Epicurian coli JM109 competent cells (Stratagene, La Jolla CA). Plasmid DNA was prepared with the PERFECTprep™ plasmid DNA kit (5 prime--->3 prime, Boulder CO). Plasmid clones were sequenced using a PCR sequencing protocol
30 (Adams *et al.*, 1991) using PCR sequencing primer pUC19F30 (SEQ ID NO:6).

E. Ligand Truncation

Boundary experiments were carried out to determine the minimal sequence necessary for high affinity binding of the RNA ligands to IL-4 using end-labeled RNA. Prior to end-labeling, RNA transcribed with T7 RNA polymerase was gel purified by UV shadowing. The 5'-end of 20 pmoles of each RNA was dephosphorylated in a reaction mixture containing 20 mM Tris-Cl (pH 8.0), 10 mM MgCl₂ and 0.1 U/ μ l shrimp alkaline phosphatase (SAP), (United States Biochemical, Cleveland OH) by incubating for 30 min at 37°C. Alkaline phosphatase activity was destroyed by incubating for 30 min at 70°C. RNA was subsequently 5'-end labeled in a reaction mixture containing 50 mM Tris-Cl (pH 7.5), 10 mM MgCl₂, 5 mM DTT, 0.1 mM EDTA, 0.1 mM spermidine, 0.75 mM g
-³²P-ATP and 1 U/ μ l T4 polynucleotide kinase (New England Biolabs, Beverly MA) by incubating for 30 min at 37°C.

3'-end-labeling of 20 pmoles of each RNA was performed in a reaction mixture containing 50 mM Tris-Cl (pH 7.8), 10 mM MgCl₂, 10 mM β -mercaptoethanol, 1 mM ATP, 0.9 μ M (5'-³²P)pCp and 1 U/ μ l T4 RNA ligase (New England Biolabs, Beverly MA) by incubating for 18 hrs at 4°C. 5'- and 3'- end-labeled RNAs were gel band purified on a 12%, 8M urea, polyacrylamide gel. After partial alkaline hydrolysis of the end-labeled RNA by addition of Na₂CO₃ to a final concentration of 50 mM and incubation in a boiling water bath for 3 min, radiolabeled RNA ligands were incubated with IL-4 at three different protein concentrations, 1) 5-fold below the approximate K_d, 2) at the approximate K_d, and 3) 5-fold above the approximate K_d. Protein-bound RNA was separated by nitrocellulose partitioning. RNA truncates were analyzed on a high-resolution denaturing 12% polyacrylamide gel. To orient the sequences, a ladder of radioactively labeled ligands terminating with G-residues was generated by RNase T1 digestion of end-labeled RNA. The T1 digest was carried out in a reaction mixture containing 7 M urea, 20 mM sodium citrate (pH 5.0), 1 mM EDTA and 5 units RNase T1 (Boehringer Mannheim, Indianapolis IN) by incubating for 5 min at 50°C.

Complementary single-stranded DNA oligonucleotides containing the sequence of the T7 promoter (5'-TAATACGACTCACTATAG-3'; fragment of SEQ ID NO:75) and the sequence of the truncated ligand were annealed to form a double-stranded template for transcription of each truncated ligand.

F. Receptor Competition

Human T-cell lymphoma cells (H-9; ATCC) were cultured in suspension in RPMI 1640 + 10% FCS. Cells were washed two times with PBS and resuspended (5.0×10^5 cells) in 200 μ l media containing RPMI 1640 + 0.02% human serum albumin/0.2% Na azide/20 mM HEPES, pH 7.4 for 2 hr at 4°C in 1.5 ml polypropylene tubes (Eppendorf, W. Germany) with various amounts of 125 I-rIL-4 in the presence or absence of a 200-fold excess of unlabeled cytokine. Following incubation, the tubes were spun (150 x g, 5 min, 4°C) and the supernatant was aspirated. The cell pellet was resuspended in 200 μ l RPMI-HSA. 100 μ l aliquots were centrifuged through a cushion of an equal volume of phthalate oils (dibutyl/dioctyl, 1:1 v/v). The tube was rapidly frozen in dry ice/ethanol and the tip containing the cell pellet was cut off and placed in a vial for gamma counting. The data was corrected for nonspecific binding and the affinity of 125 I-IL-4 was determined by Scatchard analysis. For competition with oligonucleotide, or neutralizing antibody (R & D Systems), the cells were incubated for 2 hr at 4° as above with 0.7 nM 125 I-IL-4 and increasing concentrations (0.01-500 nM) of competitor oligonucleotide. Cell-associated 125 I-IL-4 was determined as above.

EXAMPLE 4. 2'-NH₂ AND 2'-F-MODIFIED RNA LIGANDS TO IL-4

20 A. SELEX

Three libraries of RNAs modified at the 2' position of pyrimidines, 1) 2'F incorporating 2'F-CTP and 2'F-UTP, 2) 2'F/NH₂ incorporating 2'F-CTP and 2'NH₂-UTP and 3) 2'NH₂ incorporating 2'NH₂-CTP and 2'NH₂-UTP were used in simultaneous SELEX protocols to generate a diverse set of high-affinity modified RNA ligands to human IL-4. Each of these libraries contained between 10^{13} - 10^{14} molecules with a variable region of 40 nucleotides. The template and primers used for the SELEX and the conditions of the SELEX, as described in Example 3 are summarized in Tables 5 and 6, respectively.

B. RNA Sequences and Dissociation Constants

30 The random modified RNA pools bound human IL-4 with approximate Kds of greater than 20 μ M. After 17 rounds of SELEX, the approximate Kds of the evolving

pools had improved to, 1) 30 nM for the 2'F SELEX, and 2) 55 nM for the 2'F/NH₂ SELEX. Binding curves performed on 2'NH₂ RNA from an earlier round had shown an approximate K_d of 100 nM, however, difficulties with background reduction in this SELEX led to an apparent K_d after round 17 of 1 μM. It was felt that despite this
5 "masking" due to background, the high affinity unique sequence 2'NH₂ RNAs were still in the pool after round 17. These K_ds did not shift further in subsequent rounds. The RNA pools after 8 rounds of SELEX did not bind mouse IL-4, while there was a significant improvement in binding after 8 rounds for the human protein (data not shown).

In order to determine to what extent the evolving pool was still random, PCR
10 product from the final round of SELEX was sequenced as detailed above and found to be non-random. RNA from the 17th round was reverse transcribed, amplified, and cloned. The sequences of 41 of the 2'F, 57 of the 2'NH₂, and 30 of the 2'F/NH₂ individual clones were determined (Table 7; SEQ ID NOS:79-177). The sequences were analyzed for conserved sequences and aligned by this criterion (Table 7). The 2'F sequences fell into a
15 single group representing 29 of 41 sequences. The remaining 12 clones were categorized as orphans due to their lack of sequence homology with the primary group or to each other. The 2'NH₂ sequences fell into 2 distinct groups of sequences. Group 1 which represented 21 of 57 sequences were shown to bind to IL-4. The other group, representing 35 of 57 sequences were shown to bind to nitrocellulose filters. The presence of such a
20 large number of nitrocellulose filter binding RNAs was not a surprise as these sequences were cloned from a pool with high background binding. These nitrocellulose binding RNAs are identified by the presence of a direct repeat of the sequence GGAGG. A single orphan 2'NH₂ sequence was also found. The 2'F/NH₂ sequences were more heterogeneous with sequences falling into 3 groups. RNAs in group 1 and 2 bound to IL-4, while the 3rd
25 group bound to nitrocellulose filters. The clones in the nitrocellulose filter binding group also contained a single or repeat of the sequence GGAGG. It should be noted that this sequence is also found in the 3'-fixed region (underlined in Table 7).

The K_ds of individual RNAs within each group were determined by nitrocelulose filter binding as described in Example 3 above. The K_ds were determined using a
30 monophasic least squares fit of the data.

Minimal sequence requirements for high-affinity binding of the best clones were determined by 5' and 3' boundary experiments as described in Example 3. The truncated RNAs were transcribed from double-stranded templates containing the T7 promoter and the truncated sequence. For those successful transcriptions, the K_d of the truncated ligand was determined. The sequence of the truncated ligands and their K_d s, both for full-length and for the truncate (if determined) are shown in Table 8 (SEQ ID NOS:178-185).

C. Receptor Competition

Full-length 2'NH₂ (2'NH₂ random, 2'NH₂-29), 2'F (2'F random, 2'F-9) and 2'F/NH₂ (2'F/NH₂ random, 2'F/NH₂-9 and 2'F/NH₂-28) oligonucleotides were tested for their ability to inhibit receptor binding. Neither the 2'NH₂, 2'F, or 2'F/NH₂ random oligos showed inhibition, while varying degrees of inhibition was seen with the clones tested. At an IL-4 concentration of 0.7 nM the 2'F/NH₂ ligand-9 was the best competitor for receptor binding and showed 50% inhibition at approximately 40 nM. The competition by this oligonucleotide was similar to that seen by a neutralizing antibody to IL-4.

EXAMPLE 5. EXPERIMENTAL PROCEDURES FOR 2'-F MODIFIED LIGANDS TO IL-10

This Example provides general procedures followed and incorporated in Example 6 for the evolution of nucleic acid ligands to IL-10.

A. Materials

DNA sequences were synthesized by using cyanoethyl phosphoramidite under standard solid phase chemistry. 2'-F CTP and 2'-F UTP were purchased from United States Biochemicals. Human IL-10 was bought from either Bachem or R&D Systems. Neutralizing anti-human IL-10 monoclonal antibody, murine IL-10 and ELISA detection kit for human IL-10 were purchased from R & D Systems.

B. SELEX

Five nmoles of synthetic DNA template, that was purified on an 8% polyacrylamide gel under denaturing conditions were amplified by four cycles of

polymerase chain reaction (PCR). The PCR products were transcribed *in vitro* by T7 RNA polymerase (1000 U) in 1 mL reaction consisting of 2 mM each of ATP and GTP, 3 mM each of 2'-F CTP and 2'-F UTP, 40 mM Tris-HCl (pH 8.0), 12 mM MgCl₂, 1 mM Spermidine, 5 mM DTT, 0.002% Triton X-100 and 4% polyethylene glycol (w/v) for 10 -
5 12 hr. The full-length transcription products (SEQ ID NO:186) were purified on 8% denaturing polyacrylamide gels, suspended in TBS buffer [100 mM Tris-HCl, (pH 7.5) 150 mM NaCl] (binding buffer), heated to 70 °C, chilled on ice, then incubated with IL-10 at 37 °C for 10 min. The RNA-protein mixture was filtered through a pre-wet nitrocellulose filter then washed with 5 mL of the binding buffer. Bound RNAs were
10 eluted from the filter and recovered by ethanol precipitation. The RNA was reverse transcribed by avian myeloblastosis virus reverse transcriptase (Life Sciences) at 48 °C for 45 min with 5'-GCCTGTTGTGAGCCTCCTGTCGAA-3' primer (Table 9; SEQ ID NO:188). The cDNA was amplified by PCR (with 5' and 3' primers (SEQ ID NOS:187-188)) and the resulting DNA template was transcribed to obtain RNA for the
15 next round of selection. During the course of SELEX, the concentration of IL-10 was decreased gradually from 5 μM to 500 nM to progressively increase selective pressure. The selection process was repeated until the affinity of the enriched RNA pool for IL-10 was substantially increased. At that point, cDNA was amplified by PCR with primers that introduced BamHI and Hind III restriction sites at 5' and 3' ends, respectively. PCR
20 products were digested with *BamHI* and *Hind III* and cloned into pUC 18 that was digested with the same enzymes. Individual clones were screened and sequenced by standard techniques.

C. Determination of equilibrium dissociation constants (K_d).

25 Internally-labeled RNA transcripts were prepared by including [α -³²P]ATP in T7 RNA polymerase transcription reactions. Full-length transcripts were purified on 8% denaturing polyacrylamide gels to ensure size homogeneity. Gel-purified RNA was diluted to a concentration of ~ 5 nM in TEM buffer, heated to 80 °C then chilled on ice to facilitate secondary structure formation. RNA concentrations were kept lower than 100
30 pM in binding reactions. Briefly, equal amounts of RNA were incubated with varying amounts of IL-10 in 50 μL of TEM buffer for 10 min at 37 °C. RNA-protein mixtures

were passed through pre-wet nitrocellulose filters (0.2 μ) and the filters were immediately washed with 5 mL of binding buffer. Radioactivity retained on filters was determined by liquid scintillation counting. The quantities of RNA bound to filters in the absence of protein was determined and used for background correction. The percentage of input RNA retained on each filter was plotted against the corresponding log protein concentration. The nonlinear least square method to obtain the dissociation constant (K_d).

D. Sandwich ELISA

Sandwich ELISA was carried out by using commercially available ELISA kit for quantitative determination of hIL-10 (from R&D systems) according to manufacturer's instructions. Varying amounts of RNA 43, random pool RNA and anti-hIL-10 monoclonal antibody (from R&D Systems) were incubated with 125 pg/mL hIL-10 at room temperature for 10 min before added to microtiter wells.

15 EXAMPLE 6. 2'-F-MODIFIED RNA LIGANDS TO IL-10

Under nitrocellulose filter binding conditions the random sequence pool that was used to initiate the SELEX experiment did not show detectable binding to IL-10 as high as 5 μ M concentration. However, after twelve rounds of affinity selection the enriched pool exhibited improved affinity, and further selection beyond the 12th round had no effect on increasing the affinity for IL-10. Table 10 (SEQ ID NOS:189-205) shows the sequences identified from the 12th round pool. Sequences are grouped into three classes based on the sequence similarity. The 5' part in the variable 40 nucleotide region of most sequences in class I has sequence complementarity to the 3' part, suggesting that such sequences can fold into a stemloop structure.

Individual clones were initially screened for their ability to bind IL-10 at 250 nM concentration. The results show that 20-40% of input individual RNAs was bound to IL-10 at 250 nM. Based on preliminary screening, sequence 43 (SEQ ID NO:189) was chosen as a representative ligand to carry out in section B below.

The K_d of sequence 43 for binding to IL-10 is 213 nM. The ligand 43, on the other hand does not bind to other cytokines such as interferon γ and IL-4, indicating the specificity of SELEX-derived RNA sequence. Human IL-10 (hIL-10) and mouse IL-10

(mIL-10) have high degree of sequence homology at the cDNA and amino acid level (73% amino acid homology) and hIL-10 has been shown to active on mouse cells. However, ligand 43 does not bind to mIL-10 with high affinity.

5 B. RNA in IL-10 ELISA

An anti-IL10 monoclonal antibody that neutralizes the receptor binding is commercially available. The R&D systems' Quantikine Immunoassay kit is based on 96 well microtiter plates coated with the neutralizing antibody to capture hIL-10. The ELISA was used to investigate whether RNA binds at or near the neutralizing antibody binding
10 site on IL-10. RNA 43, similar to the random pool RNA (used as a control) did not show any inhibition of IL-10 binding to anti-IL-10 antibody on the plate (data not shown). These data suggest that the evolved RNA ligand does not bind to the site at or near that recognized by the neutralizing antibody. The soluble anti-IL10 that was used in the assay as a control behaved as expected, competing for binding with the same antibody on the
15 solid phase.

EXAMPLE 7. EXPERIMENTAL PROCEDURES FOR LIGANDS TO hTNF α

This Example provides general procedures followed and incorporated in Examples 8-11 for the evolution of nucleic acid ligands to hTNF α .

20

A. Materials

Recombinant human TNF α (hTNF α) was purchased from Genzyme (Cambridge, MA) or R&D Systems (Minneapolis, MN), recombinant murine TNF α (mTNF α), recombinant human TNF β (hTNF β), and soluble human TNF receptor 2 (sTNF-R2) were
25 purchased from R&D Systems. Acetylated, and nuclease free bovine serum albumin (BSA), ligase and restriction enzymes were from new England Biolabs (Beverly, MA). AMV reverse transcriptase were from Life Sciences (St. Petersburg, FL). RNasin ribonuclease inhibitor, and Taq DNA polymerase was from Promega (Madison, WI). Ultrapure nucleotide triphosphates were from Pharmacia (Piscataway, NJ). 125 I-TNF α ,
30 α - 32 P-ATP, and γ - 32 P-ATP were from DuPont NEN Research Products (Boston, MA). U937 cells were from ATCC (catalog number CRL1593). Oligonucleotides were obtained

from Operon, Inc. (Alameda, CA). Nitrocellulose/cellulose acetate mixed matrix (HA), 0.45 μm filters were from Millipore (Bedford, MA). Chemicals were at least reagent grade and purchased from commercial sources.

5 **B) SELEX**


The SELEX procedure has been described in the SELEX Patent Application (see also Tuerk and Gold, 1990; Gold *et al.*, 1993). The starting RNA contained 30 random nucleotides, flanked by 5' and 3' constant regions for primer annealing sites for cDNA synthesis and PCR amplification (Table 11; SEQ ID NO:206). The single stranded DNA
10 molecules were converted to double stranded by PCR amplification. PCR conditions were 50 mM KCl, 10 mM Tris-HCl, pH9, 0.1% Triton X-100, 3 mM MgCl_2 , 0.5 mM of each dATP, dCTP, dGTP, and dTTP, 0.1 units/ μl Taq DNA polymerase and 1 nM each of the 5' and 3' primers. Transcription reactions were done with about 5 μM DNA template, 5 units/ μl T7 RNA polymerase, 40 mM Tris-HCl (pH8), 12 mM MgCl_2 , 5 mM DTT, 1 mM
15 spermidine, 0.002% Triton X-100, 4% PEG 8000, 2-4 mM each 2'OH NTP, and 0.25 μM α - ^{32}P -ATP (800 Ci/mmol). For 2'F modified transcripts, 2'F-CTP and 2'F-UTP were used instead of 2'OH-CTP and 2'OH-UTP. Two different SELEX experiments were done. In the first SELEX experiment, SELEX-A, the protein was immobilized onto nitrocellulose filters and the RNA ligands were partitioned by capture to the immobilized protein.
20 Briefly, hTNF α was spotted on a nitrocellulose filter (Millipore, HA 0.45 μm) and following 5 min air drying over filter paper, the nitrocellulose filter was incubated in a 24-well microtiter plate with $1\text{-}2 \times 10^{-6}$ M radiolabeled RNA for 30 min at room temperature in 500 μl binding buffer (BB=10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.02% acetylated BSA, 0.02% ficol, and 0.02% PVP). The filter was then washed
25 three times for 10 minutes each in 1.5 ml BB without BSA. Binding and washing was done under rigorous agitation. The RNA bound to the immobilized protein was recovered by phenol/urea extraction and was then reverse transcribed into cDNA by AMV reverse transcriptase at 48°C for 60 min in 50 mM Tris-HCl pH8.3, 60 mM NaCl, 6 mM $\text{Mg}(\text{OAc})_2$, 10 mM DTT, 50 pmol DNA primer-1 (Table 11; SEQ ID NOS:206-208), 0.4
30 mM each of dATP, dCTP, dGTP, and dTTP, and 1 unit/ μl AMV RT. The cDNA was then PCR amplified and used to initiate the next SELEX cycle as described above. In the

second SELEX experiment, SELEX-B, the binding buffer was Dulbecco's Phosphate-Buffered Saline (DPBS) with calcium and magnesium (Life Technologies, Gaithersburg, MD, Cat. No 21300-025) and the protein-RNA complexes were partitioned by filtering through nitrocellulose/cellulose acetated mixed matrix, 0.45 μ m pore size filter disks (Millipore, Co., Bedford, MA). Nitrocellulose filter bound RNA was recovered by phenol/urea extraction. The partitioned RNA was then reverse transcribed and PCR amplified as above and used to initiate the next SELEX cycle.

C. Determination of Equilibrium Dissociation Constants

To partition the protein-RNA complexes, the binding reactions were filtered through nitrocellulose/cellulose acetated mixed matrix, 0.45 μ m pore size filter disks (Millipore, Co., Bedford, MA). For filtration, the filters were placed onto a vacuum manifold and wetted by aspirating 5 ml of DPBS. The binding reactions were aspirated through the filters and following a 5 ml wash, the filters were counted in a scintillation counter (Beckmann). Nitrocellulose partitioning was used for SELEX and for determining the equilibrium dissociation constants of RNA ligands to TNF α . RNA ligands to TNF α bind monophasically.

To obtain the equilibrium dissociation constants of RNA ligands to TNF α the binding reaction:



is converted into an equation for the fraction of RNA bound at equilibrium:

$$q = (f/2R_T)(P_T + R_T + K_D - ((P_T + R_T + K_D)^2 - 4P_TR_T)^{1/2})$$

q=fraction of RNA bound
 P_T =total protein concentration

R_T = total RNA concentration

f = retention efficiency of RNA-protein complexes

The average retention efficiency for RNA-TNF α complexes on nitrocellulose filters is
5 0.1-0.2.

The K_D s were determined by least square fitting of the data points using the software Kaleidagraph (Synergy Software, Reading, PA).

D. Cloning and Sequencing

10 RT-PCR amplified cDNA from the last round of SELEX was cloned between *Bam*HI and *Hind*III restriction sites of pUC18 plasmid (Vieira *et al.*, 1982, *Gene* 19: 259-268) in MC1061 *E. coli* (Casadaban *et al.*, 1980, *J Mol Biol* 138: 179-207). Sequencing was done using PCR products as templates with a commercially available kit (Promega, Madison WI).

15

E. Receptor Binding Competition Assay

A receptor binding competition assay was used to determine the bioactivity of the RNA ligands. 125 I labelled hTNF α at 0.1 nM was incubated in 50 μ l of binding medium (PBS with 0.5 mM Mg $^{++}$, 0.2% BSA, 0.02% sodium azide, 1U/ μ l RNasin) for 15 min at
20 4°C with serially diluted competitors at 10^{-4} to 10^{-11} M, and 1×10^4 / μ l U937 cells. Duplicate aliquots were subsequently removed, centrifuged through 2:1 dibutyl-phthalate:dinonyl-phthalate mixture to separate free and bound 125 I labelled hTNF α , and the radioactivity in the pellet was measured on a gamma counter. Nonspecific binding was determined by inclusion of a 200-fold molar excess of unlabeled
25 TNF.

The inhibition constants (K_i) of the RNA ligands were determined by a nonlinear regression analysis of the data using standard techniques. To obtain K_i values the concentration of TNF receptor was assumed to be 3.4×10^{-11} M and the K_D of the TNF α -TNFR interaction of 0.1 nM.

F. Boundary determination

For 3' boundary determination, the 6A RNA ligand was 5' end labeled with γ - ^{32}P -ATP using T4 polynucleotide kinase. 5' boundaries were established using 3' end labeled ligand with α - ^{32}P -pCp and T4 RNA ligase. After partial alkaline hydrolysis, the radiolabeled RNA ligand was incubated with hTNF α at 5, 25, and 125 nM, and the protein bound RNA was isolated by nitrocellulose partitioning. The RNA truncates were analyzed on a high resolution denaturing polyacrylamide gel. An alkaline hydrolysis ladder and a ladder of radioactively labeled ligands terminated with G-residues, generated by partial RNase T1 digestion, were used as markers.

10

EXAMPLE 8. RNA LIGANDS TO hTNF α

A. pre-SELEX characterization

Nitrocellulose filter binding could not detect any interaction of hTNF α with random RNA even at high protein concentrations. The binding curves were completely flat even up to 10 μM hTNF α and RNA up to 1 μM and the estimated dissociation constant (K_D) is greater than 10^{-3} M. No buffer conditions were found that improved the interaction of hTNF α and random RNA.

To determine whether hTNF α was binding any RNA at all we used a more sensitive technique similar to northwestern probing (Bowen *et al.*, 1980). This technique was used in various studies of protein nucleic acid interaction and aided in the cloning of various DNA binding proteins (Singh *et al.*, 1988). This experiment showed clearly that some random RNA can bind to hTNF α . RNA binding occurred only when the filter was previously spotted with hTNF α and then dried, but not if the filter was spotted with hTNF α and then placed wet in the incubation chamber. The RNA was binding only on the filters carrying hTNF α but not on filters carrying BSA possibly because, either not enough BSA was immobilized on the filter or the BSA present in the incubation mix was competing for available BSA-specific RNA ligands.

20

25

B. SELEX.

Two independent SELEX experiments (A and B) were initiated with pools of randomized RNA containing about 10^{14} unique molecules. The starting RNA and the PCR primer sequences are shown in Table 11.

5 In the A-SELEX, the protein was immobilized on a nitrocellulose filter by drying. The protein containing filter was incubated in BB (see Example 7) with labeled RNA, then washed, autoradiographed and the bound RNA was recovered by phenol-urea extraction. For the first round of A-SELEX about 1,000 pmoles of hTNF α monomer was used and the RNA concentration was at 2×10^{-6} M. For the subsequent 14 rounds, two different filters
10 containing about 500 and 100 pmoles of hTNF α monomer were incubated in the same chamber containing amplified RNA from the previous round at about 2×10^{-6} M. Only the RNA from the high protein filter was carried to the next round. A steady increase in the signal to noise ratio was observed and at round 15 the signal retained on the 500- and 100-pmole protein filters was 170- and 35-fold above background respectively. For
15 comparison, in the first round the signal was only about 3-fold above background. RNA from round 15 had a higher affinity for hTNF α with an estimated Kd of 5×10^{-5} M, representing a possible 100 fold improvement over the random RNA. To increase the stringency of the selection, we carried 8 more rounds using filters with about 10 and 1 pmole of hTNF α . For all these subsequent rounds, except for round 20, the RNA from the
20 1 pmole hTNF α filters was carried to the next round. Because of high background, at round 20 we used the RNA from the 10 pmoles hTNF α filter of round 19. The signal to noise ratio for these subsequent rounds became worse at each round but nevertheless the affinity of the evolved RNA continued to improve with estimated final Kd of 7×10^{-7} M, which represents two additional orders of magnitude improvement. In the final round, we
25 could detect signal with 10-fold shorter exposure time was detected, and with 100 - fold less hTNF α on the filter.

In parallel with the stringent phase of A-SELEX, RNA from round 15 of the A-SELEX was evolved using B-SELEX conditions (see below) for 6 more rounds. We designated this as C-SELEX. The affinity of the evolved population at the end of
30 C-SELEX was similar to the round 23 population of A-SELEX with approximate Kd= 4×10^{-7} M.

The evolved RNA from round 23 had not only improved affinity for hTNF α but it was also specific (Table 13). Binding could be detected only with hTNF α .

In the B- SELEX experiment, binding reactions were set in 25-50 μ l and after 10 min incubation at 37°C it was filtered through a 0.45 μ m HA nitrocellulose filter. For the first round of the B-SELEX, the RNA and protein were at about 4×10^{-5} M each. Under these conditions only 0.1% of the input RNA was retained on the filter. This was not surprising since the hTNF α -random-RNA interaction is very weak with a Kd too high to measure and probably in the 10^{-3} M range. Subsequent rounds were set similar to the first round. By round 8, the background binding of the RNA to the nitrocellulose filters was very high.

C. RNA sequences and Affinitites

RT-PCR amplified cDNA from round 23 of A-SELEX and round 6 of C-SELEX were cloned and sequenced as described in Example 7. 37 clones were sequenced from A-SELEX and 36 cloned from C-SELEX. From the total of 73 sequences, 48 were unique (Table 12; SEQ ID NOS:209-255). A unique sequence is defined as one that differs from all others by three or more nucleotides. Of the 47 unique clones, 18 clones could bind to hTNF α with Kd better than 1 μ M (Table 12). The best ligand, 25A, (SEQ ID NO:233) binds with affinity dissociation constant at about 40 nM. If it is assumed that the random RNA binds with a dissociation constant of greater than 10^{-3} M, then the affinity of 25A is at least four to five orders of magnitude better than the starting pool.

Using sequence alignment and conserved predicted secondary structure, 17 out of 18 clones that bind hTNF α could be assigned into two classes.

The members of the class II can be folded in stem-loop structures with internal bulges and asymmetric loops. Linear sequence alignment did not reveal any significant conserved sequences.

D. Specificity of RNA Ligands to TNF

We tested the specificity of the evolved pool of round 23 of A-SELEX against human TNF α , human TNF β and murine TNF α . The evolved pool is highly specific for human TNF α and specificity ratios are shown in Table 13.

EXAMPLE 9. Inhibition of hTNF α Binding to Cell Surface receptors

To test the ability of the TNF α ligands to competitively inhibit the binding of hTNF α to its cell surface receptor, the U937 cells were used to screen several hTNF α ligands. The observed K_is are listed in Table 14. The data show that several ligands can competitively inhibit binding of hTNF α to its cell surface receptors while random RNA cannot. Ligand 25A has the highest potency with a K_i of 21 nM. This K_i value is only 6 fold worse than the K_i observed with the sTNF-R2 under the same experimental conditions.

10

EXAMPLE 10. Effect of 2'F Pyrimidine Modification on the Binding and Inhibitory Activities of the hTNF α Ligands

Transcripts containing 2'F modified pyrimidines are resistant to RNase degradation. To obtain ligands with improved stability we tested the effect of 2'F pyrimidine modification on the binding and inhibitory activity of several hTNF α ligands. The results summarized in Table 15 show that some of the ligands retained binding activity when are modified with 2'F pyrimidines but in general the modified ligands bind worse than the unmodified counterparts. Class II ligands are in general more tolerant of the 2'F pyrimidine modification. Most of the ligands that retained binding after the 2'F pyrimidine modification lose their inhibitory activity. Only the 2'F pyrimidine modification of the most abundant ligand, 6A, did not affect its binding and inhibitory activities.

15
20**EXAMPLE 11: Experimental Procedures for DNA Ligands to RANTES**

This example provides general procedures followed and incorporated in Example 12 for the evolution of nucleic acid ligands to RANTES.

25

A. Materials

Recombinant human RANTES was purchased from Genzyme (Cambridge, MA). Taq DNA polymerase was Perkin Elmer (Norwalk, CT). T4 polynucleotide kinase was purchased from New England Biolabs (Beverly, MA). Ultrapure nucleotide triphosphates

30

were purchased from Pharmacia (Piscataway, NJ). Affinity purified streptavidin (Cat. No 21122) was from Pierce (Rockford, IL). Oligonucleotides were obtained from Operon, Inc. (Alameda, CA). Nitrocellulose/cellulose acetate mixed matrix (HA), 0.45 μ m filters were purchased from Millipore (Bedford, MA). Chemicals were at least reagent grade and
5 purchased from commercial sources.

B. SELEX

The SELEX procedure has been described in detail in the SELEX Patent Applications. The DNA template contained 40 random nucleotides, flanked by 5' and 3' constant regions for primer annealing sites for PCR (Table 16; SEQ ID NOS:256-258).
10 Primer 3G7 (SEQ ID NO:258) has 4 biotin residues in its 5' end to aid in the purification of single stranded DNA (ssDNA). For the first round, 105 pmoles of synthetic 40N7 ssDNA were 5' end labelled using T4 polynucleotide kinase in a 25 μ l reaction containing 70 mM Tris-HCl pH 7.6, 10 mM MgCl₂, 5 mM DTT, 39.5 pmoles of γ -³²P-ATP (3000
15 Ci/mmol), and 16 units kinase, for 1 h at 37°C. The kinased DNA was then purified on an 8% polyacrilamide, 7M urea, denaturing gel and then mixed with gel purified unlabeled 40N7 to achieve about 5,000 cpm/pmol specific activity. To prepare binding reactions, the DNA molecules were incubated with recombinant RANTES in Hanks' Balanced Salt Solution (HBSS) without calcium and magnesium (Life Technologies, Gaithersburg, MD,
20 Cat. No 14175) containing 0.01% human serum albumin. Two SELEX experiments were performed, one with normal salt concentration and the other with 300 mM NaCl. The high salt concentration was achieved by adding additional NaCl to the HBSS. Following incubation at room temperature for 30 minutes the protein-DNA complexes were partitioned from unbound DNA by filtering through HA nitrocellulose 0.45 μ m.
25 Nitrocellulose filter bound DNA was recovered by phenol/urea extraction. The partitioned DNA was PCR amplified in 50 mM KCl, 10mM Tris-HCl, pH9, 0.1% Triton X-100, 3mM MgCl₂, 1 mM of each dATP, dCTP, dGTP, and dTTP, with 0.1 units/ μ l Taq DNA polymerase. The 3G7 and 5G7 primers were present at 2 μ M. The 5G7 primer was 5'-end labeled before use described above. To purify ssDNA, the PCR product was ethanol
30 precipitated and then reacted with affinity purified streptavidin at a molar ratio 1:10 DNA to streptavidin in 10 mM Tris-HCl pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% sodium

azide. Following 30 incubation at room temperature, equal volume of 100% formamide tracking dye was added and the strands were denatured by incubating at 85°C for 1.5 min. The denatured strands were then electrophoresed in an 8% polyacrylamide, 7M urea gel and the nonshifted band was excised and purified from the crushed gel. The purified
5 ssDNA was then used for the next SELEX cycle.

EXAMPLE 12: DNA LIGANDS TO RANTES

A. SELEX

10 To generate DNA ligands for RANTES, two SELEX experiments were performed, one with 150 mM and the other with 300 mM NaCl. The high salt was used in order to avoid precipitation of the RANTES-DNA complexes that occurs at the lower salt concentration. The SELEX at 300 mM salt was prematurely terminated because of high background. The SELEX conditions and results for each round of the 150 mM salt
15 SELEX are summarized in Table 17. The starting pool contained 1.8×10^{15} (2,940 pmoles) of DNA for the 150 mM salt SELEX. The starting K_D values of the random DNA were $3 \times 10^{-6} M$. After 19 rounds of SELEX the evolved pools bound with a K_D of 20 nM. This represents about 150 fold improvement.

Table 1**40N7 TEMPLATES AND PRIMERS**

	SEQ ID <u>NO.</u>
40N7 ssDNA Template:	
5' GGGAGGACGAUGCGG [-40N-] CAGACGACUCGCCCCGA 3'	1
SELEX PCR Primers:	
5P7:	
5' TAATACGACTCACTATAGGGAGGACGATGCGG 3'	2
3P7:	
5' TCGGGCGAGTCGTCTG 3'	3
Cloning PCR Primers:	
5P7H:	
Hind III	
5' CCGAAGCTTAATACGACTCACTATAGGGAGGACGATGCGG 3'	4
3P7B:	
Bam HI	
5' GCCGGATCCTCGGGCGAGTCGTCTG 3'	5
PCR Sequencing Primer:	
pUC19F30:	
5' AGTCACGACGTTGTAAAACGACGGCCAGTG 3'	6

Table 2
SELEX STRATEGY

IFN-gamma		RNA Pre- filtration	Stringent Wash	NaCl 250mM	Bio-spin purified RNAs
Round	[Protein] RNA:Protein				
1	10 ⁻⁶ 5				
2	10 ⁻⁶ 2.5				
3	10 ⁻⁶ 1.5	X			
4	10 ⁻⁶ 1				
5	5 x 10 ⁻⁷ 1	X			
6	2.5 x 10 ⁻⁷ 1				
7	10 ⁻⁷ 1	X			
8	10 ⁻⁷ 1	X	X	X	
9	10 ⁻⁷ 1	X	X	X	
10	10 ⁻⁷ 1	X	X	X	
11	10 ⁻⁷ 1.5	X	X	X	X
12	10 ⁻⁷ 1.5	X	X	X	X
13	10 ⁻⁷ 1.5	X	X	X	
14	2 x 10 ⁻⁸ 5				X
15	10 ⁻⁸ 5	X	X		X
16	2 x 10 ⁻⁹ 5				X
17	10 ⁻⁹ 5	X			X

Table 3

SEQ ID
NO.

a) IFN-gamma 2'F Sequences

5' -GGGAGGACGAUGCGG (40N) CAGACGACUCGCCCGA -3'

40N

GROUP 1 (18 clones)

#1, 2, 5, 11, 12, 15, 18, 21, 26, 32, 35

ACACCCGUUAACUCUGAGGCCCGUGUCCUAUUCUUCACGCCU
#3 ACACCCGUUAGUCUGAGGCCCGUGUCCUAUUCUUCACGCCU
#10 ACACCUUUAACUCUGAGGCCCGUGUCCUAUUCUUCACGCCU
#22 ACACCUUGAAUCUGAGGCCCGUGUCCUAUUCUUCACGCCU
#29 ACACCCGUUAACUCUGAGGCCCGUGUCCUAUUCUUCACGCCU
#31 ACACCCGUAGAUCUGAGGCCCGUGUCCUAUUCUUCACGCCU
#19 ACACCCGUUAACUCUGAGGCCCGUGUCC AUUCUUCACGCCU
#13 ACACCCGUUAACUCUGAGGCCCGUGUCCUAUUCUUCACGCCU

GROUP 2 (5 clones)

#27 AACACCCCGGUCUGACGCCUUGUUCGAAUUCUUCACCCGU
#8 GAACACCCCGGUCUGACGCCUUGUUCGAAUUCUUCACCCGU
#33 AACACC CCGGUCUGACGCCUUGUUCGAAUUCUUCACCCGU
#34 AACACCCCGGUUUGACGCCUUGUUCGAAUUCUUCACCCGU
#36 AACACCCCGGUCUGACGCCUUGUUCG AAUUCUUCACCCGU

1

57

7 8 9 10 11 12 13 14

15 16 17 18 19

Table 3 (Page 2)

SEQ ID
NO.

ORPHANS (9 clones)

#4 GGUUCCUGUUCUACUUUCUAAUUAUCCGCACCUCCUCCU
#6 UGGAGUUUUAAUCUUACUCCUACUCUUGCUCACUGGGU
#7 GAUUCAUUUUGAUCUUUCUUCUUAUCCCGCUGUGCCU
#23 AUUCCUUUUCCUUUCUUCUUUGACCGACUGAUCCGCCU
#25 UAAUCUACAUUAUUAUUUUUUUUUUUCCACCAUCGU
#28 AGGUUUGGAGGGGUCCUUUUUUUGUCUGCGGACCGU
#16 CAUCCCUAGAGCAGCCAGCCGGAAGAAGUCACGCCUGCU
#17 UAGUGACCGUCAGGUAGGUGGUUAGGCCAUUACGUACGU
#30 GUGCCAACA AUGGAGGUCGGGUUAGGUAAAGCCAACGGGU

b) IFN-gamma 2'NH, Sequences

5' -GGGAGGACGAUGCGG (40N) CAGACGACUCGCCCGA -3'

40N

GROUP 1 (25 clones)

#7 UAGUAGCGCGAUUAAGCG CUGGUAGGGUUGCCGGUGGAU
#B4, B5, B6 UAGUAGCGCGAUUAAGCG CUGGUAGGGUAGCCGGUG AU
#8 UUGUAGCGCGGAUAUAGCG CUGGUAGGGUUGCCGGUGGAU

20
21
22
23
24
25
26
27
28

58

1

29
30
31

Table 3 (Page 3)

SEQ ID	NO	SEQ ID	NO
#B23	32	UGGUAGCGCGAUUAGCG	CUGGUAGGGUAGCCGGUG AU
#17, 24, B3, B10	33	UGGUAGCGCGAUUAGCG	CUGGUAGGGUAGCCGGUG AU
#33	34	UUUUAGCGCGAUUAGCG	CUGGUAGGGUAGCCGGUG AU
#31	35	UGGUAGCGCGAUUAGCG	CUGGUAGGGUAGCCGGUGGGU
#B7	36	UUUUAGCGCGAUUAGCG	CUGGCAGGGUAGCCGGUGGGU
#11	37	UGGCAGCGCGAGAUAGCG	CUGGUAGGGUAGCCGGUGGAU
#B13	38	UGGUAGCGCGACAUAAGCG	CUGGUAGGGUAGCCGGUG AU
#6, 14	39	AAGUGGUAUCCCAUAGGGGUCGGU	GGUAGGGUAGCCGGUGGAGCGGUG
#23	40	UGUGUGGGGUGCCAUAUAACC	CCGGUUGGGUAGACGGGUGU
#13, 15, 18, 22, B8	41	UAGUGCUCACAGAGC	GGUUGGGUAGCCGGUGGAGCGGUG
#25	42	UGUGUGGCAAUUAAGCACCGGUGGUGGUAUUCGGUGGCU	
#12	43	AGGCUCAAAGGC C	GGUUGGGUAGGUAACUGUGUGCGGUG

GROUP 2 (15 clones)

#16	44	UAUGGUGGGUUUACGCGAGAGUAAGGGUCCGCGUGGU
#29	45	ACGUUAGGUGGGUUCGUAGUAUUGGGCUCGUAGCGUGGGU
#30	46	CAGGUAAUUACAUGAAGGUGGGUAGGUACUUUCAGGGU
#B9, B22	47	UAGGUAAUUACAUGAAGGUGGGUAGGUACUUUCAGGGU
#B12	48	CAGUAAAUUCGGUAGGUGGGUAGGUAGGUAUCGUGAGGGU
#35	49	UAUGGUGGGUUGCACGUAAUUAAGGGACGUACAUCUGUGCU
#B14	50	UAUAGGUAAUUAUACAGGUGGGUAGUGGGGAAACGGGCUUGUGGU
#32	51	UACAGGUGGGUCCUGGAUAAUUGGGCACGCUCUAUCUCCU
#B16	52	CACUAGGUGGGUCCUGGUGGUGGUAACGUAACUUCGCGU

Table 3 (Page 4)

SEQ ID	NO.
53	
54	
55	
56	
57	

#B24	UACUAGGUGGUCGUGGUGUUGGGCACGUAAUUCGCGU
#34	ACGUGGCCUUAGAUAGGCAGGUGGUAAGCAUAUUCAGU
#10	UUCGGGCCUAAUUAAGGCAGAGGUAAGCAUUGCU
#B2	UGACUACGCCUCUGUAGUAGGUCGGGUUAGG CAUUGGGCGU
#B11	UGCGCAAUUGCGCAGGUCGGGUUAGGUUAUCUGGGUAGCU

c) IFN-gamma 2'F/NH, Sequences

5' -GGGAGGACGAUGCGG (40N) CAGACGACUCGCCCGA -3'

40N

GROUP 1 (11 clones)

#3	UUCAGAGGGUAGGUAAUGUGGGAGGAAAUUGCCGUUUCGCCU
#4	AGGUAAAGAGGGAGGACCUUCCAGUGAAUGCGCGUGGU
#14	AGGCCUGUGGAGGAUUUGUGGGUGGUUGGCCACGCGCGU
#32	UCCAAAGAGGGUGGUUGUGGGUGGCACUAAGGUACCGCGU
#2	UAUUCGUAAGGCCAGAGCUCGGGUGGGACCUCCGGCCU
#3, A8, 13	CCAUAGUGGGUGGUAUUGGAGUGGAAUAGUGCCGAGCGU
#15, 23, 33	UGCACAUGAGGGUGGUGUGGGAGGAAACGUGACGCAUGGU
#1	UUCGUCGUGGGUAUGGUUUUGGGUAUACCGGCUUGGU

1

60

58
59
60
61
62
63
64
65

Table 4

SEQ ID
NO.

Truncated IFN-gamma Ligands

2'F

#1 (Kd=6.8/320 nM full-length; Kd=4.4/716 nM truncate)
5'-gggaggacgaugcggACACCGUUAUCUGAGGCCCUUCCUUAUCCUUCACGCCUCaga-3'

66

#6 (Kd=3.2/314 nM full-length)
5'-GUUUUAUCUUAACUCCUACUCUUGCUCACUGGGUcagacgacuc-3' (orphan)

67

#16 (Kd=9.3/232 nM full-length)
5'-gggaggacgaugcggCAUCCUAGAGCAGCCAGCCGGAAGAAGUCACGCCUUCUca-3' (orphan)

68

#27 (Kd=8.8/384 nM full-length)
5'-gggaggacgaugcggAACACCCCGUCUAGCGCUUGUCCGAUUCUCCACCGUcagacgac-3'

61

69

#28 (Kd=35 nM full-length; Kd=53 nM truncate)
5'-gggaggacgaugcggAGGUUGGAGGGGUCCUUCU-3' (orphan)

70

2'NH₂

#17 (Kd=1.8/750 nM full-length; Kd=12.4 nM truncate)
5'-gggaggacgaugcggUGGUAGCGCGAUADAGCCUGGUGAGGGUUGCCGGUG-3'

71

#30 (Kd=2.7/103 nM full-length; Kd=11 nM truncate)
5'-gggaggacgaugcggCAGGUAAUUAUACAUGAAGGUGGGUUAAGGUA-3'

72

2'F/NH₂

#3 (Kd=106 nM full-length; Kd=119 nM truncate)
5'-(g)ggacgaugcggUUCAGAGGGUAGGUAAUGGGAGGAAAAAUGCCGUUAUCG-3'

73

73

Table 5

SEQ ID
NO.

ON8 TEMPLATES AND PRIMERS

40N8 ssDNA Template

5' GGGAGACAAGAAATAAACGCTCAA [-40N-] TTCGACAGGAGGCTCACAACAGGC 3' 74

SELEX PCR Primers:

5P8:

5' TAATACGACTCACTATAGGGAGACACAAGAAATAAACGCTCAA 3' 75

3P8:

5' GCCTGTTGTGAGCCTCCTGTCGAA 3' 76

Cloning PCR Primers:

5P8H:

Hind III

5' CCGAAGCTTTAATACGACTCACTATAGGGAGACAAGAAATAAACGCTCAA 3' 77

3P8B:

Bam HI

5' GCCGGATCCGCCCTGTTGTGAGCCTCCTGTCGAA 3' 78

PCR Sequencing Primer:

pUC19F30:

5' AGTCACGACGTTGTAAACGACGGCCAGTG 3' 6

Table 6
SELEX STRATEGY

Interleukin-4 (IL-4)

Round	IP Protein	RNA:Protein	RNA Pre-filtration	Stringent Wash	Bio-spin purified RNAs
1	10^{-6}	5			
2	10^{-6}	2.5			
3	10^{-6}	1.5			
4	10^{-6}	1			
5	10^{-6}	1	X		
6	10^{-6}	1			
7	5×10^{-7}	1	X		
8	10^{-7}	1	X	X	
9	10^{-7}	1	X	X	
10	10^{-7}	1	X	X	
11	10^{-7}	1.5	X	X	X
12	10^{-7}	1.5	X	X	X
13	10^{-7}	1.5	X	X	
14	2×10^{-8}	5			X
15	10^{-8}	5			X
16	2×10^{-9}	5	X	X	X
17	10^{-9}	5	X		X

Table 7

SEQ ID
NO.

a) IL-4 2'F Sequences

5' -GGGAGACAAGAAUAAACGCUCAA (40N) UUCGACAGGAGGCUCACAACAGGC-3'

40N

GROUP 1 (29 clones)

#2	CUAUGGGGAGCCACAUU	AACGGCAUAAAUCAUUACGAC	79
#3	CUAUGGGGAGCCACAUUU	AACGGCUAUAAAAACAUAUACGAC	80
#6	CUCGGGAGCCAGAGUAAC	AACGGCAUUAUAUAUUUACU	81
#7, 8, 11, 16	UCCCAACGGGUGCCACGGUUUA	AACGGCUUAAUAUGAAU	82
#12	GUCUGACUAUUGGGCGCCACAUAUC	AACGGCUGUAC	83
#17	UCCCAACGGGUGCCACGGUUUA	AACGGCUUAAUAUUUACU	84
#19	GUCUUCCAUGGGGAGCCACAUU	AACGGCGCAUAUCUGAAC	85
#22, 27, 34, 40	CUCGGGAGCCAGAGUAAC	AACGGCACUAUAUAUUUACU	86
#26	CUAUGGGGAGCCACAUUU	AACGGCAUAAAUCAUUACGAC	87
#28	AGUGGGGAGCCACACUAA	AACGGCAUAUUGACAUCGUGCCC	88
#31	UCUCCUCAUGGGCGCCACAUGGUUUUA	AACGGCAUAUCACU	89
#32	CUAUGGGGAGCCACAUUU	AACGGCUAUAUAUAUUACGAC	90
#35	ACUGGGGAGCCACAGAUUU	AACGGCGCAUAUGAGUUGAGC	91
#39	CUCUCACUGGGGAGCCACAGUUUA	AACGGCAAGGGAGA	92
#41	CAUCAGAUGGGGUGCCACAUAUCA	AACGGCUAUUA	93
#44	ACUGGGGAGCCACAGAUUU	AACGGCACUAUAUGAUUGAGC	94
#42	AACGGCUGUAACAACAAGGUGGGGGCCACACCAG	AGCGGC	95
#9, 15, 1, 33, 46			
	ACGGCUGUAACAACAAGGUGGGGGCCACACAGCGGUUCGAC		96
#25	ACGGCUGUGACAACAACAAGGUGGGGGCCACACAGAGCGGG		97

DI QES
No.

[illegible]

Table 7 (Page 3)

SEQ ID	NO.	
#B31	113	GAGCUGG UGAGCCACG UAUA CGGUCUUAGGGGCUUGGGCG
#17	114	GUUAUUGG GGAGCCACAU UACAACGGCACAGGCAACCAGGG
#31	115	GUGCUGG UGAGCCACGC AUA CGGUCUUAGGGGCUUGAGCG
#B14, B19	116	UAAAUUGG AGAGCCACAC UA A CGGCGUAUGAAACACUCA
#B16, B17	117	UCACAAGCACCCUUGG GGAGCCACA UUAA CGGCCUAGGC
#B26	118	AUGG AGAGCCACA UUAA CGGCAGCAUAUCACAGUAGGAA
#B8	119	UGUGG GGAGCCACAG UUAA CGGCUUCAACUGAUUAGAA
#B24	120	AGAUUUAAAGUAUUUGG GGAGCCACA UCAA CGGCAUUGUG
#B29	121	UGACUGAACGAUGGUAUUGG AGAGCCACA UCAA CGGCAAU
#22	122	CAGAUUGUAUCUAGUGG AGAGCCACA UCAA CGGCGCAGA
#B5	123	CGAUAGUAUACACAUGAUGG GGAGCCACG UGUA CGGC
#B18, B20	124	CGAUGG AGCGCCACAUCGCUAUAACGGCAUUUAACAAAU
#B33, B34	125	GCGGUCUGAUUGAGCCACCG UGGA GGGUACGUGGAGGGA
#6'ACA	126	UUUCACACAGAAACAGCUAUGACCAUGAUUACGCCA
ORPHAN (1 clone)	127	AGCUUUGG GGAGCCACA UAUAACGGCAUGAUCAAUAUAG
#32	128	AUACAAUGUGGUUGAAGCUACCUCCACUCUGUAGUGGCC
NITROCELLULOSE FILTER BINDERS (35 clones)		
#1, B4	129	CCGUAGCCUCCAGCGGAACGCGGAGGGUACGUGGAGGGG
#2, 3, 24, 25, 26, 36, B9, B15, B22	130	CCGUAGCCUCCAGCGGAUUGCGGAGGGCACGUGGAGGGG
#5	131	GAGCCUCCGUGAAUGACGUGGAGGCACGC GGAGGGGAA
#8	132	UCGAUACUACUCCUGGAGAAAAGGGAGGACCGU GGAGGA
#10	133	UCGAUACUACUCCUGGAGAAAAGGGAGGAUCCU GGAGGA

Table 7 (Page 4)

	SEQ ID	NO.
#11, B6	134	GCGGUCUGAUUGAGCCUCCGUGGAGGGUACGUGGAGGGA
#18	135	AGGGUGGAUUGU GGAGGAUAGAUUGUCUAUGGACUCCA
#19	136	UCGAUACUACUCCUGGAGAAAGGGAGGAUCGU GGAGGAA
#28	137	CCGAUACUACUCCUGGAGAAAGGGAGGAUCGU GGAGGAA
#30	138	GGGAGGAUAGU GGAGGAAGAGCGUGUAAUAUGUUACGA
#34	139	UCGUAGCCUCCAGCGGAUUGCGGAGGGCACGUGGAGGGG
#35	140	UCGAUACUACUCCUGGAGAAAGGGAGGAUCGU GGAGGAA
#B3	141	CCGCAGCCUCCAGCAUUGCGGAGGGCACGUGGAGGGG
#B7	142	GAGCCUCCGAGAAUGACGUGGAGGGUACGUGGAGGGGUA
#B11	143	CCGUAGCCUCCAGCGGAACGCGGAGGGCACGUGGAGGGG
#B12	144	UGCCGAGAGGAGGGCUGA GGAGGACGCGCAUUAAGUGA
#B13	145	UCGAUACUACUCCUGGAGAAAGGGAGGAUCGU GGAGGAU
#B23	146	GAGCCUCCGAGAAUGACGUGGAGGGCACGUGGAGGGGAA
#B25	147	UGCUGAGAGGAGGGCUGA GGAGGACACGGCAGUAUGAGA
#B27	148	ACGUAGCCUCCAGCGGAUUGCGGAGGGCACGUGGAGGGG
#B28	149	GCGGUCUGAUCCAGCCUCCUGGAGGGUACGUGGAGGGGA
#B30	150	GCGGUCUGAUUGAGCCUCCUGGAGGGCACGUGGAGGGGA
#B32	151	UGCCGAGAGGAGGGCUGA GGAGGACACGGCAGUAUGUAA
#B36	152	CCGUAGCCUCCAGCGGAUUGUGGAGGGCACGUGGAGGGG
#9	153	AAGGUGGGUUCGU GGAGGAUAGAGCUCGCCAGCUAA

67

c) IL-4 2'F/NH₂ Sequences

5' -GGGAGACAAGAAACGCUCAA (40N) UUCGACAGGAGGCUCACAACAGGC -3'

Table 7 (Page 5)

SEQ ID
NO.

40N

GROUP 1 (7 clones)

#9	AGAGUGCAGGUCUGGGGCCACA	AUUACA	ACGG	CAAUAA
#19	GUCUCCAUUGGGAGCCACAUA	ACGGCG	CAAUACUGAAC	
#13	CUCGGGAGCCAG	AGUACA	ACGGCACUAUAUAUUUAC	
#25	AGAGCCGUUUUGGGACCCAC	AGUA	ACGGUUUAUGGUA	
#8,10	GUCGGAGCGAUGGAGGCCACG	AUAU	ACGGUCUGUGCGC	
#41	AGUAACGUGGGAGCCACACGU	AAU	ACGGCACUAA	

154
155
156
157
158
159

GROUP 2 (11 clones)

#16	GGUACGA	CCAAG	GAAUGUGGGUGGAAG	AGGGCGCCGUACC
#28	GAUCCUGCGACGCCA		GGGUGGAU	AGGGGGAAGGGAGCGG
#2	GACGAACGA	CCAAG	GGACGGGUGGGCAAU	AGGGAUGCCG
#11,22,29,30,44,45				
	GGUACGA	CCAAG	GAAUGUGGGUGGAAG	AGGGUGCCGUACC
#43	CAACGCUGA	CCA	UGGGAGGAUUGUGGGAAGGGCGCCAGCG	
#14	CAGCCA		AGGGUUGGAUAGGGGUAGGGAGCCGUAGCAGCG	

160
161
162

163
164
165

ORPHAN (1 clone)

#18 CCGCCUGGAUAGUAGACCGUUGAGCUGAGAGCAACACU

166

NITROCELLULOSE FILTER BINDERS (11 clones)

Table 7 (Page 6)

		SEQ ID
		NO.
#1	AAGGUGGGUUGAGGAGGAAAGUAGCGUGAGUCAGUACCA	167
#4	AGGGAGGAUUGUGGAGGAGGAGGAGUGGAAGUGUCCAGCC	168
#5	GGAUGACCAAGCGUCCGAAACGAGGGAGGAUUGUGGUGGAGG	169
#12	GGGUGGAUUGUGGAGGAGGAAGUAGCGCAGGGUCCGUAAGCC	170
#21	AGGAGCGCCAUGAAGCAAGCAAGGAGGAUUGUGGUGGAAGGC	171
#24	ACUGGAGCCAUACAGACGAGAGGAUGGGUGUGGAGGGA	172
#31	AGGGAGGAUUGUGGAGGAGGAGGAGUGGAAGUGUCUCAGCC	173
#32	UCGGGUGAGGACUGGUAGAAAGGAGGGUUGUGGAGGAG	174
#34	ACCUGAUAAACCGCGGAGGAGGAGGAUAGAGGAGGAAGUGCCG	175
#35	AGGCAGCCCCUCGACGAGAAAGGUGGGUAGUGGAGGGAAC	176
#42	CUUACGACACCAAGGAGGAGGAUUGUGGUGGAUUGGGGUCG	177

Table 8

Truncated IL-4 Ligands		SEQ ID NO.
<u>2'F</u>		
#9 (Kd=14.7 nM full-length; Kd=18 nM truncate) 5'-(99g)aaACGGCUGUAACAACAAGGUGGGGGCCACACA-3'		178
#12 (Kd=30 nM full-length) 5'-gggagacaagaauaaacgcucaaaGUCGACUAUUGGGGGCCACAAUAUCAAGGC-3'		179
#18 (Kd=43 nM full-length) 5'-aagaaauaaacgcucaaaGCGCCCAAGGAUUUAACUUGGACCGCGAUCU-3' (orphan)		180
#21 (Kd=11 nM full-length) 5'-AAGCAAAGGGAGGAUUGUGGGAAGGCUUC-3' (orphan)		181
<u>2'NH₂</u>		
#29 (Kd=8.3 nM full-length; Kd=10 nM truncate) 5'-(99g)acgcucaaaGAGCUGGUGAGCCACGUAUACGGCCUUAAGGGGCUUGGGCG-3'		182
<u>2'F/NH₂</u>		
#9 (Kd=3.3 nM full-length) 5'-gggagacaagaauaaacgcucaaaAGAGUGCAGGUCUGGGGGCCACAAUUAAGACGGCA-3'		183
#18 (Kd=30 nM full-length) 5'-gcucaaaCCGCCUGCGAUAGUAGACCG-3' (orphan)		184
#28 (Kd=8.7 nM full-length) 5'-CCUGCGACGCCAGGGGUGGAUAGGGGAAGGAGCGGuucgacagga-3'		185

Table 9

	SEQ ID NO.
Initial random sequence RNA pool:	
5'-GGGAGACAAGAAUAAACGCUCAA-(N) ₄₀ -UUCGACAGGAGGCUCACAAACAGGC-3'	186
5'-Primer:	
5'-TAATACGACTCACTATAGGGAGACAAGAATAAACGCTCAA-3'	187
3'-Primer:	
5'-GCCTGTTGTGAGCCTCCTGTCGAA-3'	188

Table 10

			SEQ ID
			<u>NO.</u>
43	(10) :	ACAUCGUAA--CUCUA-AGGGCCUGGAUAUACGAUGAA	189
64	:	ACAUCGUAA--CUCUA-AGCGCCUGGAUAUACGAUGAA	190
64a	:	ACAUCGUAA--CUCUA-AGAGCCUGGAUAUACGAUGAA	191
64b	:	ACAUCGUAA--CUCUA-AGUGCCUGGAUAUACGAUGAA	192
55	5 :	ACAUCGUAAAU--CUCUA-AGAGCCUGGAUAUACGAUGAA	193
68	:	ACAUCGUAAAUUCUCUCUA-AGAGCCUGGA-AUACGAUGAA	194
6	:	AUCCCA-AU--CUCUA-AGAGCCUGGA-U--AAGAAUGCGCAUUGGGC	195
54	:	AUCCCA-AU--CUCUA-AGAGCCUGGA-U--GACAAU-CGCAUUGGGC	196
57	:	AUCCCA-AU--CUCUA-AGAGCCUGGA-U--GAGAAUGCGCAUUGGGC	197
10	:	CUGAGAU--CUCUA-AGAGCCUGGACU-CAG-CUCCGACUGACC	198
34	:	CUGAGAU--CUCUA-AGAGCCUGGACU-CAG-CUCCGAUUGAUCC	199
41	:	CUGAGAU--CUCUA-AGAGCCUGGACU-CAG-CUCCGAUUGAACC	200
15	(2) :	UCUCUA-UGAGCCUGGA-U-CGACGAACUCUCUACGGGCUGUG	201
56	(2) :	UCUCUA-AGAGCCUGGA-U-GUCGAGGGGCCAUUUCGCACGC	202
2	:	AUCUCUACUGAGCCUGGA-U-UCGCCAGAAGUUUAUCACAGU	203
59	:	CGUAAAAGUUAUCGAU--CUCUG-UGAGCCUGGA-U-CGAUUAC	204
3	:	CUGAGAU--CUCUA-AGAGCCUGGACUCAGCUACGAUUGAGCGUUUAUUCUUG	205

Table 11

SEQ ID
NO.

STARTING RNA:

5'-GGGAGCUCAGAAUAAACGCUCAA (N₃₀) UUCGACAUGAGGCCCGGAUCCGGC 206

PCR PRIMER 1:

BamH I

5'-GCCGGATCCGGGCCTCATGTCGAA 207

PCR PRIMER 2:

Hind III

5'-CCGAAGCTTAATACGACTCACTATAGGGAGCTCAGAATAAACGCTCAA 208
T7 promoter

Sequences of the hTNF α ligands^a
TABLE 12

Clone	5' constant	random	3' constant	K _{0.1} nM ^d	Class	SEQ ID NO
1A ^b (2) ^c	gggagctcagaataaaacgctcaaacgctgacacgctggacttgcgtattg		ttcgacatgaggcccggtatccggc			209
2A (3)	gggagctcagaataaaacgctcaaacgcttgaccatttgcgtagggtcgcccttg		ttcgacatgaggcccggtatccggc			210
3A (2)	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc	135	I	211
4A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc	320	II	212
5A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			213
6A (7)	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc	120	II	214
7A (2)	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			215
8A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc	785	I	216
9A (4)	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			217
10A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			218
11A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			219
12A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			220
13A (2)	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			221
14A (4)	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			222
15A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			223
16A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			224
17A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			225
18A (2)	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			226
19A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			227
20A (3)	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			228
21A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			229
22A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			230
23A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc	52	I	231
24A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			232
25A (2)	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc	40	I	233
26A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			234
27A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			235
28A	gggagctcagaataaaacgctcaaacgctcgaatcgacgcatcgagtcgctcgccttc		ttcgacatgaggcccggtatccggc			236

TABLE 12 (Page 2)

Sequences of the hTNF α ligands^a

Clone	5' constant	random	3' constant	K _d nM ^b	Class	SEQ ID NO
1C	gggagctcagaataaaacgctcaacgggtgaatcacggctgggtgcgttgcccc		ttcgacatgagggcccggtatccggc			237
2C (2)	gggagctcagaataaaacgctcaacgtcgacgcactgtgcgccttcacacacgcg		ttcgacatgagggcccggtatccggc			238
3C (2)	gggagctcagaataaaacgctcaacgggaacgtcatgcccgttcattgcccacg		ttcgacatgagggcccggtatccggc			239
4C	gggagctcagaataaaacgctcaactaggccacacgctcccttctaacacacgtc		ttcgacatgagggcccggtatccggc	92	I	240
5C	gggagctcagaataaaacgctcaacagtcacgaacgtgcgcccgggaagacgctc		ttcgacatgagggcccggtatccggc			241
6C	gggagctcagaataaaacgctcaatgtcgacacgtgtccggcccgccctacccc		ttcgacatgagggcccggtatccggc			242
7C (2)	gggagctcagaataaaacgctcaacagggtggcaccgccccttccaacacggtgcg		ttcgacatgagggcccggtatccggc	297	I	243
8C (2)	gggagctcagaataaaacgctcaacttgccgagcggtccttagtg		ttcgacatgagggcccggtatccggc	430	II	244
9C	gggagctcagaataaaacgctcaaatggtggagggccatctcaaacccacgacac		ttcgacatgagggcccggtatccggc	120	I	245
10C	gggagctcagaataaaacgctcaacgcccagagacccacccctcataaacacccgtacc		ttcgacatgagggcccggtatccggc	500	I	246
11C	gggagctcagaataaaacgctcaatgaggcggccacacaggtggccctcaacccc		ttcgacatgagggcccggtatccggc	140	I	247
12C	gggagctcagaataaaacgctcaagtcgccgatgatgttcgaacacagcatacaac		ttcgacatgagggcccggtatccggc	690	I	248
13C	gggagctcagaataaaacgctcaagggtggtgcccctacgtgccccttcgttta		ttcgacatgagggcccggtatccggc			249
14C	gggagctcagaataaaacgctcaacggcttgacaggtcgccggaatgacccgacaca		ttcgacatgagggcccggtatccggc	60	II	250
15C	gggagctcagaataaaacgctcaactagttcaaccgtcccttctaacacacccgtc		ttcgacatgagggcccggtatccggc	124	I	251
16C	gggagctcagaataaaacgctcaacctgtgtggtcggtcgccctcagcctcaagg		ttcgacatgagggcccggtatccggc	200	I	252
17C	gggagctcagaataaaacgctcaagatcgaaagtgtcggtccgctcagcgaactc		ttcgacatgagggcccggtatccggc			253
18C	gggagctcagaataaaacgctcaatgtcgagtgcgatggagtaggatgca		ttcgacatgagggcccggtatccggc	460	O	254
19C	gggagctcagaataaaacgctcaatgtcgatcggtcagggtccgctcctacttc		ttcgacatgagggcccggtatccggc	83	I	255

^aOnly unique sequences are shown. A unique sequence is defined as one that differs from all others by three or more nucleotides.

^bClone numbers followed by "A" were obtained from the round 23A or the round 6C pool. Clone numbers followed by "C" were obtained only from the round 6C pool.

^cThe number in parentheses indicates the occurrence of the clone in the sequenced pool.

^dNo value is shown for ligands that have K_d greater than 1 μ M.

TABLE 13

Binding specificity of the evolved
pool of ligands from round 23A

Target	KD, nM	Ratio: $K_{D \text{ Target}} / K_{D \text{ hTNF}\alpha}$
hTNF α	700	1
hTNF β	>1,000,000	>1,400
mTNF α	>1,000,000	>1,400

TABLE 14

Ki values of hTNF α competitors on the
U937 cell competition assay.

Competitor	Ki, nM	R*
sTNF-R2	3.3	0.99323
random RNA	>1,000,000	
6A	9,100	0.93776
25A	21	0.98105
4C	1,200	0.93496
14C	930	0.88453
18C	2,500	0.97483

*Fit correlation coefficient

TABLE 15

Effect of 2'-F-pyrimidine modification in the affinities
and inhibitory activities of the hTNF α ligands

Clone	2'OH K _D , nM	2'F K _D , nM	2'OH ^a K _i , nM	2'F K _i , nM	Class
3A (2)	135	623			I
4C	92	NB ^b	1,200		I
7C (2)	297	442			I
8A	785	ND ^c			I
9C	120	400			I
10C	500	NB			I
11C	140	NB			I
12C	690	NB			I
15C	124	NB			I
16C	200	123	~313	9,191	I
19C	83	NB			I
23A	52	400	~241	14,671	I
25A (2)	40	445	21		I
4A	320	178			II
6A (7)	120	74	9,100	8,156	II
8C (2)	430	503			II
14C	60	133	930	11,540	II
18C	460	NB	2,500		O

^aK_i values were obtained based on 5-8 point curves except for 16C and 23A 2'OH ligands where only 3 points were used.

^bNo binding.

^cNot determined.

Table 16.

SEQ ID
NO.

Starting DNA:

40N7:

5'GGGAGGACGATGCGG [-40N-] CAGACGACTCGCCCGA 3' 256

SELEX PCR Primers:

5G7:

5'GGGAGGACGATGCGG 3' 257

3G7:

5'XXXXTCGGGCGAGTCGTCTG 3' 258

X=biotin

TABLE 17
Conditions and progress of the SELEX Process against RANTES

Round	[DNA], M	[RANTES], M	net % bound	Signal/ noise	PF ^a	PS ^b	B-Wash ^c (ml)	U-Wash ^d (ml)	SPKD ^e , M KD ^f	nM
150 mM NaCl										
1	3.00E-05	3.0E-06	0.5	35.0	+		25	25	1.24E-03	3000
2	3.30E-06	3.3E-07	0.1	7.8	+		25	25	1.01E-03	
3	3.00E-06	3.0E-07	0.1	1.4	+		25	25	1.85E-03	
4	1.00E-06	1.0E-07	0.2	1.5	+		25	25		
5	3.00E-07	3.0E-08	0.2	1.5	+		25	50	2.20E-40	
6	1.00E-07	1.0E-08	0.2	1.9	+		50	100	4.09E-05	
7	1.00E-07	1.0E-08	0.4	1.5	+		50	100	7.89E-06	
8	3.00E-08	3.0E-09	0.3	1.9	+	+	50	100	1.91E-06	890
9	3.50E-08	3.0E-09	0.5	1.9	+	+	50	100	1.89E-06	
10	3.00E-08	3.0E-09	0.3	1.4	+	+	50	100	9.85E-07	
11	2.70E-08	3.0E-09	1.4	6.1	+	+	50	100	1.90E-07	
12	1.20E-08	3.0E-09	0.1	1.2	+	+	50	100	2.44E-06	
13	3.00E-08	1.0E-08	0.6	2.0	+	+	50	100	1.60E-06	159
14	2.50E-08	1.0E-08	0.2	2.0	+	+	10		4.96E-06	
15	2.50E-08	1.0E-08	0.7	3.0	+	+	5		1.39E-06	
16	2.50E-08	1.0E-08	0.5	3.5	+	+	5		1.96E-06	
17	9.00E-09	3.0E-09	0.2	1.5	+	+	5		1.48E-06	
18	6.00E-09	3.0E-09	0.2	1.4	+	+	5		1.49E-06	49
19	9.00E-09	3.0E-09	0.2	1.3	+	+	5		1.48E-06	18

^aPrefiltered DNA through nitrocellulose to counter select for nitocellulose binding molecules

^bPreadsorption of the DNA under binding conditions

^cVolume of buffer used to wash the captured complexes

^dVolume of 0.5M urea wash following the buffer wash

^eCalculated single point K_b from the binding data at each round

^fK_b values obtained from binding curves

References

References

- Adams, D. O., and T. A. Hamilton (1984) *Annu Rev. Immunol.* 2:283-318.
- Adams, S. M., and R. Blakesley (1991) *Focus* 13 (2):56-58.
- Aggarwal, B. B., W. J. Kohr, P. E. Hass, B. Moffat, S. A. Spencer, W. J. Henzel, T. S. Bringman, G. E. Nedwin, D. V. Goeddel, R. N. Harkins (1985) *J. Biol. Chem.* 260:2345-2354.
- Alam, R., S. Stafford, P. Forsythe, R. Harrison, D. Faubic, M. A. Lett-Brown, J. A. Grant (1993) *J. Immunol.* 150:3442-3447.
- Allen, P. M., and E. R. Unanue (1987) *Adv. Exp. Med. Biol.* 225:147-154.
- Anderson, P., Y. K. Yip, J. Vilcek (1982) *J. Biol. Chem.* 257:11301-11304.
- Bancroft, G. J., R. D. Schreiber, G. C. Bosma, M. J. Bosma, E. R. Unanue (1987) *J. Immunol.* 139:1104-1107.
- Bancroft, G. J., K. C. F. Sheehan, R. D. Schreiber, E. R. Unanue (1989) *J. Immunol.* 143:127-130.
- Bazan, J. F. (1990) *Immunol. Today* 11:350-354.
- Belosevic, M., D. S. Finbloom, P. H. VanderMeide, M. V. Slayter, C. A. Nacy (1989) *J. Immunol.* 143:266-274.
- Beutler, B., and A. Cerami (1989) *Ann. Rev. Immunol.* 7:625-655.
- Beutler, B., I. W. Milsark, A. C. Cerami (1985) *Science* 229:869-871.
- Bischoff, S. C., M. Krieger, T. Brunner, A. Rot, V. V. Tschärner, M. Baggiolini, C. A. Dahinden (1993) *Eur. J. Immunol.* 23:761-767.
- Bowen, B., J. Steinberg, U. K. Laemmli, H. Weintraub (1980) *Nucl. Acids Res.* 8:1-20.
- Brennan, F. M., D. Chantry, A. Jackson, R. Maini, M. Feldmann (1989) *Lancet* 2:244-247.
- Briscoe, D. M., R. S. Cotran, J. S. Pober (1992) *J. Immunol.* 147:2954-2960.

- Brockhaus, M., H. J. Schoenfeld, E. J. Schlaege, W. Hunziker, W. Lesslauer (1990) *Proc. Natl. Acad. Sci. USA* 87:3127-3131.
- Brown, M. A., J. H. Pierce, C. J. Watson, J. Falco, J. N. Ihle, W. E. Paul (1987) *Cell* 50:809-818.
- Buchmeier, N. A., and R. D. Schreiber (1985) *Proc. Natl. Acad. Sci. USA* 82:7404-7408.
- Casadaban, M., and S. Cohen (1980) *J. Mol. Biol.* 138:179-207.
- Casey, L. C., R. A. Balk, R. C. Bone (1993) *Ann. Intern. Med.* 119:771-777.
- Clerici, M., and G. M. Shearer (1993) *Immunol. Today* 14:107-111.
- Coffman, R. L., J. O'Hara, M. W. Bond, J. Carty, A. Zlotnik, W. E. Paul (1986) *J. Immunol.* 136:4538-4541.
- Crawford, R. M., D. S. Finbloom, J. O'Hara, W. E. Paul, M. S. Meltzer (1987) *J. Immunol.* 139:135-141.
- Davanloo, P., A. H. Rosenberg, J. J. Dunn, F. W. Studier (1984) *Proc. Natl. Acad. Sci. USA* 81:2035-2039.
- Del Prete, G., E. Maggi, P. Parronchi, I. Chraetien, A. Tiri, D. Macchia, M. Ricci, J. Banchereau, J. DeVries, S. Romagnani (1988) *J. Immunol.* 140:4193-4198.
- Derynck, R., D. W. Leung, P. W. Gray, D. V. Goedell (1982) *Nucl. Acids Res.* 10:3605-3615.
- Dinareello, C. A., and J. G. Cannon (1993) *Ann. Intern. Med.* 119:853-854.
- Ding, A. H., C. F. Nathan, D. J. Stuehr (1988) *J. Immunol.* 141:2407-2412.
- Duh, E. J., W. J. Maury, T. M. Folks, A. S. Fauci, A. B. Rabson (1989) *Proc. Natl. Acad. Sci. USA* 86:5974-5978.
- Eck, M. J., B. Beutler, G. Kuo, J. P. Merryweather, S. R. Sprang (1988) *J. Biol. Chem.* 263:12816-12819.
- Erbe, J. E., Collins, L. Shen, R. F. Graziano, M. W. Fanger (1990) *Mol. Immunol.* 27:57-67.
- Feldmann, M. (1989) *Immunology Supplement* 2:66-71.
- Ferrara, J. L. M., and H. J. Deeg (1991) *N. Engl. J. Med.* 324:667-674.

- Fiedler, V. B., I. Loof, E. Sander, V. Voehringer, C. Galanos, M. A. Fournel (1992) *J. Lab. Clin. Med.* **120**:574-588.
- Finkelman, F. D., I. M. Katona, J. F. Urban, Jr., C. M. Snapper, J. Ottara, W. E. Paul (1986) *Proc. Natl. Acad. Sci. USA* **83**:9765-9778.
- Finkelman, F. D., J. Holmes, I. M. Katona, J. F. Urban, Jr., M. P. Beckman, L. S. Park, K. Schooley, R. L. Coffman, T. R. Mosmann, W. E. Paul (1990) *Annu Rev. Immunol.* **8**:303-333.
- Finkelman, F. D., I. M. Katona, J. F. Urban, Jr., W. E. Paul (1989) In Ciba Foundation Symposium. IgE, Mast Cells and the Allergic Response. Wiley. Chichester, pp.3-22.
- Folks, T. M., K. A. Clouse, J. Justment, A. Rabson, E. Duh, J. H. Kehrl, A. S. Fauci (1989) *Proc. Natl. Acad. Sci. USA* **86**: 2365-2368.
- Galizzi, J. P., C. E. Zuber, N. Harada, D. M. Gorman, O. Djossou, R. Kastelein, J. Banchereau, M. Howard, A. Miyajima (1990) *Int. Immunol.* **2**:669-675.
- Gao, J. L., D. B. Kuhns, H. L. Tiffany, D. McDermott, X. Li, U. Francke (1993) *J. Exp. Med.* **177**:1421-1427.
- Gazzinelli, R. T., I. P. Oswald, S. L. James, A. Sher (1992) *J. Immunol.* **148**:1792-1796.
- Gleichmann, E., E. H. VanElven, J. P. W. VanderVeen (1982) *Eur. J. Immunol.* **12**:152-159.
- Gold, L., C. Tuerk, P. Allen, J. Binkley, D. Brown, L. Green, S. MacDougall, D. Schneider, D. Tasset, S. Eddy (1993) In the RNA World. Gesteland, R. F., and J. F. Atkins (eds.). Cold Spring Harbor Laboratory Press.
- Grau, G. E., L. F. Fajardo, P. F. Piguet, B. Allet, P. H. Lambert, P. Vassalli (1987) *Science* **237**:1210-1212.
- Green, S. J., R. M. Crawford, J. T. Hockmeyer, M. S. Meltzer, C. A. Nacy (1990) *J. Immunol.* **145**:4290-4297.
- Greenlund, A. C. (1992) *J. Interferon Res. (Abstr.)* **12**:S103.
- Gu, D., L. Wogensen, N. A. Calcutt, C. Xia, S. Zhu, J. P. Merlie, H. S. Fox (1995) *J. Exp. Med.* **181**:547-557.

- Haak-Frendscho, M., S. A. Marsters, J. Mordenti, S. Brady, N. A. Gillett, S. A. Chen, A. Ashkenazi (1994) *J. Immunol.* **152**:1347-1353.
- Harada, N., B. E. Castle, D. M. Gorman, N. Itoh, J. Schreurs, R. L. Barrett (1990) *Proc. Natl. Acad. Sci. USA* **87**:857-861.
- Heinzel, F. P., M. D. Sadick, S. S. Mutha, R. M. Locksley (1991) *Proc. Natl. Acad. Sci. USA* **88** 7011-7015.
- Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman, R. M. Locksley (1989) *J. Exp. Med.* **169**:59-72.
- Hershey, G. K. K., D. W. McCourt, R. D. Schreiber (1990) *J. Biol. Chem.* **265**:17868-17875.
- Higuchi, C. M., J. A. Thompson, C. G. Lindgren, S. Gillis, M. B. Widmer, D. E. Kern, A. Fefer (1989) *Cancer Research* **49**:6487-6492.
- Hinshaw, L. B., T. E. Emerson, Jr., F. B. Taylor, Jr., A. C. Chang, M. Duerr, G. T. Peer, D. J. Flournoy, G. L. White, S. D. Kosanke, C. K. Murray (1992) *J. Trauma* **33**:568-573.
- Hohmann, H. P., R. Remy, M. Brockhaus, A. P. G. M. Van-Loon (1989) *J. Biol. Chem.* **264**:14927-14934.
- Hoon, D. S. B., E. Okunn, M. Banez, R. F. Irie, D. L. Morton (1991) *Cancer Research* **51**:5687-5693.
- Horuk, R., C. E. Chitnis, W. C. Darbonne, T. J. Colby, A. Rybicki, T. J. Hadley, L. H. Miller (1993) *Science* **261**:1182-1184.
- Howard, J. G., C. Hale, F. Y. Liew (1980) *Nature* **288**:161-162.
- Howard, M., J. Farrar, M. Hilfiker, B. Johnson, K. Takatsu, T. Hamaoka, W. E. Paul (1982) *J. Exp. Med.* **155**:914-923.
- Hsieh, C. -S., S. E. Macatonia, C. S. Tripp, S. F. Wolf, A. O'Garra, K. M. Murphy (1993) *Science* **260**:547-549.
- Hu-Li, J., E. M. Shevach, J. Mizuguchi, J. O'Hara, T. Mosmann, W. E. Paul (1987) *J. Exp. Med.* **165**:157-172.
- Idzerda, R. L., C. J. March, B. Mosley, S. D. Lyman, T. V. Bos, S. D. Gimpel, W. S. Din, K. H. Grabstein, M. B. Widmer, L. S. Park, D. Cosman, M. P. Beckman (1990) *J. Exp. Med.* **171**:861-73.

- Isakson, P. C., E. Pure, E. S. Vitetta, P. H. Krammer (1982) *J. Exp. Med.* **155**:734-748.
- Jansen, J. H., G.-J. H. M. Wientjens, W. E. Fibbe, R. Willemze, H. C. Kluin-Nelemans (1989) *J. Exp. Med.* **170**:577-582.
- Jones, E. Y., D. I. Stuart, N. P. C. Walker (1989) *Nature* **338**:225-228.
- Jung, V., A. Rashidbaigi, C. Jones, J. Tischfield, T. B. Shows (1987) *Proc. Natl. Acad. Sci. USA* **84**:4151-4155.
- Katona, I. M., J. F. Urban, Jr., S. S. Kang, W. E. Paul, F. Finkelman (1991) *J. Immunol.* **146**:4215-4221.
- Keffer, J., L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, G. Kollias (1991) *EMBO J.* **10**:4025-4031.
- Khorram, O., R. N. Taylor, I. P. Ryan, T. J. Schall, D. V. Landers (1993) *Am. J. Obstet. Gynecol.* **169**:1545-1549.
- Kishimoto, T., T. Taga, S. Akira (1994) *Cell* **76**:253-262.
- Kühn, R., J. Löhler, D. Rennick, K. Rajewsky, W. Müller (1993) *Cell* **75**:263-274.
- Kühn, R., R. Rajewsky, W. Müller (1991) *Science* **254**:707-710.
- Kuna, P., S. R. Reddigari, T. J. Schall, D. Rucinski, M. Sadick, A. P. Kaplan (1993) *J. Immunol.* **150**:1932-1943.
- Kuna, P., S. R. Reddigari, T. J. Schall, D. Rucinski, M. Y. Veksman, A. P. Kaplan (1992) *J. Immunol.* **149**:636-642.
- Landolfo, S., F. Cofano, M. Giovarelli, Maria Pratt, G. Cavallo, G. Forni (1985) *Science* **229**:176-179.
- Le Beau, M. M., R. S. Lemons, R. Espinosa III, R. A. Larson, N. Arai, J. D. Rowley (1989) *Blood* **73**:647-50.
- Leal, L. M. C. C., D. W. Moss, R. Kühn, W. Miller, F. Y. Liew (1993) *Eur. J. Immunol.* **23**:566-569.
- Lebman, D. A., Coffman, R. L. (1988) *J. Exp. Med.* **168**:853-862.
- Lee, F., T. Yokota, T. Otsuka, P. Meyerson, D. Villaret, R. Coffman, T. Mossman, D. Rennick, N. Roehm, C. Smith, A. Zlotnik, K.-I. Arai (1986) *Proc. Natl. Acad. Sci. USA* **83**:2061-2065.

- Lenardo, M. J., and D. Baltimore (1989) *Cell* 58:227-229.
- Lewis, D. B., H. D. Liggitt, E. L. Effman, S. T. Motley, S. L. Teitelbaum, K. J. Jepsen (1993) *Proc. Natl. Acad. Sci. USA* 90:11618-11622.
- Liew, F. Y., S. Millott, J. Li, R. Lechuk, Y. L. Chan, H. Ziltener (1989) *Eur. J. Immunol.* 19:1227-1232.
- Loetscher, H., M. Steinmetz, W. Lesslauer (1991) *Cancer Cells* 3:221-226.
- Loetscher, H., Y.-C. E. Pan, H.-W. Lahm, R. Gentz, M. Brockhaus, H. Tabuchi, W. Lesslauer (1990) *Cell* 61:351-359.
- Lowenthal, J. W., D. W. Ballard, E. Boehnlein, W. C. Green (1989) *Proc. Natl. Acad. Sci. USA* 86:2331-2335.
- Lowenthal, J. W., B. E. Castle, J. Christiansen, J. Schreuers, D. Rennick, N. Arai, P. Hoy, Y. Takebe, M. Howard (1988) *J. Immunol.* 140:456-464.
- Mantovani, A., and E. Dejana (1989) *Immunol. Today* 10:370-375.
- McGee, D. P. C., C. Vargeese, Y. Zhai, G. P. Kirschenheuter, A. Settle, C. R. Siedem, W. A. Pieken (1995) *Nucleosides & Nucleotides* 14:1329-1339.
- McInnes, A., and D. M. Rennick (1988) *J. Exp. Med.* 167:598-611.
- Mogi, M., M. Harada, P. Riederer, H. Narabayashi, K. Fujita, T. Nagatsu (1994) *Neurosc. Lett.* 165:208-210.
- Mohler, K. M., D. S. Torrance, C. A. Smith, R. G. Goodwin, K. E. Stremler, V. P. Fung, H. Madani, M. B. Widmer (1993) *J. Immunol.* 151:1548-1561.
- Moore, K. W., P. Vieira, D. F. Fiorentino, M. L. Trounstein, T. A. Kahn, T. R. Mosmann (1990) *Science* 248:1230-1234.
- Moore, K. W., A. O'Garra, R. deWaal Malefyt, P. Vieira, T. R. Mossman (1993) *Ann. Rev. Immunol.* 11:165-190.
- Mosely, B., M. P. Beckman, C. J. March, R. L. Idzerda, S. D. Gimpel, T. VandenBos, D. Friend, A. Alpert, D. Anderson, J. Jackson, J. M. Wignall, C. Smith, B. Gallis, J. E. Sims, D. Urdal, M. B. Widmer, D. Cosman, L. S. Park (1989) *Cell* 59:335-348.
- Mosmann, T. R., M. W. Bond, R. L. Coffman, J. O'Hara, W. E. Paul (1986) *Proc. Natl. Acad. Sci. USA* 83:5654-5658.

- Mosmann, T. R., and R. L. Coffman (1989) *Annu. Rev. Immunol.* 7:145-173.
- Mulkerrin, M. G., and R. Wetzel (1989) *Biochemistry* 28:6556-6561.
- Munro, J. M., J. S. Pober, R. S. Cotran (1989) *Am. J. Path.* 135:121-131.
- Nelson, P. J., H. T. Kim, W. C. Manning, T. J. Goralski, A. M. Krensky (1993) *J. Immunol.* 151:2601-2612.
- Neote, K., W. Darbonne, J. Ogez, R. Horuk, T. J. Schall (1993) *J. Biol. Chem.* 268:12247-12249.
- Noma, Y., P. Sideras, T. Naito, S. Bergstedt-Lindquist, C. Azuma, E. Severinson, T. Tanabe, T. Kinashi, F. Matsuda, Y. Yaoita, T. Honjo (1986) *Nature* 319:640-46.
- Oliff, A., D. Defeo-Jones, M. Boyer, D. Martinez, D. Kiefer, G. Vuocolo, A. Wolfe, S. H. Socher (1987) *Cell* 50:555-563.
- Oliver, K., R. J. Noelle, J. W. Uhr, P. H. Krammer, E. S. Vitetta (1985) *Proc. Natl. Acad. Sci. USA* 82:2465-2467.
- Osborn, L., S. Kunkel, G. J. Nabel (1989) *Proc. Natl. Acad. Sci. USA* 86:2336-2340.
- Park, L. S., D. Friend, K. Grabstein, D. L. Urdal (1987) *Proc. Natl. Acad. Sci. USA* 84:1669-1673.
- Parrillo, J. E. (1991) *Annals Int. Med.* 115:491-492.
- Paul, W. E. (1991) *Blood* 77:1859-870.
- Paul, W. E., and R. A. Seder (1994) *Cell* 76:241-251.
- Pennica, D., V. T. Lam, N. K. Mize, R. F. Weber, M. Lewis, B. M. Fendley, M. T. Lipari, D. V. Goeddel (1992) *J. Biol. Chem.* 267:21172-21178.
- Pieken, W., D. B. Olsen, F. Benseler, H. Aurup, F. Eckstein (1991) *Science* 253:314-317.
- Piguet, P. F. (1992) TNF and Alloreaactions. Involvement of TNF in the Effector Phase of Graft-Versus-Host and host-Versus-Graft Reactions. TUMOR NECROSIS FACTORS: The Molecules and Their Emerging Role in Medicine. New York, Raven Press, Ltd.
- Plaut, M., J. H. Pierce, C. J. Watson, J. Hanley-Hyde, R. P. Nordan, W. E. Paul (1989) *Nature* 339:64-67.

- Pober, J. S., M. A. Gimbrone, Jr., L. A. Lapierre, D. L. Mendrick, W. Fiers, R. Rothlein, T. A. Springer (1986) *J. Immunol.* 137:1893-1896.
- Rabin, E., J. O'Hara, W. E. Paul (1985) *Proc. Natl. Acad. Sci. USA* 82:2935-2939.
- Rapoport, M. J., A. Jaramillo, D. Zipris, A. H. Lazarus, D. V. Serreze, E. H. Leiter, P. Cyopick, J. S. Danska, T. L. Delovitch (1993) *J. Exp. Med.* 178:87-99.
- Rathanaswami, P., M. Hachicha, M. Sadick, T. J. Schall, S. R. McColl (1993) *J. Biol. Chem.* 268:5834-5839.
- Ravetch, J. V. (1994) *Cell* 78:553-560.
- Rinderknecht, E., B. H. O'Connor, H. Rodriguez (1984) *J. Biol. Chem.* 259:6790-6797.
- Rot, A., M. Krieger, T. Brunner, S. C. Bischoff, T. J. Schall, C. A. Dahinden (1992) *J. Exp. Med.* 176:1489-1495.
- Salgame, P., J. S. Abrams, C. Clayberger, H. Goldstein, J. Convit, R. L. Modlin, B. R. Bloom (1991) *Science* 254:279-282.
- Sato, T. A., M. B. Widmer, F. D. Finkelman, H. Madani, C. A. Jacobs, K. H. Grabstein, C. R. Maliszewski (1993) *J. Immunol.* 150:2717-2723.
- Scahill, S. J., R. Devos, J. VanDerHeyden, W. Fiers (1983) *Proc. Natl. Acad. Sci. USA* 80:4654-4658.
- Schall, T. J. (1991) *CYTOKINE* 3:165-183.
- Schall, T. J., K. Bacon, K. J. Toy, D. V. Goeddel (1990) *Nature* 347:669-671.
- Schall, T. J., M. Lewis, J. Koller, A. Lee, G. C. Rice, G. H. Wong, T. Granger, G. A. Granger, R. Lentz, H. Raab (1990) *Cell* 52:415-423.
- Schall, T. J., N. J. Simpson, J. Y. Mak (1992) *Eur. J. Immunol.* 22:1477-1481.
- Schreiber, R. D., and A. Celada (1985) *Lymphokines*. 11:87-118.
- Schreiber, R. D., M. A. Farrar, G. K. Hershey, J. Fernandez-Luna (1992) *Int. J. Immunopharmac.* 14:413-419.
- Shanafelt, A. B., A. Miyajima, T. Kitamura, R. A. Kastelein (1991) *EMBO J.* 10:4105-4112.

- Sher, A, and R. L. Coffman (1992) *Ann. Rev. Immunol.* 10:385-409.
- Sher, A., R. T. Gazzinelli, I. P. Oswald, M. Clerici, M. Kullberg, E. J. Pearce, J. A. Berzofsky, T. R. Mosmann, S. L. James, H. L. Morse (1992) *Immunol. Rev.* 127:183-204.
- Singh, H., J. H. LeBowitz, A. S. J. Baldwin, P. A. Sharp (1988) *J. Biol. Chem.* 262:6951-6954.
- Snapper, C. M., and W. E. Paul (1987) *Science* 236:944-947.
- Smith, R. A., and C. Baglioni (1987) *J. Biol. Chem.* 262:6951-6954.
- Spits, H., H. Yssel, Y. Takebe, N. Arai, T. Yakota, F. Lee, K.-I. Arai, J. Banchereau, J. E. DeVries (1987) *J. Immunol.* 139:1142-1147.
- Steinman, L. (1993) *Scientific American* 269 (3):107-114.
- Strunk, R. C., F. Sessions Cole, D. H. Perlmutter, H. R. Colten (1985) *J. Biol. Chem.* 260:15280-15285.
- Suzuki, Y., M. A. Orellana, R. D. Schreiber, J. S. Remington (1988) *Science* 240:516-518.
- Sylvestre, D. L., Ravetch, J. V. (1994) *Science* 265:1095-1098.
- Te Velde, A. A., J. P. G. Klomp, B. A. Yard, J. E. DeVries, C. G. Figdor (1988) *J. Immunol.* 140:1548-1554.
- Tepper, R. I., P. K. Pattengale, P. Leder (1989) *Cell* 57:503-512.
- Tepper, R. I., D. A. Levinson, B. Z. Stanger, J. Campos-Torres, A. K. Abbas, P. Leder (1990) *Cell* 62:457-467.
- Thornhill, M. H., S. M. Wellicome, D. L. Mehioz, J. S. S. Lanchbury, U. Kyan-Aung, D. O. Haskard (1991) *J. Immunol.* 146:592-598.
- Traugott, U., and P. Lebon (1988) *J. Neurol. Sci.* 84:257-264.
- Trenn, G., H. Takayama, J. Hu-Li, W. E. Paul, M. V. Sitkovsky (1988) *J. Immunol.* 140:1101-1106.
- Trinchieri, G., and B. Perussia (1985) *Immunol. Today* 6:131-135.
- Tuerk, C., and L. Gold (1990) *Science* 249:505-510.

- Umland, S. P., S. Razac, D. K. Nahrebne, B. W. Seymour (1992) *Clin. Immunol. Immunopathol.* 63:66-73.
- Ushiyama, C., T. Hirano, H. Miyajima, K. Okumura, Z. Ovary, H. Hashimoto (1995) *J. Immunol.* 154:2687-2696.
- van Leeuwen, B. H., M. E. Martinson, G. C. Webb, I. G. Young (1989) *Blood* 73:1142-1148.
- van Rappard-van Der Veen, F. M., A. G. Rolink, E. Gleichmann (1982) *J. Exp. Med.* 155:1555-1560.
- Van-Riper, G., S. Sicilianl, P. A. Fischer, R. Meurer, M. S. Springer, H. Rosen (1993) *J. Exp. Med.* 177:851-856.
- Vassalli, P. (1992) *Annu. Rev. Immunol.* 10:411-452.
- Via, C. S., and G. M. Shearer (1988) *Immunol. Today* 9:207-212.
- Vieira, J., and J. Messing (1982) *Gene* 19:259-268.
- Vieira, P., R. deWaal-Malefyt, M. N. Dang, K. E. Johnson, R. Kastelein, D. F. Fiorentino, J. E. DeVries, M. G. Roncarlo, T. R. Mosmann, K. W. Moore (1991) *Proc. Natl. Acad. Sci. USA* 88:1172-1176.
- Visvanathan, K. V., and S. Goodbourn (1989) *EMBO J.* 8:1129-1138.
- Vitetta, E. S., J. O'Hara, C. D. Myers, J. E. Layton, P. H. Krammer, W. E. Paul (1985) *J. Exp. Med.* 162:1726-1731.
- Walter, M. R., W. J. Cook, B. G. Zhao, R. P. Cameron, Jr., S. E. Ealick, R. L. Walter, Jr., P. Reichert, T. L. Naqab-hushan, P. P. Trotta, C. E. Bugg (1992) *J. Biol. Chem.* 267:20371-20376.
- Wang, J. M., D. W. McVicar, J. J. Oppenheim, D. J. Kelvin (1993) *J. Exp. Med.* 177:699-705.
- Wheelock, E. F. (1965) *Science* 149:310-311.
- Widmer, M. B., and K. H. Grabstein (1987) *Nature* 326:795-798.
- Wiedermann, C. J., E. Kowald, N. Reinisch, C. M. Kaehler, I. von-Luettichau, J. J. Pattison, P. Huie, R. K. Sibley, P. J. Nelson, A. M. Krensky (1993) *Current Biology* 3:735-739.

Williams, R. O., M. Feldmann, R. N. Maini (1992) *Proc. Natl. Acad. Sci. USA* 89:9784-9788.

Yokota, T., T. Otsuka, T. Mossman, J. Banchereau, T. DeFrance, D. Blanchard, J. E. DeVries, F. Lee, K.-I. Arai (1986) *Proc. Natl. Acad. Sci. USA* 83:5894-5898.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: NEXSTAR PHARMACEUTICALS, INC.

DIANE TASSET

NIKOS PAGRATIS

SUMEDHA JAYASENA

LARRY GOLD

(ii) TITLE: HIGH AFFINITY NUCLEIC ACID LIGANDS OF CYTOKINES

(iii) NUMBER OF SEQUENCES: 258

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Swanson and Bratschun, L.L.C.

(B) STREET: 8400 East Prentice Avenue, Suite #200

(C) CITY: Denver

(D) STATE: Colorado

(E) COUNTRY: USA

(F) ZIP: 80111

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage

(B) COMPUTER: IBM compatible

(C) OPERATING SYSTEM: MS-DOS

(D) SOFTWARE: WordPerfect 6.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: Unassigned

(B) FILING DATE:

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 08/477,829

(B) FILING DATE: 07-JUNE-1995

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 08/481,710

(B) FILING DATE: 07-JUNE-1995

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Barry J. Swanson

(B) REGISTRATION NUMBER: 33,215

(C) REFERENCE/DOCKET NUMBER: NEX41/PCT

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (303) 793-3333

(B) TELEFAX: (303) 793-3433

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 71 base pairs

(B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: RNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
GGGAGGACGA UGCGGNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN 50
NNNNNCAGAC GACUCGCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
TAATACGACT CACTATAGGG AGGACGATGC GG 32

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
TCGGGCGAGT CGTCTG 16

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
CCGAAGCTTA ATACGACTCA CTATAGGGAG GACGATGCGG 40

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GCCGGATCCT CGGGCGAGTC GTCTG

25

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

AGTCACGACG TTGTAAAACG ACGGCCAGTG

30

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GGGAGGACGA UGCGGACACC GUUAAUCUGA GGCCUGUCC UAUUCCUUA
CGCCUCAGAC GACUCGCCCCG A

50

71

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGGAGGACGA UGCGGACACC GUUAGUCUGA GGCCUGUCC UAUUCCUUA
CGCCUCAGAC GACUCGCCCCG A

50

71

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GGGAGGACGA UGCGGACACC UUUAUCUGA GGCCUGUCC UAUUCCUUA 50
CGCCUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GGGAGGACGA UGCGGACACC UUGAAUCUGA GGCCUGUCC UAUUCCUUA 50
CGCCUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GGGAGGACGA UGCGGACACC GUUAUCUGA GGCCUGUCC UAUUCCUUA 50
CGCCUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

GGGAGGACGA UGCGGACACC GUAGAUCUGA GGCCCUGUCC UAUUCCUCCA 50
CGCCUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 70 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GGGAGGACGA UGCGGACACC GUUAAUCUGA GGCCCUGUCC AUUCCUUCAC 50
GCCUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

GGGAGGACGA UGCGGACACC GUUAAACUGA GGCCCUGUCC UAUUCCUUCA 50
CGCCUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

GGGAGGACGA UGCGGAACAC CCCC GGUCUG ACGCUUGUUC CGAAUUCUC 50
CACCGUCAGA CGACUCGCCC GA 72

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 73 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: RNA
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
 GGGAGGACGA UGCGGGAACA CCCCCGGUCU GACGCUUGUU CCGAAUCCU 50
 CCACCGUCAG ACGACUCGCC CGA 73

(2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERIZATION:
 - (A) LENGTH: 71 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: RNA
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
 GGGAGGACGA UGCGGAACAC CCCGGUCUGA CGCUUGUCC GAAUCCUCC 50
 ACCGUCAGAC GACUCGCCCC A 71

(2) INFORMATION FOR SEQ ID NO: 18:

- (i) SEQUENCE CHARACTERIZATION:
 - (A) LENGTH: 72 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: RNA
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
 GGGAGGACGA UGCGGAACAC CCCGGUUUG ACGCUUGUUC CGAAAUCCUC 50
 CACCGUCAGA CGACUCGCCC GA 72

(2) INFORMATION FOR SEQ ID NO: 19:

- (i) SEQUENCE CHARACTERIZATION:
 - (A) LENGTH: 71 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

GGGAGGACGA UGCGGAACAC CCCC GGUCUG ACGCUUGUUC CGAAUCCUCC 50
ACCGUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 70 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

GGGAGGACGA UGCGGGGUUC CUGUUCUACU UUCUAAUUUAU CCGCACCUC 50
UCCUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 71 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

GGGAGGACGA UGCGGUGGAG UUUUAAUCUU ACUCCUACU CUUGCUC 50
UGGUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 71 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:
GGGAGGACGA UGCGGGAUUC AUUUUGAUCU UUCUUUCUCU UAUCCCGCUG 50
UGCCUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:
GGGAGGACGA UGCGGAUUC UUUUUCUUU CUCUUUCUG ACCGACUGAU 50
CCGCCUCAGA CGACUCGCCC GA 72

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 75 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:
GGGAGGACGA UGCGGUAUUC UACACUUAUA UUUUUUUUCU UUUUCUUUCC 50
ACCCAUCGUC AGACGACUCG CCCGA 75

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:
GGGAGGACGA UGCGGAGGGU UGGGAGGGGU CCUUCUUUUC GUCUGCGUGG 50
ACCGUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 26:

100

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 71 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

GGGAGGACGA UGCGGCAUCC CUAGAGCAGC CAGCCGGAAA GAAGUCACGC 50
CUGCUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 71 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

GGGAGGACGA UGCGGUAGUG ACCGUCAGGU AGGUGGGUUA GGCCAUUACG 50
UACGUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 70 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

GGGAGGACGA UGCGGGUGCC AACAAUGGAG GUCGGGUUAG GUAAGCCAAC 50
GGGUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 70 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

GGGAGGACGA UGCGGUAGUA GCGCGAUUAU GCGCUGGUAG GGUUGCCGGU 50
GGAUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 69 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

GGGAGGACGA UGCGGUAGUA GCGCGAUUAU GCGCUGGUAG GGUAGCCGGU 50
GAUCAGACGA CUCGCCCCGA 69

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 70 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

GGGAGGACGA UGCGGUUGUA GCGCGAUUAU GCGCUGGUAG GGUUGCCGGU 50
GGAUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 69 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

102

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:
 GGGAGGACGA UGCGGUGGUA GCGCGAUUAU GCGCUGGUAG GGUAGCCGGU 50
 GAUCAGACGA CUCGCCCCGA 69

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 69 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:
 GGGAGGACGA UGCGGUGGUA GCGCGAUUAU GCGCUGGUAG GGUUGCCGGU 50
 GAUCAGACGA CUCGCCCCGA 69

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 69 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:
 GGGAGGACGA UGCGGUUGUA GCGCGAUUAU GCGCUGGUAG GGUUGCCGGU 50
 GAUCAGACGA CUCGCCCCGA 69

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 70 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:
 GGGAGGACGA UGCGGUGGUA GCGCGAUUAU GCGCUGGUAG GGUUGCCGGU 50
 GGGUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 70 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

GGGAGGACGA UGCGGUUGUA GCGCGAUUAU GCGCUGGCAG GGUUGCCGGU 50
GGGUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 70 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

GGGAGGACGA UGCGGUGGCA GCGCGAGUAU GCGCUGGUAG GGUUGCCGGU 50
GGAUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 69 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

GGGAGGACGA UGCGGUGGUA GCGCGACUAU GCGCUGGUAG GGUUGCCGGU 50
GAUCAGACGA CUCGCCCCGA 69

(2) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

GGGAGGACGA UGCGGAAGUG GUGAUCCCAU CUAGGGGUCG GUUGGGUCGA 50
CGGUGCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 72 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

GGGAGGACGA UGCGGUGUGU GGGGUGCCAU AUAACCCCGG UUGGGUUGAC 50
GGUGUCAGAG CGACUCGCCC GA 72

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 70 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

GGGAGGACGA UGCGGUAGUG CUCACAGAGC GGUUGGGUAG CCGGUGGAUG 50
CGGUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 71 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:
GGGAGGACGA UGCGGUGUGG UGCAAUCUAA GCACCGGUUG GGUAGUUCGG 50
UGGCUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:
GGGAGGACGA UGCGGAGGCU CAAAAGGCCG GUUGGGUUAG GUAACUGUGU 50
GCGGUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 67 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:
GGGAGGACGA UGCGGUAUGG UGGGUUUACG CGAGAGUAAG GGUCGCGUGG 50
UCAGACGACU CGCCCCGA 67

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:
GGGAGGACGA UGCGGACGUA UGGUGGGUUC GUAGUAUUGG GCUCGUAGCG 50
UGGGUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 70 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

GGGAGGACGA UGCGGCAGGU AAUACAUGA AGGUGGGUUA GGUACUUUCA 50
 GGGUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 70 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

GGGAGGACGA UGCGGUAGGU AAUACAUGA AGGUGGGUUA GGUACUUUCA 50
 GGGUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

GGGAGGACGA UGCGGCAGUA AAUUCGGUAG GUGGGUUAGG UAGGAUCGUG 50
 AGGGUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

GGGAGGACGA UGCGGUAUGG UGGGUUGCAC GUAUUAAGGG ACGUACAUCU 50
GUGCUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 77 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

GGGAGGACGA UGCGGUAUAG GUAACUAUCA GGUGGGUAGU CGGUGGAAAC 50
GGGCUGUJGG UCAGACGACU CGCCCCGA 77

(2) INFORMATION FOR SEQ ID NO: 51:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 71 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

GGGAGGACGA UGCGGUACAG GUGGGUCGUG GAUAAUUGGG CACGCUCUAU 50
CUCCUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 71 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:
GGGAGGACGA UGCGGCACUA GGUGGGUCGU GGUUGUUGGG CACGUAACUU 50
CGCGUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:
GGGAGGACGA UGCGGUACUA GGUGGGUCGU GGUUGUUGGG CACGUAACUU 50
CGCGUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:
GGGAGGACGA UGCGGACGUG GCCUAGAUUA GGCAGGUGGG UUAGGCAUUA 50
UCAGUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 70 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:
GGGAGGACGA UGCGGUUCGC GGCCUAAUUA AAGGCAGGAG GGUUAGGCAU 50
UGCUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 70 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

GGGAGGACGA UGCGGUGACU ACGCCUGUAG UAGGUCGGGU UAGGCAUUGG 50
GCGUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 57:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 70 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

GGGAGGACGA UGCGGUGCGC AAUUGCGCAG GUCGGGUUAG GUAUCUGGGU 50
AGCUCAGACG ACUCGCCCCGA 70

(2) INFORMATION FOR SEQ ID NO: 58:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 73 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

- (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

GGGAGGACGA UGCGGUUCAG AGGGUAGGUA AGUGGGAGGA AAAAUGCCGU 50
AUCGCCUCAG ACGACUCGCC CGA 73

(2) INFORMATION FOR SEQ ID NO: 59:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 71 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

110

- (D) TOPOLOGY: linear
(ii) MOLECULAR TYPE: RNA
(ix) FEATURE:
(D) OTHER INFORMATION: All U's are 2'-NH₂ modified
(ix) FEATURE:
(D) OTHER INFORMATION: All C's are 2'-F modified
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:
GGGAGGACGA UGCGGAGGUA AGAGGGAGGG ACCUCCAGU GAAUGUGCGC 50
GUGGUCAGAC GACUCGCCCCG A 71
- (2) INFORMATION FOR SEQ ID NO: 60:
(i) SEQUENCE CHARACTERIZATION:
(A) LENGTH: 71 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULAR TYPE: RNA
(ix) FEATURE:
(D) OTHER INFORMATION: All U's are 2'-NH₂ modified
(ix) FEATURE:
(D) OTHER INFORMATION: All C's are 2'-F modified
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:
GGGAGGACGA UGCGGAGGCC UGUGGUGAGG AUUGUGGGUG GUUGGCCACG 50
CGCGUCAGAC GACUCGCCCCG A 71
- (2) INFORMATION FOR SEQ ID NO: 61:
(i) SEQUENCE CHARACTERIZATION:
(A) LENGTH: 71 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULAR TYPE: RNA
(ix) FEATURE:
(D) OTHER INFORMATION: All U's are 2'-NH₂ modified
(ix) FEATURE:
(D) OTHER INFORMATION: All C's are 2'-F modified
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:
GGGAGGACGA UGCGGUCCAA AGAGGGUGGU UGUGGGUGGC ACUAAGGUAC 50
CGCGUCAGAC GACUCGCCCCG A 71
- (2) INFORMATION FOR SEQ ID NO: 62:
(i) SEQUENCE CHARACTERIZATION:
(A) LENGTH: 70 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

GGGAGGACGA UGCGGUAUUC GUAAGGCCAG AGCUGCGGGU GGGACCUC CG 50
GCCUCAGACG ACUCGCCCCG 70

(2) INFORMATION FOR SEQ ID NO: 63:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 70 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

GGGAGGACGA UGCGGCCAUA GUGGGUGGGU UUGGAGUGGA AUAGUGCCGA 50
GCGUCAGACG ACUCGCCCCG 70

(2) INFORMATION FOR SEQ ID NO: 64:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 71 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

GGGAGGACGA UGCGGUGCAC AUGAGGGUGG UGUGGGAGGA AACGUGACGC 50
AUGGUCAGAC GACUCGCCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 71 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

GGGAGGACGA UGCGGUUCCG UCCGUGGGAU AGGUUUGUGG GAUGUACCGG 50
CUGGUCAGAC GACUCGCCCC A 71

(2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 59 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

GGGAGGACGA UGCGGACACC GUUAAUCUGA GGCCUGUCC UAUUCCUUA 50
CGCCUCAGA 59

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 46 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

GUUUUAAUCU UACUCCUAC UCUUGCUGCA CUGGGUCAGA CGACUC 46

(2) INFORMATION FOR SEQ ID NO: 68:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

GGGAGGACGA UGCGGCAUCC CUAGAGCAGC CAGCCGAAA GAAGUCACGC 50
CUGCUCA 57

113

(2) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 64 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

GGGAGGACGA UGCGGAACAC CCCC GGUCUG ACGCUUGUUC CGAAUCCUC
CACCGUCAGA CGAC

50
64

(2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 37 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

GGGAGGACGA UGCGGAGGGU UGGGAGGGGU CCUUCUU

37

(2) INFORMATION FOR SEQ ID NO: 71:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 51 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

GGGAGGACGA UGCGGUGGUA GCGCGAUUA GCGCUGGUAG GGUUGCCGGU
G

50
51

(2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 44 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

GGGAGGACGA UGCGGCAGGU AAUACAUGA AGGUGGGUUA GGUA

44

(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 50 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

GGACGAUGCG GUUCAGAGGG UAGGUAAGUG GGAGGAAAAA UGCCGUAUCG

50

(2) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

GGGAGACAAG AATAACGCT CAANNNNNNN NNNNNNNNNN NNNNNNNNNN

50

NNNNNNNNNN NNNTTCGACA GGAGGCTCAC AACAGGC

87

(2) INFORMATION FOR SEQ ID NO: 75:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 40 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

TAATACGACT CACTATAGGG AGACAAGAAT AAACGCTCAA

40

(2) INFORMATION FOR SEQ ID NO: 76:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:
GCCTGTTGTG AGCCTCCTGT CGAA

24

(2) INFORMATION FOR SEQ ID NO: 77:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 49 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:
CCGAAGCTTT AATACGACTC ACTATAGGGA GACAAGAATA AACGCTCAA

49

(2) INFORMATION FOR SEQ ID NO: 78:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:
GCCGGATCCG CCTGTTGTGA GCCTCCTGTC GAA

33

(2) INFORMATION FOR SEQ ID NO: 79:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F
modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:
GGGAGACAAG AAUAAACGCU CAACUAUGGG GAGCCACAUU AACGGCAAUA
AAUCAUUACG ACUUCGACAG GAGGCUCACA ACAGGC

50

86

(2) INFORMATION FOR SEQ ID NO: 80:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 89 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULAR TYPE: RNA
(ix) FEATURE:
(D) OTHER INFORMATION: All pyrimidines are 2'-F modified
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80:
GGGAGACAAG AAUAAACGCU CAACUAUGGG GAGCCACAUU UAACGGCUAU 50
AAAAAACAUU ACGACUUCGA CAGGAGGCUC ACAACAGGC 89
- (2) INFORMATION FOR SEQ ID NO: 81:
(i) SEQUENCE CHARACTERIZATION:
(A) LENGTH: 86 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULAR TYPE: RNA
(ix) FEATURE:
(D) OTHER INFORMATION: All pyrimidines are 2'-F modified
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:
GGGAGACAAG AAUAAACGCU CAACUCGGGA GCCAGAGUAA CAACGGCAUU 50
AUUAUUUA CUUUCGACAG GAGGCUCACA ACAGGC 86
- (2) INFORMATION FOR SEQ ID NO: 82:
(i) SEQUENCE CHARACTERIZATION:
(A) LENGTH: 87 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULAR TYPE: RNA
(ix) FEATURE:
(D) OTHER INFORMATION: All pyrimidines are 2'-F modified
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:
GGGAGACAAG AAUAAACGCU CAAUCCCACC GGGGUGCCAC GGUUUAACG 50
GCUUAAUAUG AAUUUCGACA GGAGGCUCAC AACAGGC 87
- (2) INFORMATION FOR SEQ ID NO: 83:
(i) SEQUENCE CHARACTERIZATION:
(A) LENGTH: 85 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULAR TYPE: RNA
(ix) FEATURE:
(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

117

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83:
GGGAGACAAG AAUAAACGCU CAAGUCUGAC UAUUGGGGCG CCACAAUAUC 50
AACGGCUGUA CUUCGACAGG AGGCUCACAA CAGGC 85

(2) INFORMATION FOR SEQ ID NO: 84:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 88 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84:
GGGAGACAAG AAUAAACGCU CAAUCCCACC GGGGUGCCAC GGUUAAACG 50
GCUUAAUAUU UACUUUCGAC AGGAGGCUCA CAACAGGC 88

(2) INFORMATION FOR SEQ ID NO: 85:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85:
GGGAGACAAG AAUAAACGCU CAAGUCUUC AUGGGGAGCC ACAUUAACGG 50
CGCAUACUG AACUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 86:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86:
GGGAGACAAG AAUAAACGCU CAACUCGGGA GCCAGAGUAA CAACGGCACU 50
AUAAUUAUU ACUUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 87:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87:

GGGAGACAAG AAUAAACGCU CAACUAUGGG GAGCCACAUU UAACGGCAAU 50
AAAUCAUUAC GACUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 88:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88:

GGGAGACAAG AAUAAACGCU CAAAGUGGGG AGCCACACUA AAACGGCAUA 50
UUGACAUCGU CCCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 89:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 88 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89:

GGGAGACAAG AAUAAACGCU CAAUCUCCUC AUGGGGCGCC ACAUGGUUUU 50
AACGGCAUAU CACUUUCGAC AGGAGGCUCA CAACAGGC 88

(2) INFORMATION FOR SEQ ID NO: 90:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F
modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90:

GGGAGACAAG AAUAAACGCU CAACUAUGGG GAGCCACAUU UAACGGCUAU 50
AAAUCAUUAC GACUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 91:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F
modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91:

GGGAGACAAG AAUAAACGCU CAAACUGGGG AGCCACAGAU UUAACGGCGC 50
AUAUGAGUUG AGCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 92:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 86 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F
modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92:

GGGAGACAAG AAUAAACGCU CAACUCUCAC UGGGGAGCCA CAGUUUUAAA 50
CGGCAAGGGA GAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 93:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 84 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F
modified

120

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93:
 GGGAGACAAG AAUAAACGCU CAACAUCAGA UGGGGUGCCA CAUCAUAAA 50
 CGGCUAUUAU UUCGACAGGA GGCUCACAAC AGGC 84

(2) INFORMATION FOR SEQ ID NO: 94:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94:
 GGGAGACAAG AAUAAACGCU CAAACUGGGG AGCCACAGAU UUAACGGCAC 50
 AUAUGAUUGA GCUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 95:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 89 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95:
 GGGAGACAAG AAUAAACGCU CAAAACGGCU GUAACAAACA AGGUGGGGGG 50
 CCACACCAGA GCGGCUUCGA CAGGAGGCUC ACAACAGGC 89

(2) INFORMATION FOR SEQ ID NO: 96:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 93 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96:
 GGGAGACAAG AAUAAACGCU CAAACGGCUG UAACAAACAA GGUGGGGGGC 50
 CACACAGAGC GGGUUCGACU UCGACAGGAG GCUCACAACA GGC 93

(2) INFORMATION FOR SEQ ID NO: 97:

121

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 97:

GGGAGACAAG AAUAAACGCU CAAACGGCUG UGACAAACAA GGUGGGGGGC 50
CACACAGAGC GGGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 98:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98:

GGGAGACAAG AAUAAACGCU CAAAUAGCAG AGCCCAUGGC GGGAGGGAGG 50
AUUGUGGUGG AAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 99:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99:

GGGAGACAAG AAUAAACGCU CAACAUCGAC GGACCAGAGG UAGUGGGGGG 50
GAUGGGAUGC CCGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 100:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

122

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100:

GGGAGACAAG AAUAAACGCU CAAACCUAAC AUCUUACCAU AUUCAAUUUA	50
CAUUACACAC UAUUUCGACA GGAGGCUCAC AACAGGC	87

(2) INFORMATION FOR SEQ ID NO: 101:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 86 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101:

GGGAGACAAG AAUAAACGCU CAAGCUGCCC AAGGAAUUA ACUUGGACCG	50
CGAUCUGGAG UCUUCGACAG GAGGCUCACA ACAGGC	86

(2) INFORMATION FOR SEQ ID NO: 102:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102:

GGGAGACAAG AAUAAACGCU CAAAGGAGCG CCAUGAAGCA AAGGGAGGAU	50
UGUGGUGGAA GGCUUCGACA GGAGGCUCAC AACAGGC	87

(2) INFORMATION FOR SEQ ID NO: 103:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 80 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

123

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103:
GGGAGACAAG AAUAAACGCU CAACCGUAUU AACACUUAUU UUACAAUUUU 50
UUCAUAUUCG ACAGGAGGCU CACAACAGGC 80

(2) INFORMATION FOR SEQ ID NO: 104:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104:
GGGAGACAAG AAUAAACGCU CAAGGUACGA CCAAGGAAUG UGGGUGGAAG 50
AGGGUGCCGU ACCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 105:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105:
GGGAGACAAG AAUAAACGCU CAAGACGAAC GACCACGGGA UGGGUGGGCA 50
AAUAGGGAUG CCGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 106:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106:
GGGAGACAAG AAUAAACGCU CAAGCUAACC CGUACAAAUU UUCUUUUUCA 50
UUUUCaucac UAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 107:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107:

GGGAGACAAG AAUAAACGCU CAACUCGGGA GCCAGAGUAA CAACGGCACU 50
AUUAUUUUU ACCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 108:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 85 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108:

GGGAGACAAG AAUAAACGCU CAACGACCCG ACCAAGGGUA GGCAUGUGGG 50
GGGGUGCCCG GUUCGACAGG AGGCUCACAA CAGGC 85

(2) INFORMATION FOR SEQ ID NO: 109:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109:

GGGAGACAAG AAUAAACGCU CAAUCCGAAC AUGGGGUGCC AAAAAACGG 50
CUAUUAUCAC UAUUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 110:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110:

GGGAGACAAG AAUAAACGCU CAAGGACUGG UGAGCCACGU AUACGGUCUU 50
AGGGGCUUGG GCGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 111:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111:

GGGAGACAAG AAUAAACGCU CAACCUUGUG GGGAGCCACG UAUACGGCCA 50
UAGCAUACCG CAAUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 112:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112:

GGGAGACAAG AAUAAACGCU CAAGAGCUGG UGAGCCACGU AUACGGCCUU 50
AGGGGCUUGG GCGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 113:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

126

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 113:
GGGAGACAAG AAUAAACGCU CAAGAGCUGG UGAGCCACGU AUACGGUCUU 50
AGGGGCUUGG GCGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 114:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 114:
GGGAGACAAG AAUAAACGCU CAAGUAUUGG GGAGCCACAU UACAACGGCA 50
CAGGCAACCA GGGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 115:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 115:
GGGAGACAAG AAUAAACGCU CAAGUGCUGG UGAGCCACGC AUACGGUCUU 50
AGGGGCUUGA GCGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 116:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 116:
GGGAGACAAG AAUAAACGCU CAAUAAUUGG AGAGCCACAC UAACGGCGUA 50
UGAAAACACU CAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 117:

127

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 117:

GGGAGACAAG AAUAAACGCU CAAUCACAAG CACCCUUGGG GAGCCACAUU 50
 AACGGCCUAG GCUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 118:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118:

GGGAGACAAG AAUAAACGCU CAAUGGAGA GCCACAUUAA CGGCAGCAUA 50
 UCACAGUAGG AAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 119:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 85 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119:

GGGAGACAAG AAUAAACGCU CAAUGUGGGG AGCCACAGUU AACGGCUUCA 50
 ACUGAUUAGA AUUCGACAGG AGGCUCACAA CAGGC 85

(2) INFORMATION FOR SEQ ID NO: 120:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120:

GGGAGACAAG AAUAAACGCU CAAAGAUUUA AAGUAUUUGG GGAGCCACAU	50
CAACGGCAUU GUGUUCGACA GGAGGCUCAC AACAGGC	87

(2) INFORMATION FOR SEQ ID NO: 121:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 121:

GGGAGACAAG AAUAAACGCU CAAUGACUGA ACGAUGGUUAU UGGAGAGCCA	50
CAUCAACGGC AAUUCGACA GGAGGCUCAC AACAGGC	87

(2) INFORMATION FOR SEQ ID NO: 122:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 86 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122:

GGGAGACAAG AAUAAACGCU CAACAGAUGG UAUCUAGUGG AGAGCCACAU	50
CAACGGCGCA GAUUCGACAG GAGGCUCACA ACAGGC	86

(2) INFORMATION FOR SEQ ID NO: 123:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

129

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 123:
GGGAGACAAG AAUAAACGCU CAACGAUAGU AUACACAUGA UGAUGGGGAG 50
CCACGUGUAC GGCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 124:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 124:
GGGAGACAAG AAUAAACGCU CAACGAUGGA GCGCCACAUC GCUAUAACGG 50
CAUUUAACAA AAUUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 125:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 125:
GGGAGACAAG AAUAAACGCU CAAGCGGUCU GAUUGAGCCA CCGUGGAGGG 50
UACGUGGAGG GAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 126:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 126:
GGGAGACAAG AAUAAACGCU CAAACAAUUU CACACAGAAA CAGCUAUGAC 50
CAUGAUUACG CCAUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 127:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127:

GGGAGACAAG AAUAAACGCU CAAAGCUUUG GGGAGCCACA UAUAACGGCA 50

UGAUCAAUA UAGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 128:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 128:

GGGAGACAAG AAUAAACGCU CAAAUACAAU GUGGUUGAAG CUACCUCCCA 50

CUCGUAGUGG GCCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 129:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 86 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 129:

GGGAGACAAG AAUAAACGCU CAACCGUAGC CUCCAGCGGA ACGCGGAGGG 50

UACGUGGAGG GGUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 130:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 86 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

131

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 130:

GGGAGACAAG AAUAAACGCU CAACCGUAGC CUCCAGCGGA AUGCGGAGGG 50
CACGUGGAGG GGUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 131:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 85 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 131:

GGGAGACAAG AAUAAACGCU CAAGAGCCUC CGUGAUGAC GUGGAGGCAC 50
GCGGAGGGGA AUUCGACAGG AGGCUCACAA CAGGC 85

(2) INFORMATION FOR SEQ ID NO: 132:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 86 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 132:

GGGAGACAAG AAUAAACGCU CAAUCGAUAC UACUCCUGGA GAAAAGGGAG 50
GACCGUGGAG GAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 133:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 86 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

132

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 133:
GGGAGACAAG AAUAAACGCU CAAUCGAUAC UACUCCUGGA GAAAAGGGAG 50
GAUCGUGGAG GAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 134:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 134:
GGGAGACAAG AAUAAACGCU CAAGCGGUCU GAUUGAGCCU CCGUGGAGGG 50
UACGUGGAGG GAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 135:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 135:
GGGAGACAAG AAUAAACGCU CAAAGGGUGG AUUGUGGAGG AAUGAGUUGU 50
CUAUGGACUC CAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 136:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 136:
GGGAGACAAG AAUAAACGCU CAAUCGAUAC UACUCCUGGA GAAAAGGGAG 50
GAUCGUGGAG GAAUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 137:

133

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 137:

GGGAGACAAG AAUAAACGCU CAACCGAUAC UACUCCUGGA GAAAAGGGAG 50
GAUCGUGGAG GAAUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 138:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138:

GGGAGACAAG AAUAAACGCU CAAGGGAGGA UAGUGGAGGA AGAGCGUGUA 50
AUAUGUUAC GAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 139:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 139:

GGGAGACAAG AAUAAACGCU CAAUCGUAGC CUCCAGCGGA AUGCGGAGGG 50
CAGGUGGAGG GGUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 140:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 140:

GGGAGACAAG AAUAAACGCU CAAUCGAUAC UACUCCUGGA GAAAAGGGAG 50
GAUCGUGGAG GAAUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 141:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 84 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 141:

GGGAGACAAG AAUAAACGCU CAACCGCAGC CUCCAGCAAU GCGGAGGGCA 50
CGUGGAGGGG UUCGACAGGA GGCUCACAAC AGGC 84

(2) INFORMATION FOR SEQ ID NO: 142:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 86 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 142:

GGGAGACAAG AAUAAACGCU CAAGAGCCUC CGAGAAUGAC GUGGAGGGUA 50
CGUGGAGGGG UAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 143:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 86 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

135

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 143:
GGGAGACAAG AAUAAACGCU CAACCGUAGC CUCCAGCGGA ACGCGGAGGG 50
CACGUGGAGG GGUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 144:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 144:
GGGAGACAAG AAUAAACGCU CAAUGCCGAG AGGAGGGCUG AGGAGGACGC 50
GGCAUUAAGU GAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 145:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 145:
GGGAGACAAG AAUAAACGCU CAAUCGAUAC UACUCCUGGA GAAAAGGGAG 50
GAUCGUGGAG GAUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 146:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 146:
GGGAGACAAG AAUAAACGCU CAAGAGCCUC CGAGAAUGAC GUGGAGGGCA 50
CGUGGAGGGG AAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 147:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 147:

GGGAGACAAG AAUAAACGCU CAAUGCUGAG AGGAGGGCUG AGGAGGACAC 50
 GGCAGUAUGA GAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 148:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 148:

GGGAGACAAG AAUAAACGCU CAAACGUAGC CUCCAGCGGA AUGCGGAGGG 50
 CACGUGGAGG GGUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 149:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 149:

GGGAGACAAG AAUAAACGCU CAAGCGGUCU GAUCGAGCCU CCGUGGAGGG 50
 UACGUGGAGG GAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 150:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 150:

GGGAGACAAG AAUAAACGCU CCAGCGGUCU GAUUGAGCCU CCGUGGAGGG 50
CACGUGGAGG GAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 151:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 86 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 151:

GGGAGACAAG AAUAAACGCU CAAUGCCGAG AGGAGGGCUG AGGAGGACAC 50
GGCAGUAUGU AAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 152:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 86 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 152:

GGGAGACAAG AAUAAACGCU CAACCGUAGC CUCCAGCGGA AUGUGGAGGG 50
CACGUGGAGG GGUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 153:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 85 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 153:
 GGGAGACAAG AAUAAACGCU CAAAAGGUGG GUCGUGGAGG AAUGAGCUCG 50
 CUCCCAGCUA AUUCGACAGG AGGCUCACAA CAGGC 85

(2) INFORMATION FOR SEQ ID NO: 154:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

- (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 154:
 GGGAGACAAG AAUAAACGCU CAAAGAGUGC AGGUCUGGG CGCCACAAUU 50
 ACAACGGCAA UAAUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 155:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

- (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 155:
 GGGAGACAAG AAUAAACGCU CAAGUCUCC AUGGGGAGCC ACAUUAACGG 50
 CGCAAUACUG AACUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 156:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

- (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 156:
 GGGAGACAAG AAUAAACGCU CAACUCGGA GCCAGAGUAA CAACGGCACU 50

AUAUAAUUUU ACUUCGACAG GAGGCUCACA ACAGGC

86

(2) INFORMATION FOR SEQ ID NO: 157:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

- (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 157:

GGGAGACAAG AAUAAACGCU CAAAGAGCCG UUUUGGGGAC CCACAGUAAC	50
GGGUUUAUGG UAUUCGACAG GAGGCUCACA ACAGGC	86

(2) INFORMATION FOR SEQ ID NO: 158:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

- (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 158:

GGGAGACAAG AAUAAACGCU CAAGUCGGAG CGAUGGAGAG CCACGAUAUA	50
CGGUCUGUGC GCUUCGACAG GAGGCUCACA ACAGGC	86

(2) INFORMATION FOR SEQ ID NO: 159:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 82 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

- (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 159:

GGGAGACAAG AAUAAACGCU CAAAGUAACG UGGGGAGCCA CACGUAAUAC	50
GGCACUAAUU CGACAGGAGG CUCACAACAG GC	82

(2) INFORMATION FOR SEQ ID NO: 160:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

- (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 160:

GGGAGACAAG AAUAAACGCU CAAGGUACGA CCAAGGAAUG UGGGUGGAAG 50
AGGGCGCCGU ACCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 161:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

- (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 161:

GGGAGACAAG AAUAAACGCU CAAGAUCCUG CGACGCCAGG GGUGGAUAGG 50
GGGAAGGGAG CGGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 162:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

- (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 162:

GGGAGACAAG AAUAAACGCU CAAGACGAAC GACCAAGGGA CGGGUGGGCA 50
AAUAGGGAUG CCGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 163:

(i) SEQUENCE CHARACTERIZATION:

141

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: RNA
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All U's are 2'-NH₂ modified
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 163:
GGGAGACAAG AAUAAACGCU CAAGGUACGA CCAAGGAAUG UGGGUGGAAG 50
AGGGUGCCGU ACCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 164:

- (i) SEQUENCE CHARACTERIZATION:
 - (A) LENGTH: 87 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: RNA
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All U's are 2'-NH₂ modified
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 164:
GGGAGACAAG AAUAAACGCU CAACAACGCU GACCAUGGGA GGAAUGUGGG 50
AAGGGCGCCA GCGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 165:

- (i) SEQUENCE CHARACTERIZATION:
 - (A) LENGTH: 87 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: RNA
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All U's are 2'-NH₂ modified
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 165:
GGGAGACAAG AAUAAACGCU CAACAGCCAA GGGUUGGAUA GGGGGUAGGG 50
AGCCGUAGCA GCGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 166:

- (i) SEQUENCE CHARACTERIZATION:
 - (A) LENGTH: 87 base pairs
 - (B) TYPE: nucleic acid

142

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: RNA
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All U's are 2'-NH₂ modified
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 166:
 GGGAGACAAG AAUAAACGCU CAACCGCCUG CGAUAGUUAG ACCGUUGAGC 50
 UGAGAGCAAC ACUUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 167:

- (i) SEQUENCE CHARACTERIZATION:
 - (A) LENGTH: 86 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: RNA
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All U's are 2'-NH₂ modified
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 167:
 GGGAGACAAG AAUAAACGCU CAAAGGUGG GUUGAGGAGG AAAGUAGCGU 50
 GAGUCAGUAC CAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 168:

- (i) SEQUENCE CHARACTERIZATION:
 - (A) LENGTH: 87 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: RNA
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All U's are 2'-NH₂ modified
- (ix) FEATURE:
 - (D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 168:
 GGGAGACAAG AAUAAACGCU CAAAGGGAGG AUUGUGGAGG AAGGGAGUGG 50
 AAGUGUCCCA GCCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 169:

- (i) SEQUENCE CHARACTERIZATION:
 - (A) LENGTH: 87 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 169:

GGGAGACAAG AAUAAACGCU CAAGGAUGAC CAAGCGUCGA ACGAGGGAGG 50
AUUGUGGUGG AGGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 170:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 170:

GGGAGACAAG AAUAAACGCU CAAGGGUGGA UUGUGGAGGA AGUAGCGCAG 50
GGUCCGUAA GCCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 171:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 171:

GGGAGACAAG AAUAAACGCU CAAAGGAGCG CCAUGAAGCA AAGGGAGGAU 50
UGUGGUGGAA GGCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 172:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 86 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

144

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 172:

GGGAGACAAG AAUAAACGCU CAAACUGGAG CCAUACAGAC GAGAGGAUGG 50

GUGUGUGGAG GAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 173:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 173:

GGGAGACAAG AAUAAACGCU CAAAGGGAGG AUUGUGGAGG AAGGGAGUGG 50

AAGUGUCUCA GCCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 174:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 174:

GGGAGACAAG AAUAAACGCU CAAUCGGGUG AGGACUGGUA GAAAAAGGAG 50

GGUUGUGGAG GAGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 175:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

145

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 175:

GGGAGACAAG AAUAAACGCU CAAACCUGAU AACCGCGGAG GGAGGAUAGA 50
GGAGGAAGUG CGGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 176:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 176:

GGGAGACAAG AAUAAACGCU CAAAGGCAGC CCCUCGACGA GAAAGGUGGG 50
UAGUGGAGGA ACUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 177:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 177:

GGGAGACAAG AAUAAACGCU CAACUUACGA CACCAAAGGG AGGAUUGUGG 50
UGGAAUGGGG UCGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 178:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 178:

GGGAAACGGC UGUAACAAAC AAGGUGGGGG GCCACACA

38

(2) INFORMATION FOR SEQ ID NO: 179:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 56 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 179:

GGGAGACAAG AAUAAACGCU CAAGUCUGAC UAUUGGGGCG CCACAAUAUC
AACGGC

50

56

(2) INFORMATION FOR SEQ ID NO: 180:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 49 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 180:

AAGAAUAAAC GCUCAAGCUG CCAAGGAU UUAACUUGGA CCGCGAUCU

49

(2) INFORMATION FOR SEQ ID NO: 181:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 181:

AAGCAAAGGG AGGAUUGUGG UGGAAGGCUU C

31

(2) INFORMATION FOR SEQ ID NO: 182:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 51 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

147

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-NH₂ modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 182:

GGGACGCUCA AGAGCUGGUG AGCCACGUAU ACGGCCUUG GGGCUUGGGC
G

50

51

(2) INFORMATION FOR SEQ ID NO: 183:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 59 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 183:

GGGAGACAAG AAUAAACGCU CAAAGAGUGC AGGUCUGGGG CGCCACAAU
AGAACGGCA

50

59

(2) INFORMATION FOR SEQ ID NO: 184:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 184:

GCUCAACCGC CUGCGAUAGU UAGACCG

27

(2) INFORMATION FOR SEQ ID NO: 185:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 47 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All U's are 2'-NH₂ modified

148

(ix) FEATURE:

(D) OTHER INFORMATION: All C's are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 185:
 CCUGCGACGC CAGGGGUGGA UAGGGGGAAG GGAGCGGUUC GACAGGA

47

(2) INFORMATION FOR SEQ ID NO: 186:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 186:
 GGGAGACAAG AAUAAACGCU CAANNNNNNN NNNNNNNNNN NNNNNNNNNN
 NNNNNNNNNN NNNUUCGACA GGAGGCUCAC AACAGGC

50

87

(2) INFORMATION FOR SEQ ID NO: 187:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 40 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 187:
 TAATACGACT CACTATAGGG AGACAAGAAT AAACGCTCAA

40

(2) INFORMATION FOR SEQ ID NO: 188:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 188:
 GCCTGTTGTG AGCCTCCTGT CGAA

24

(2) INFORMATION FOR SEQ ID NO: 189:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 84 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F modified

149

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 189:
GGGAGACAAG AAUAAACGCU CAAACAUCGU AUAACUCUAA GGGCCUGGAU 50
AUACGAUGAA UUCGACAGGA GGCUCACAAC AGGC 84

(2) INFORMATION FOR SEQ ID NO: 190:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 84 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 190:
GGGAGACAAG AAUAAACGCU CAAACAUCGU AUAACUCUAA GCGCCUGGAU 50
AUACGAUGAA UUCGACAGGA GGCUCACAAC AGGC 84

(2) INFORMATION FOR SEQ ID NO: 191:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 84 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 191:
GGGAGACAAG AAUAAACGCU CAAACAUCGU AUAACUCUAA GAGCCUGGAU 50
AUACGAUGAA UUCGACAGGA GGCUCACAAC AGGC 84

(2) INFORMATION FOR SEQ ID NO: 192:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 84 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 192:
GGGAGACAAG AAUAAACGCU CAAACAUCGU AUAACUCUAA GUGCCUGGAU 50
AUACGAUGAA UUCGACAGGA GGCUCACAAC AGGC 84

(2) INFORMATION FOR SEQ ID NO: 193:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 85 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 193:

GGGAGACAAG AAUAAACGCU CAAACAUCGU AUAUCUCUA AGAGCCUGGA 50
UAUACGAUGA AUUCGACAGG AGGCUCACAA CAGGC 85

(2) INFORMATION FOR SEQ ID NO: 194:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 194:

GGGAGACAAG AAUAAACGCU CAAACAUCGU AUAUCUCUC UAAGAGCCUG 50
GAAUACGAUG AAUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 195:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 88 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 195:

GGGAGACAAG AAUAAACGCU CAAAUCCCAA UCUCUAAGAG CCUGGAUAAG 50
AAUGCGCAUU GGGCUUCGAC AGGAGGCUCA CAACAGGC 88

(2) INFORMATION FOR SEQ ID NO: 196:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F
modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 196:

GGGAGACAAG AAUAAACGCU CAAAUCCCAA UCUCUAAGAG CCUGGAUGAC 50
AAUCGCAUUG GGCUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 197:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 88 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F
modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 197:

GGGAGACAAG AAUAAACGCU CAAAUCCCAA UCUCUAAGAG CCUGGAUGAG 50
AAUGCGCAUU GGGCUUCGAC AGGAGGCUCA CAACAGGC 88

(2) INFORMATION FOR SEQ ID NO: 198:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 86 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F
modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 198:

GGGAGACAAG AAUAAACGCU CAACUGAGAU CUCUAAGAGC CUGGACUCAG 50
CUCCGACUGA CCUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 199:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 87 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

(D) OTHER INFORMATION: All pyrimidines are 2'-F
modified

152

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 199:
GGGAGACAAG AAUAAACGCU CAACUGAGAU CUCUAAGAGC CUGGACUCAG 50
CUCCGAUUGA UCCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 200:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 200:
GGGAGACAAG AAUAAACGCU CAACUGAGAU CUCUAAGAGC CUGGACUCAG 50
CUCCGAUUGA ACCUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 201:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 201:
GGGAGACAAG AAUAAACGCU CAAUCUCUAU GAGCCUGGAU CGACGAACUC 50
UCUACGGGCU GUGUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 202:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 86 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 202:
GGGAGACAAG AAUAAACGCU CAAUCUCUAA GAGCCUGGAU GUCGAGGGGC 50
CAUUUCGCAC GCUUCGACAG GAGGCUCACA ACAGGC 86

(2) INFORMATION FOR SEQ ID NO: 203:

153

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 88 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 203:

GGGAGACAAG AAUAAACGCU CAAUUCUCUA CUGAGCCUGG AUUCGCCAGA 50
AGUUUUAUCA CAGUUUCGAC AGGAGGCUCA CAACAGGC 88

(2) INFORMATION FOR SEQ ID NO: 204:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 204:

GGGAGACAAG AAUAAACGCU CAACGUAAAA GUUAUCGAU CUCUGUGAGC 50
CUGGAUCGAU UACUUCGACA GGAGGCUCAC AACAGGC 87

(2) INFORMATION FOR SEQ ID NO: 205:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 97 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(ix) FEATURE:

- (D) OTHER INFORMATION: All pyrimidines are 2'-F modified

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 205:

GGGAGACAAG AAUAAACGCU CAACUGAGAU CUCUAAGAGC CUGGACUCAG 50
CUACGAUUGA GCGUUUAUUC UUGUUCGACA GGAGGCUCAC AACAGGC 97

(2) INFORMATION FOR SEQ ID NO: 206:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: RNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 206:

GGGAGCUCAG AAUAAACGCU CAANNNNNNNN NNNNNNNNNN NNNNNNNNNN 50
NNNUUCGACA UGAGGCCCGG AUCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 207:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 207:

GCCGGATCCG GGCCTCATGT CGAA 24

(2) INFORMATION FOR SEQ ID NO: 208:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 48 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 208:

CCGAAGCTTA ATACGACTCA CTATAGGGAG CTCAGAATAA ACGCTCAA 48

(2) INFORMATION FOR SEQ ID NO: 209:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 209:

GGGAGCTCAG AATAAACGCT CAAACGGCTG ACAACGGCTG GACTTGCGTA 50
TTGTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 210:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 210:

GGGAGCTCAG AATAAACGCT CAAGCGCTTG ACCATTTCGT AGGGTCGCCC 50

TTGTTTCGACA TGAGGCCCGG ATCCGGC

77

(2) INFORMATION FOR SEQ ID NO: 211:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 77 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 211:

GGGAGCTCAG AATAACGCT CAAGATCGAC GCATCGAGTC GCCTCATCGC

50

TCCTTCGACA TGAGGCCCGG ATCCGGC

77

(2) INFORMATION FOR SEQ ID NO: 212:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 77 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 212:

GGGAGCTCAG AATAACGCT CAACGCACTC GGACGGAATC TCCGTAGGAC

50

ACGTTCGACA TGAGGCCCGG ATCCGGC

77

(2) INFORMATION FOR SEQ ID NO: 213:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 77 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 213:

GGGAGCTCAG AATAACGCT CAATGTCATG CATGTGTGTC GCCTCATCAC

50

GCATTTCGACA TGAGGCCCGG ATCCGGC

77

(2) INFORMATION FOR SEQ ID NO: 214:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 77 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 214:

GGGAGCTCAG AATAACGCT CAACCACTGG CTAGGAATC GAGTACTGGG

50

TGGTTCGACA TGAGGCCCGG ATCCGGC

77

156

(2) INFORMATION FOR SEQ ID NO: 215:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 215:

GGGAGCTCAG AATAACGCT CAATTCGAAG CCACGTTTCA TGTCCGTCGC 50
TGCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 216:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 216:

GGGAGCTCAG AATAACGCT CAACAGTGGA GGCTGTCAA ACCCACCAC 50
CCCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 217:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 76 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 217:

GGGAGCTCAG AATAACGCT CAAGTGGAGG GTACGTGGAG GGGAGAGCGA 50
TATTCGACAT GAGGCCCGGA TCCGGC 76

(2) INFORMATION FOR SEQ ID NO: 218:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 76 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 218:

GGGAGCTCAG AATAACGCT CAATCTCATG CTCGCGTGCG TCGCCTCAAC 50
CATTCGACAT GAGGCCCGGA TCCGGC 76

(2) INFORMATION FOR SEQ ID NO: 219:

(i) SEQUENCE CHARACTERIZATION:

157

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 219:
GGGAGCTCAG AATAACGCT CAATCCCTCA GTGTCAAGTG CGTCGCCTCA 50
GCATTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 220:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 78 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 220:
GGGAGCTCAG AATAACGCT CAACTTCTTG GCCCCGTCTC AATGTCCGTA 50
CTTCTTCGAC ATGAGGCCCG GATCCGGC 78

(2) INFORMATION FOR SEQ ID NO: 221:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 221:
GGGAGCTCAG AATAACGCT CAACGTGATT TGGCCACGGG AAAGAGCCAT 50
ACCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 222:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 222:
GGGAGCTCAG AATAACGCT CAACGTTGAA CGCTTGTTT CATGTCCCTC 50
GCCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 223:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid

158

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 223:
GGGAGCTCAG AATAACGCT CAACGTCGAT CGCGTGCTGT AGCCTCAGGC 50
ACCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 224:

- (i) SEQUENCE CHARACTERIZATION:
 - (A) LENGTH: 78 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 224:
GGGAGCTCAG AATAACGCT CAAGGTGGAA GGCCTTTGAA GCCCGTACAT 50
CTCCTTCGAC ATGAGGCCCG GATCCGGC 78

(2) INFORMATION FOR SEQ ID NO: 225:

- (i) SEQUENCE CHARACTERIZATION:
 - (A) LENGTH: 77 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 225:
GGGAGCTCAG AATAACGCT CAAGGTCGAA CTAGCGCTGG AGCGTGC GTT 50
GGTTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 226:

- (i) SEQUENCE CHARACTERIZATION:
 - (A) LENGTH: 77 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 226:
GGGAGCTCAG AATAACGCT CAAGTCGCTC GATCGTTTCA TGCCCGTCCG 50
ACCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 227:

- (i) SEQUENCE CHARACTERIZATION:
 - (A) LENGTH: 77 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 227:

GGGAGCTCAG AATAAACGCT CAAGTCGATG CGCAGTCCGC CTCAGCTGCA 50
CTGTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 228:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 228:

GGGAGCTCAG AATAAACGCT CAAGGTGTGC CCAAGGCCCT TGAGAGAGGC 50
GTGTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 229:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 229:

GGGAGCTCAG AATAAACGCT CAACGTCTAG GAACTGCGTC GCCTCAACAG 50
CGCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 230:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 72 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 230:

GGGAGCTCAG AATAAACGCT CAAGTCGGAT GGTTTTGC GC GTTTCCCGTT 50
CGACATGAGG CCCGGATCCG GC 72

(2) INFORMATION FOR SEQ ID NO: 231:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

160

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 231:
GGGAGCTCAG AATAAACGCT CAACCTCATC CTCGCACGCC ATCGCCTGAA 50
CCGTTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 232:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 232:
GGGAGCTCAG AATAAACGCT CAAGGTGTGC CAAAGGCCCT TGAGAGAGGC 50
GTATTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 233:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 233:
GGGAGCTCAG AATAAACGCT CAAGGCCGCA TGCCCCTCCT AACAGCATGC 50
AACTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 234:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 234:
GGGAGCTCAG AATAAACGCT CAACCCTCGT GCGTGCGCTT GGAGCGTGGC 50
GCATTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 235:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 235:
GGGAGCTCAG AATAAACGCT CAAGTCGCTC GATCGTTTCA TGTCGGTTCC 50

161

ACCTTCGACA TGAGGCCCGG ATCCGGC

77

(2) INFORMATION FOR SEQ ID NO: 236:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 74 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 236:

GGGAGCTCAG AATAAACGCT CAAGTCCACA CTTTGCCGAG CGTCCTAGTG
TTCGACATGA GGCCCGGATC CGGC

50

74

(2) INFORMATION FOR SEQ ID NO: 237:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 76 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 237:

GGGAGCTCAG AATAAACGCT CAACGGGTGA ATCACGGCTG GTGCGTTGCC
CCTTCGACAT GAGGCCCGGA TCCGGC

50

76

(2) INFORMATION FOR SEQ ID NO: 238:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 238:

GGGAGCTCAG AATAAACGCT CAACGTGAC GCACTGTGCC GCCTCACACA
CGCTTCGACA TGAGGCCCGG ATCCGGC

50

77

(2) INFORMATION FOR SEQ ID NO: 239:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 239:

GGGAGCTCAG AATAAACGCT CAAGCGAACG TCATGCCGCC TCATCATGCC
ACGTTCGACA TGAGGCCCGG ATCCGGC

50

77

162

(2) INFORMATION FOR SEQ ID NO: 240:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 76 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 240:

GGGAGCTCAG AATAACGCT CAACTAGGCC CACCGTCCCT TCTAACAACG 50
TCTTCGACAT GAGGCCCGGA TCCGGC 76

(2) INFORMATION FOR SEQ ID NO: 241:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 241:

GGGAGCTCAG AATAACGCT CAACAGTCAC GAACGTGCGC CGGAAGAACG 50
CTCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 242:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 242:

GGGAGCTCAG AATAACGCT CAATGTCGCA CGTGTCCCGG CCCGCCCTAC 50
CCCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 243:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 243:

GGGAGCTCAG AATAACGCT CAACAGGTGG CACCGCCCTT CCAACACGGT 50
GCGTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 244:

(i) SEQUENCE CHARACTERIZATION:

163

- (A) LENGTH: 74 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 244:
GGGAGCTCAG AATAACGCT CAAGTCCACA CTTTGCCGAG CGTCCTAGTG 50
TTCGACATGA GGCCCGGATC CGGC 74

(2) INFORMATION FOR SEQ ID NO: 245:

(i). SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 245:
GGGAGCTCAG AATAACGCT CAAATGGTGG AGGCCATCTC AAACCCACGA 50
CACTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 246:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 246:
GGGAGCTCAG AATAACGCT CAACGCCGAG ACCCACCTCA TAACACCGCT 50
ACCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 247:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 247:
GGGAGCTCAG AATAACGCT CAATGAGGCG CGCCACAGGA TGGCCCTCAA 50
CCCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 248:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid

164

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 248: .
GGGAGCTCAG AATAAACGCT CAAGTCCGCA TGATGCTTCG AACAGCATAC 50
AACTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 249:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 249:
GGGAGCTCAG AATAAACGCT CAAGGTGTGC CCCTACGTGC GGCCCTTCGT 50
TTATTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 250:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 250:
GGGAGCTCAG AATAAACGCT CAACGGCTTG CAGGTCGCCG AAATGACCGC 50
ACATTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 251:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 251:
GGGAGCTCAG AATAAACGCT CAACTAGTTC AACCGTCCCT TCTAACAACC 50
GTCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 252:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 77 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

165

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 252:

GGGAGCTCAG AATAAACGCT CAACCTGGTG GTCGTGCGGC TGTCGCCTCA 50
AGGTTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 253:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 77 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 253:

GGGAGCTCAG AATAAACGCT CAAGATCGAA GTTGTCGTCC GCCTCAGCGA 50
CTCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 254:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 77 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 254:

GGGAGCTCAG AATAAACGCT CAATGTCGAG TGCGATGGAG GAGTAGGGAT 50
GCATTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 255:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 77 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 255:

GGGAGCTCAG AATAAACGCT CAATGTCGAT CGTGTCAAGG TCCGTCCTAC 50
TTCTTCGACA TGAGGCCCGG ATCCGGC 77

(2) INFORMATION FOR SEQ ID NO: 256:

(i) SEQUENCE CHARACTERIZATION:

(A) LENGTH: 71 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

166

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 256:
GGGAGGACGA TCGGNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN 50
NNNNNCAGAC GACTCGCCCG A 71

(2) INFORMATION FOR SEQ ID NO: 257:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 257:
GGGAGGACGA TCGG 15

(2) INFORMATION FOR SEQ ID NO: 258:

(i) SEQUENCE CHARACTERIZATION:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(ix) FEATURE:

- (D) OTHER INFORMATION: N at positions 1-4 is biotin

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 258:
NNNNTCGGGC GAGTCGTCTG 20

WE CLAIM:

1. A method of identifying nucleic acid ligands to a cytokine, comprising:
 - a) contacting a candidate mixture of nucleic acids with said cytokine, wherein nucleic acids having an increased affinity to said cytokine relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; and
 - b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and
 - c) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acid sequences with relatively higher affinity and specificity for binding to said cytokine, whereby nucleic acid ligands of said cytokine may be identified.
2. The method of claim 1 further comprising:
 - d) repeating steps a), b), and c).
3. The method of claim 1 wherein said candidate mixture of nucleic acids is comprised of single stranded nucleic acids.
4. The method of claim 3 wherein said single stranded nucleic acids are ribonucleic acids.
5. The method of claim 4 wherein said nucleic acids are modified nucleic acids.
6. The method of claim 5 wherein said nucleic acids are 2'-amino (2'-NH₂) modified ribonucleic acids.
7. The method of claim 5 wherein said nucleic acids are 2'-fluoro (2'-F) modified ribonucleic acids.
8. The method of claim 3 wherein said single stranded nucleic acids are deoxyribonucleic acids.
9. The method of claim 1 wherein said cytokine is selected from the group consisting of IFN-gamma, IL-10, IL-4, TNF-alpha, and RANTES.
10. The method of claim 1 wherein said cytokine is IFN-gamma.
11. The method of claim 1 wherein said cytokine is IL-10.
12. The method of claim 1 wherein said cytokine is IL-4.

13. The method of claim 1 wherein said cytokine is TNF-alpha.
14. The method of claim 1 wherein said cytokine is RANTES.
15. A method for treating a cytokine-mediated disease comprising administering a pharmaceutically effective amount of a nucleic acid ligand of a cytokine.
16. The method of claim 15 wherein said nucleic acid ligand of a cytokine is identified according to the method of claim 1.
17. The method of claim 16 wherein said cytokine is IFN-gamma.
18. The method of claim 17 wherein said ligand is selected from one of the ligands of Tables 3 and 4 (SEQ ID NOS:7-73).
19. The method of claim 16 wherein said cytokine is IL-4.
20. The method of claim 17 wherein said ligand is selected from one of the ligands of Tables 7 and 8 (SEQ ID NOS:100-185).
21. The method of claim 16 wherein said cytokine is IL-10.
22. The method of claim 21 wherein said ligand is selected from one of the ligands of Table 10 (SEQ ID NOS:189-205).
23. The method of claim 16 wherein said cytokine is TNF-alpha.
24. The method of claim 23 wherein said ligand is selected from one of the ligands of Table 12 (SEQ ID NOS:209-255).
25. A purified and isolated non-naturally occurring nucleic acid ligand to a cytokine.
26. The purified and isolated non-naturally occurring nucleic acid ligand of claim 25 wherein said nucleic acid ligand is single-stranded.
27. The purified and isolated non-naturally occurring nucleic acid ligand of claim 26 wherein said nucleic acid ligand is ribonucleic acid.
28. The purified and isolated non-naturally occurring nucleic acid ligand of claim 26 wherein said nucleic acid ligand is deoxyribonucleic acid.
29. A nucleic acid ligand to a cytokine identified according to the method comprising:

a) contacting a candidate mixture of nucleic acids with said cytokine, wherein nucleic acids having an increased affinity to said cytokine relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; and

b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

c) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acid sequences with relatively higher affinity and specificity for binding to said cytokine, whereby nucleic acid ligands of said cytokine may be identified.

30. The purified and isolated non-naturally occurring ribonucleic acid ligand of claim 27, wherein said ligand is IFN-gamma.

31. The purified and isolated non-naturally occurring ribonucleic acid ligand to IFN-gamma of claim 30 wherein said ligand is selected from the group consisting of the sequences set forth in Tables 3 and 4 (SEQ ID NOS:7-73).

32. The purified and isolated non-naturally occurring ribonucleic acid ligand to IFN-gamma of claim 30 wherein said ligand is substantially homologous to and has substantially the same ability to bind IFN-gamma as a ligand selected from the group consisting of the sequences set forth in Tables 3 and 4 (SEQ ID NOS:7-73).

33. The purified and isolated non-naturally occurring ribonucleic acid ligand to IFN-gamma of claim 30 wherein said ligand has substantially the same structure and substantially the same ability to bind IFN-gamma as a ligand selected from the group consisting of the sequences set forth in Tables 3 and 4 (SEQ ID NOS:7-73).

34. The purified and isolated non-naturally occurring ribonucleic acid ligand of claim 27 wherein said ligand is to IL-4.

35. The purified and isolated non-naturally occurring ribonucleic acid ligand to IL-4 of claim 34 wherein said ligand is selected from the group consisting of the sequences set forth in Tables 7 and 8 (SEQ ID NOS:79-185).

36. The purified and isolated non-naturally occurring ribonucleic acid ligand to IL-4 of claim 34 wherein said ligand is substantially homologous to and has substantially the

same ability to bind IL-4 as a ligand selected from the group consisting of the sequences set forth in Tables 7 and 8 (SEQ ID NOS:79-185).

37. The purified and isolated non-naturally occurring ribonucleic acid ligand to IL-4 of claim 34 wherein said ligand has substantially the same structure and substantially the same ability to bind IL-4 as a ligand selected from the group consisting of the sequences set forth in Tables 7 and 8 (SEQ ID NOS:79-185).

38. The purified and isolated non-naturally occurring ribonucleic acid ligand of claim 27 wherein said ligand is to IL-10.

39. The purified and isolated non-naturally occurring ribonucleic acid ligand to IL-10 of claim 38 wherein said ligand is selected from the group consisting of the sequences set forth in Table 10 (SEQ ID NOS:189-205).

40. The purified and isolated non-naturally occurring ribonucleic acid ligand to IL-10 of claim 38 wherein said ligand is substantially homologous to and has substantially the same ability to bind IL-10 as a ligand selected from the group consisting of the sequences set forth in Table 10 (SEQ ID NOS:189-205).

41. The purified and isolated non-naturally occurring ribonucleic acid ligand to IL-10 of claim 38 wherein said ligand has substantially the same structure and substantially the same ability to bind IL-10 as a ligand selected from the group consisting of the sequences set forth in Table 10 (SEQ ID NOS:189-205).

42. The purified and isolated non-naturally occurring ribonucleic acid ligand of claim 27 wherein said ligand is to TNF-alpha.

43. The purified and isolated non-naturally occurring ribonucleic acid ligand to TNF-alpha of claim 42 wherein said ligand is selected from the group consisting of the sequences set forth in Table 12 (SEQ ID NOS:209-255).

44. The purified and isolated non-naturally occurring ribonucleic acid ligand to TNF-alpha of claim 42 wherein said ligand is substantially homologous to and has substantially the same ability to bind TNF-alpha as a ligand selected from the group consisting of the sequences set forth in Table 12 (SEQ ID NOS:209-255).

45. The purified and isolated non-naturally occurring ribonucleic acid ligand to TNF-alpha of claim 42 wherein said ligand has substantially the same structure and

substantially the same ability to bind TNF-alpha as a ligand selected from the group consisting of the sequences set forth in Table 12 (SEQ ID NOS:189-205).

46. The purified and isolated non-naturally occurring nucleic acid ligand of claim 25 wherein said ligand is to RANTES.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/09537

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07H 21/02, 21/04; C12P 19/34; C12Q 1/68

US CL :435/6, 91.2; 536/22.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.2; 536/22.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,270,163 A (GOLD ET AL.) 14 December 1993, column 5, column 46, Example 6.	1-17, 19, 21, 23, 25-30, 34, 38, 42, 46
Y	WO 92/14843 A1 (GILEAD SCIENCES, INC.) 03 September 1992, pages 12-15.	1-17, 19, 21, 23, 25-30, 34, 38, 42, 46

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

A	document defining the general state of the art which is not considered to be of particular relevance	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E	earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O	document referring to an oral disclosure, use, exhibition or other means	*Z*	document member of the same patent family
P	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

23 AUGUST 1996

Date of mailing of the international search report

05 SEP 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

STEPHANIE W. ZITOMER, Ph.D.

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/09537

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 18, 20, 22, 24, 31-33, 35-37, 39-41, 43-45
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

These claims were not searched because they are drawn to nucleotide sequences identified by their SEQ ID NO:s and the required Sequence Listing/CRF has not been submitted nor is it in the prior US applications.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)